Neurology® Podcast

Weekly podcast of content from Neurology®, the official journal of the American Academy of Neurology.

Last build: Thursday, 19 Oct 2017 11:31:52 CDT

The Neurology podcast is introduced by Editor-in-Chief Robert A. Gross, MD, PhD, who discusses several highlighted articles in the current issue of Neurology®. The podcast regularly features content from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation. Opening segments include interviews with authors who summarize a current article and discuss the main findings and clinical implications for neurologists. It concludes with the Lesson of the Week, a short segment on a topic such as a laboratory technique, statistical methods, or historical neurology. Regular features also include Delayed Recall, ePearls, and What’s Trending. Podcast listeners can earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions related to Neurology content in the online Podcast Quiz. (Delayed recall, Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation contents are excluded from the CME program). The exams are posted weekly on Wednesday.

download this now episode segments

October 17 2017 Issue

Qualitative study of burnout, career satisfaction, and well-being among US neurologists in 2016

Published: Monday, 16 Oct 2017 13:00:00 CDT

Show description/summary: 1) Qualitative study of burnout, career satisfaction, and well-being among US neurologists in 2016 2) What’s Trending: gene editing in human embryos This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 17, 2017, issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Janis Miyasaki about her paper on burnout, career satisfaction and well-being among US neurologists. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Shoukhrat Mitalipov on gene editing in human embryos for correction of a pathogenic mutation. DISCLOSURES: Dr. Miyasaki has received honoraria from Davis Phinny Foundation, Sunovion, and NINDS; receives publishing royalties from “Up to Date: Psychogenic Movement Disorders;” has consulted for Cynapsus and GE; has served on a scientific advisory board for Parkinson Society Canada; and has received research support from Allergan, PCORI, and Parkinson Alberta. Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer” (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq. Dr. Korb and Dr. Crowell report no disclosures.

download this now episode segments

October 10 2017 Issue

Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update

Published: Monday, 09 Oct 2017 13:00:00 CDT

Show description/summary: 1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update 2) Neurology Today® paper on Parkinson disease and autoimmunity In the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 3 2017 Issue

Functional impairments for outcomes in a randomized trial of of unruptured brain AVMs

Published: Monday, 02 Oct 2017 13:00:00 CDT

Show description/summary: 1) Functional impairments for outcomes in a randomized trial of of unruptured brain AVMs 2) What’s Trending: Hurricane Harvey and patient care in Texas This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 3, 2017, issue of Neurology. In the first segment, Dr. Andrew Southerland talks with Dr. JP Mohr about his paper on functional impairment outcome measurements in a randomized trial of unruptured brain arteriovenous malformations. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Aziz Shaibani on Hurricane Harvey and its effect on patient care in Texas. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Mohr serves as Associate Editor for History of Stroke and Cerebrovascular Disease; has consulted for Schering-Plough; has given expert testimony on unruptured brain AVMs; and has received research support from NINDS associated with the ARUBA trial. Dr. Crowell reports no disclosures. Dr. Shaibani is President-Elect for the Texas Neurology Society.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - October 2017

Practice Current: Neuromyelitis Optica Treatment

Published: Saturday, 30 Sep 2017 13:00:00 CDT

This special Delayed Recall episode is the second installment of our new Practice Current segment. In this episode, Dr. Luca Bartolini speaks with neuromyelitis optica (NMO) experts Dr. Tarso Adoni and Dr. Michael Levy. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding NMO treatment, and share their thoughts on best practices. This is the first appearance of this interview in the podcast.

download this now episode segments

September 26 2017 Issue

Neurology® Genetics: ExACtly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies

Published: Monday, 25 Sep 2017 13:00:00 CDT

Show description/summary: 1) Neurology® Genetics: ExACtly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies 2) What’s Trending: Orphan drug pricing This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 26, 2017 issue of Neurology. In the first segment, Dr. Jim Kiely talks with Dr. Samuel Berkovic about his Neurology® Genetics paper on assessing genetic variants in mild epilepsies. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Gordon Smith on orphan drug pricing. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Kiely is employed at InTouch Health Physician Services as a teleneurologist, and holds stock with InTouch Health. Dr. Berkovic serves on scientific advisory board for UCB Pharma and Eisai Australia; has served on editorial boards for Brain, Epileptic Disorders, and Lancet Neurology; is an investor listed on a Bionomics Inc patent on diagnostic testing using SCN1A gene (WO2006/133508), and is an investor on a pending patent for a therapeutic compound related to a genetic cause of familial epilepsy with mental retardation in females (WO61/010176); receives research support from UCB, SciGen, and Eisai Australia, the National Health and Medical Research Council of Australia (Program Grant #1091593; 2016-2020), and NINDS (U01 NS077367-01; 2011-2014). Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606). Dr. Crowell reports no disclosures.

download this now episode segments

September 19 2017 Issue

Medication-overuse headache: An entrenched idea in need of scrutiny

Published: Monday, 18 Sep 2017 13:00:00 CDT

Show description/summary: 1) Medication-overuse headache: An entrenched idea in need of scrutiny 2) What’s Trending: DAWN Trial This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 19th, 2017 issue of Neurology. In the first segment, Dr. Alex Menze talks with Dr. Elizabeth Loder about her paper on medication overuse headache. In the second part of the podcast, Dr. Kevin Barrett focuses his interview with Dr. Tudor Jovin on the DAWN trial on Trevo thrombectomy for acute ischemic stroke. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Menze reports no disclosures. Dr. Loder has received travel funding from the American Headache Society and American Migraine Foundation and The British Medical Journal; has served on the editorial boards of The British Medical Journal, Cephalalgia, and Headache; receives publishing royalties from Cambridge University Press; and has received research support from Harvard Medical School. Dr. Barrett serves on the editorial boards of Neurology and Neurohospitalist; receives publishing royalties from Wiley-Blackwell; and has received research support from NINDS. Dr. Jovin has served on the Codman Neurovascular Data Safety Monitoring Board; has received travel funding from Stryker Neurovascular and Fundacio Ictus; and holds stock/stock options in Silk Road Medical, Anaconda, and Blockade Medical.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 12 2017 Issue

National randomized controlled trial of virtual house calls for Parkinson disease

Published: Monday, 11 Sep 2017 15:00:00 CDT

Show description/summary: 1) National randomized controlled trial of virtual house calls for Parkinson disease 2) Neurology Today: Interview with Joseph Safdieh, the new Editor-in-Chief of Neurology Today® This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 12, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Ray Dorsey about his paper on virtual house calls for Parkinson disease. In the second part of the podcast, Dr. Andy Southerland interviews Dr. Joseph Safdieh about Dr. Safdieh’s new position as Editor in Chief of Neurology Today. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Dorsey has served on the scientific advisory boards of Shire Pharmaceuticals and Huntington's Disease Society of America; has received travel funding and/or honoraria from the American Academy of Neurology and the American Neurological Association; has served on the editorial boards of the Journal of Huntington's Disease, HD Insights, and Digital Biomarkers; has been a consultant for 23andMe, Abbott Nutrition, Abbvie, Amgen, Biogen, Clintrex, GlaxoSmithKline, Grand Rounds, Lundbeck MC10, MedAvante, Medico Legal services, NIH/NINDS Optio, Shire, Sunovion Pharma, Teva, UCB, Voyager Therapeutics, State of Georgia, Mednick Associates, and Putnam Associates; has performed clinical practice, including telemedicine, as a movement disorder neurologist; has received research support from Abbvie, AMC Health, Avid Radiopharmaceuticals, BioMarin, GlaxoSmithKline, Great Lakes Neurotechnologies, Lundbeck, Medtronic, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Teva Pharmaceuticals, National Institute of Neurological Disorders and Stroke, Patient-Centered Outcomes Research Institute, University of California Irvine, Duke University, Burroughs Wellcome Fund, Davis Phinney Foundation, Michael J. Fox Foundation, Safra Foundation, Greater Rochester Health Foundation, Huntington Study Group, and National Science Foundation; holds Grand Rounds and BlackFlynn stock options; and has received compensation for expert testimony. Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Safdieh has served on the scientific advisory board for Upsher Smith; is the Editor-in-Chief of Neurology Today, has received publishing royalties from Elsevier, and has performed consultant work regarding legal proceedings.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 5 2017 Issue

Longitudinal diffusion changes following postoperative delirium in older people without dementia

Published: Monday, 04 Sep 2017 15:00:00 CDT

Show description/summary: 1) Longitudinal diffusion changes following postoperative delirium in older people without dementia 2) What’s Trending: Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 5, 2017 issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Michele Cavallari and Dr. David Alsop about their paper on longitudinal diffusion changes following postoperative delirium in people without dementia. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Barbara Bendlin on poor sleep and biomarkers of amyloid pathology in cognitively normal adults. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Alsop serves as associate editor for Magnetic Resonance in Medicine; has received research support from GE Healthcare Technologies, NIH (P01 AG031720, R01 MH080729, R01 NS047029, R21 EB014471, R01 CA169470, P20 DK108276, R44 DK111260); and receives royalty payments for Patent 7,545,142 (arterial spin labeling with pulsed radio frequency sequences) and from GE Healthcare, Philips Healthcare, Siemens Medical, Hitachi Medical, and Animage Technology. Dr. Cavallari has received research support from NIA (P01AG03172). Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001). Dr. Bendlin serves as associate editor for Journal of Alzheimer's Disease; and has received research support from NIH/NIA (Alzheimer's Disease Connectome Project, U01AG051216, P50 AG033514, R01AG037639, R56AG052698, R21AG053738, P50 AG033514, 1U54AI117924). Dr. Korb reports no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - September 2017

Concussion and Chronic Traumatic Encephalopathy

Published: Thursday, 31 Aug 2017 23:00:00 CDT

The first interview in this month’s Delayed Recall episode is from March 17, 2015; in this interview, Dr. Howard Goodkin and Dr. Robert Stern discuss the effect that age of first exposure to football has on later-life cognitive impairment in former NFL players. The second interview, from August 29, 2017, is a discussion between Dr. Jason Crowell and Dr. Jesse Mez about a July 2017 JAMA paper on occurrence of CTE in American football players. In the third interview, Dr. Christopher Giza speaks with Dr. John Hart about Dr. Hart’s paper regarding depressive symptoms and white matter dysfunction in retired NFL players with concussion history. This interview originally appeared in the July 1, 2013 episode. The fourth and final interview is a discussion between Dr. Ted Burns and former NFL player Ben Utecht, regarding Mr. Utecht’s Sept 23, 2014 editorial, “Concussed.”

download this now episode segments

August 29 2017 Issue

Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome

Published: Monday, 28 Aug 2017 15:00:00 CDT

Show description/summary: 1) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome 2) What’s Trending: CTE and American football players This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 29, 2017 issue of Neurology. In the first segment, Dr. Nicholas Brenton talks with Dr. Kevin Rostásy about his paper on the prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jesse Mez on chronic traumatic encephalopathy and American football players. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Rostásy serves on a scientific advisory board for Novartis regarding a fingolimod project, and has received speaker honoraria for Merck-Serono. Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606). All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 22 2017 Issue

Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome

Published: Monday, 21 Aug 2017 13:00:00 CDT

Show description/summary: 1) Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome 2) Neurology Today: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows Progression This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 22, 2017 issue of Neurology. In the first segment, Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. In the second part of the podcast, Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurology Today® story about the FDA-approval of edaravone for the treatment of ALS. Disclosures can be found at Neurology.org. DISCLOSURES: All participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 15 2017 Issue

Quality improvement in neurology: Inpatient and emergency care quality measure set executive summary

Published: Monday, 14 Aug 2017 13:00:00 CDT

Show description/summary: 1) Quality improvement in neurology: Inpatient and emergency care quality measure set executive summary 2) Neurology Today: Incidental findings and normal variants on MRI of the brain in adults for primary headaches In the first segment, Dr. Jason Crowell talks with Dr. Paul Vespa about his paper on quality improvement in inpatient and emergency neurologic care. In the second part of the podcast, Dr. Teshamae Monteith focuses her interview with Dr. Randolph Evans on a Neurology Today® story about incidental findings and normal variants on brain MRI for primary headache in adults. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Vespa serves on scientific advisory boards for Intouch Health, Edge Pharmaceuticals, and Sage Pharmaceuticals; serves on editorial boards for Critical Care Medicine, Neurocritical Care, and Surgical Neurology International; has consulted for General Electric and Neuren; receives research support from NINDS; holds stock in Intouch Health and stock options in Pfizer; and gave expert testimony about brain trauma. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Crowell and Dr. Evans report no disclosures.

download this now episode segments

August 8 2017 Issue

Barriers and Facilitators to ER Physician Use of the Test and Treatment for BPPV

Published: Monday, 07 Aug 2017 15:00:00 CDT

Show description/summary: 1) Neurology® Clinical Practice: Barriers and Facilitators to ER Physician Use of the Test and Treatment for BPPV 2) What’s Trending: New crowd-funding research initiative from ABF In the first segment, Dr. Jim Siegler talks with Dr. Kevin Kerber and Dr. William Meurer about their Neurology® Clinical Practice article on ER physician use of the test and treatment for benign paroxysmal positional vertigo. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Robert Griggs and Jane Ransom on the new crowd-funding research initiative from the American Brain Foundation. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Siegler serves on the Resident and Fellow Section Team for Neurology, and has received research support from NIH (U10 StrokeNet grant, 2017-2018). Jane Ransom is Executive Director of the American Brain Foundation. Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants. Dr. Meurer serves as Decision Editor for the Annals of Emergency Medicine; serves as Methodology Statistics Reviewer for Academic Emergency Medicine; and has received research support from the Massey Foundation for TBI research. Dr. Griggs has served on scientific advisory boards for National Hospital Queen Square, Marathon Pharmaceuticals, Taro Pharmaceuticals, and Sarepta Pharmaceuticals; has served on the data monitoring and safety board for PTC Therapeutics, Inc.; serves on the editorial board for NeuroTherapeutics and Current Treatment Opinions in Neurology; serves as Correspondence Editor for Neurology; receives publishing royalties from Andreoli and Carpenter’s Cecil Essentials of Medicine (Eighth Edition, Elsevier), Cecil Textbook of Medicine (multiple editions, Elsevier), and Evaluation and Treatment of Myopathies (2014, Oxford); has consulted for Marathon, PTC Therapeutics, Sarepta, Taro Pharmaceuticals, Idera Pharmaceuticals, and Strongbridge Pharmaceuticals; receives data royalties and research support from Taro Pharmaceuticals and Marathon Pharmaceuticals; has received research support from NINDS (T32 NS07338, 5U01NS061799, 1R13NS084687), the FDA (R01 FD003923), Parent Project Muscular Dystrophy, Inc., and the Muscular Dystrophy Association; and is the recent past Chair of Executive Committee of the Muscle Study Group.

download this now episode segments

August 1 2017 Issue

On being sick: Musings about kindness, side effects, and slowing down

Published: Monday, 31 Jul 2017 13:00:00 CDT

Show description/summary: 1) On being sick: Musings about kindness, side effects, and slowing down 2) Resident & Fellow Section Update: Annual Writing Award In the first segment, Dr. Alberto Espay talks with Dr. Ted Burns about his Special Editorial, “On being sick: Musings about kindness, side effects, and slowing down.” In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. John Millichap on the annual Resident & Fellow writing award. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures. Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 25 2017 Issue

Neurology and the Humanities: Discovering the patient within

Published: Monday, 24 Jul 2017 15:00:00 CDT

Show description/summary: 1) Neurology and the Humanities: Discovering the patient within 2) Topic of the Month: immunosuppressants in neurology In the first segment, Dr. Ted Burns talks with Dr. Richard Morton about his Neurology and the Humanities paper, “Discovering the Patient Within.” In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Anne Cross on immunosuppressants in neurology. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Burns serves as a section editor for the Neurology® podcast; serves on advisory boards for Argenx, UCB, and CSL Behring; receives travel or speaker honoraria from Argenx and Alexion; and received support for consulting from UCB Pharma and CSL Behring. Dr. Morton reports no disclosures. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Cross has served on advisory boards for Roche and Genentech; has served on editorial boards for Brain Pathology, Journal of Neuroimmunology, and Annals of Clinical Translational Neurology; receives research support from Roche, Teva Neuroscience, OBOE, NIH, Barnes-Jewish Hospital Foundation, and Conrad N Hilton Foundation; consults with Biogen, Sanofi-Aventis/Genzyme, Novartis, Teva Neuroscience, Gerson Lehrman Group, Guidepoint Global, LLC, AbbVie, EMD Serono, Genentech, and Bayer; and receives honoraria from Projects in Knowledge, Prime Education, Inc., Race to Erase MS, Conrad N. Hilton Foundation, and WebMD.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 18 2017 Issue

Diagnosis of DWI-negative acute ischemic stroke: a meta-analysis

Published: Monday, 17 Jul 2017 15:00:00 CDT

Show description/summary: 1) Diagnosis of DWI-negative acute ischemic stroke: a meta-analysis 2) Topic of the Month: Multiple sclerosis therapeutics and pediatric multiple sclerosis patients This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 18, 2017 issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Brian L. Edlow about his paper on the diagnosis of DWI-negative acute ischemic stroke: a meta-analysis. In the second part of the podcast Dr. Stacey Clardy focuses her interview with Dr. Emmanuelle Waubant on MS therapeutics and pediatric MS patients. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Barrett has served on the editorial boards of both Neurology® and The Neurohospitalist; receives publishing royalities from the book Stroke; and receives research support from NINDS. Dr. Edlow receives research support from Guger Technologies, NIH, American Academy of Neurology/American Brain Foundation, and the James S. McDonnell Foundation. Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Waubant volunteers on a Novartis advisory board; serves on the editorial board of Annals of Clinical and Translational Neurology; serves as editor of MSARD; receives royalties from the publication of the book Demyelinating disorders of the central nervous system in childhood; and receives research support from Roche, Novartis, NIH, National MS Society, and Race to Erase MS.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 11 2017 Issue

Neurology® Neuroimmunology & Neuroinflammation: Antiepileptic drug therapy in patients with Autoimmune Epilepsy

Published: Monday, 10 Jul 2017 13:00:00 CDT

Show description/summary: 1) Neurology® Neuroimmunology & Neuroinflammation: Antiepileptic drug therapy in patients with Autoimmune Epilepsy 3) Topic of the Month: immunotherapy in neurology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 11, 2017 issue of Neurology. In the first segment, Dr. Lara Marcuse talks with Dr. Anteneh Feyissa about his Neurology: Neuroimmunology & Neuroinflammation paper on antiepileptic drug therapy in patients with autoimmune epilepsy. In the second part of the podcast Dr. Stacey Clardy focuses her interview with Dr. Jeffrey A. Cohen on new immunotherapies in neurology. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Cohen has served on scientific advisory boards for Adamas, Celgene, Genentech, Genzyme/Sanofi, Merck, and Novartis; serves as co-editor for Multiple Sclerosis Journal; receives publishing royalties from Multiple Sclerosis Therapeutics (Cambridge University Press, 4th ed., 2011); and has received research support form the Department of Defense, NIH, National MS Society, and Consortium of MS Centers. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 4 2017 Issue

Intake of dairy foods and risk of Parkinson disease

Published: Monday, 03 Jul 2017 13:00:00 CDT

Show description/summary: 1) Intake of dairy foods and risk of Parkinson disease 2) Topic of the Month: Immunotherapies in neurology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 4, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Katherine C. Hughes about her paper on intake of dairy foods and risk of Parkinson disease. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Dennis Bourdette on new immunotherapies in neurology. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Fullard has received training support from NIH. Dr. Hughes received research support from the U.S. Department of Defense. Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Bourdette serves as an editorial board member on Neurology®, receives funding for travel from the National Multiple Sclerosis Society, the Consortium of MS Centers, and the Paralyzed Veterans of America; consults with Magellan Health and is a patient consultant for Best Doctors, Inc.; has a patent and a second patent pending for drug treatments of multiple sclerosis; and serves as a PI for the National MS Society.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - July 2017

Lessons of the Week with Dr. Kait Nevel - Neuro-oncology

Published: Saturday, 01 Jul 2017 07:50:00 CDT

In this month's Delayed Recall episode, we are featuring four interviews by Dr. Kait Nevel on the topic of neuro-oncology. In the first interview, Dr. Nevel speaks with Dr. Jennie Taylor about neuro-oncology and seizures. In the second, she discusses intracranial pressure with Dr. Mariza Daras. These interviews originally appeared in the March 7 and March 14 episodes, respectively. Next, Dr. Nevel and Dr. Lisa DeAngelis talk about metastatic diseases in neurology, in a segment that appeared in the March 21 episode. Last, Dr. Nevel discusses gliomas with Dr. David Schiff in an interview from March 28.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 13 2017 Issue

Evaluating the safety of beta-interferons in MS: A series of nested case-control studies

Published: Monday, 12 Jun 2017 17:00:00 CDT

Show description/summary: 1) Evaluating the safety of beta-interferons in multiple sclerosis 2) Neurology® Today: New Classifications of Seizures and Epilepsies Include New Seizure Types, Simpler Terms This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 13, 2017 issue of Neurology. In the first segment, Dr. Michael Levy talks with Dr. Helen Tremlett and Dr. Hilda De Jong about their paper on evaluating the safety of beta-interferons in multiple sclerosis. In the next part of the podcast Dr. Nathan Fountain focuses his interview with Dr. Robert Fisher on the new classifications of seizures and epilepsies presented by the International League Against Epilepsy. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Levy serves on advisory boards for Asterias, Chugai, and Alexion; serves as Editorial Board member of Multiple Sclerosis and Related Disorders; holds patents for an aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica, and for use of a peptide for diagnostic and therapeutic developments; has consulted for Guidepoint Global, Gerson Lehrman Group, and Cowen Group; and has received research support from Viropharma/Shire, Acorda, ApoPharma and Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT, National Institute of Neurological Diseases and Stroke, and Guthy-Jackson Charitable Foundation. Dr. Tremlett has served on scientific advisory boards for US National MS Society and the Centers for Disease Control and Prevention; is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis; has received research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, Canada Foundation for Innovation, the Multiple Sclerosis Society of Canada, US National Multiple Sclerosis Society, Multiple Sclerosis Scientific Research Foundation, Michael Smith Foundation for Health Research, and the UK MS Trust; has received speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, the National MS Society, ECTRIMS, the Chesapeake Health Education Program, US Veterans Affairs, Novartis Canada, Biogen Idec, American Academy of Neurology. Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort). All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Practice Current: Antiepileptic Drug Discontinuation

Practice Current: Antiepileptic Drug Discontinuation

Published: Monday, 12 Jun 2017 12:15:00 CDT

Delayed Recall - June 2017 In this special Delayed Recall episode, Dr. Luca Bartolini speaks with epilepsy experts Dr. Greg Cascino, Dr. Ali Asadi-Pooya, and Dr. Ley Sander. They discuss the results of a recent Practice Current (a section of Neurology® Clinical Practice) survey regarding antiepileptic drug discontinuation, and share their thoughts on best practices with regard to the case studies presented to the survey respondents. This is the first appearance of this interview in the podcast.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Responsible Opioid Prescribing—Special Podcast #4

Responsible Opioid Prescribing—Special Podcast #4

Published: Monday, 12 Jun 2017 11:30:00 CDT

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 3 and 4, Dr. Andy Southerland interviews Dr. Gary Franklin. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 6 2017 Issue

Post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage

Published: Monday, 05 Jun 2017 17:00:00 CDT

Show description/summary: 1) Post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage 2) Neurology Today® paper on migraine and young adults' risk of cervical artery dissection This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 6, 2017 issue of Neurology. In the first segment, Dr. Rahul Guha talks with Dr. Anna-Maija Lahti about her paper on post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage. In the next part of the podcast Dr. Andrew Southerland talks with Dr. Valeria De Giuli about a Neurology Today® story on migraine and young adults' risk of cervical artery dissection. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 30 2017 Issue

Evidence-based guideline summary: Reducing brain injury following cardiopulmonary resuscitation

Published: Monday, 29 May 2017 17:00:00 CDT

Show description/summary: 1) Evidence-based guideline summary: Reducing brain injury following cardiopulmonary resuscitation 2) Neurology Today® paper: “Prolonged Holter-ECG monitoring found to improve detection of atrial fibrillation after acute stroke” This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 30, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer talks with Dr. Romergryko Geocadin about the AAN practice guideline on reducing brain injury following cardiopulmonary resuscitation. In the next part of the podcast Dr. Matthew Ehrlich focuses his interview with Dr. Rolf Wachter on the Neurology Today feature, “Prolonged Holter-ECG monitoring found to improve detection of atrial fibrillation after acute stroke.” Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Geocadin serves on the DSMB for the PEARL Study: “A Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography for Post-Cardiac Arrest Patients with No ST Segment Elevation on the ECG” funded by the State of Arizona Biomedical Research Commission; serves on editorial boards for Neurocritical Care and Resuscitation; receives research support from NIH (grant R01 HL071568); and is co-author of "Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care." All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 23 2017 Issue

A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study

Published: Tuesday, 23 May 2017 11:00:00 CDT

Show description/summary: 1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study 2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH. Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Responsible Opioid Prescribing—Special Podcast #3

Responsible Opioid Prescribing—Special Podcast #3

Published: Tuesday, 16 May 2017 17:00:00 CDT

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 3 and 4, Dr. Andy Southerland interviews Dr. Gary Franklin from the University of Washington. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 16 2017 Issue

Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE

Published: Monday, 15 May 2017 17:00:00 CDT

Show description/summary: 1) Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE 2) Neurology Today® paper on a new guideline for preventing, diagnosing, and treating diabetic neuropathy This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 16, 2017 issue of Neurology. In the first segment, Dr. Justin Sattin talks with Dr. Yilong Wang about his paper on risks and benefits of clopidogrel-aspirin in minor stroke. In the next part of the podcast Dr. Michelle Mauermann focuses her interview with Dr. Rodica Pop-Busui on diabetic neuropathy. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Wang receives research support from the Ministry of Science and Technology of the People's Republic of China (No. 2011BAI08B02) and the National Natural Science Foundation of China (No. 81322019). Dr. Mauermann serves on the editorial board for Mayo Clinic Proceedings; receives publishing royalties from Autonomic Neurology (Oxford 2015); and receives research support from Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceauticals. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 9 2017 Issue

Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports

Published: Monday, 08 May 2017 17:00:00 CDT

Show description/summary: 1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports 2) What's Trending: Biomarker validation and precision medicine in Parkinson disease. This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Responsible Opioid Prescribing—Special Podcast #2

Responsible Opioid Prescribing—Special Podcast #2

Published: Wednesday, 03 May 2017 17:00:00 CDT

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Responsible Opioid Prescribing—Special Podcast #1

Responsible Opioid Prescribing—Special Podcast #1

Published: Wednesday, 03 May 2017 10:00:00 CDT

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 2 2017 Issue

Outcome of intracerebral hemorrhage associated with different oral anticoagulants

Published: Tuesday, 02 May 2017 17:00:00 CDT

Show description/summary: 1) Outcome of intracerebral hemorrhage associated with different oral anticoagulants 2) Neurology Resident & Fellow section yearly recruitment This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 2, 2017 issue of Neurology®. In the first segment, Dr. Andrew Southerland talks with Dr. David Werring about his paper on outcome of intracerebral hemorrhage with oral anticoagulants. Then, for our “What's Trending” feature of the week, Dr. Southerland focuses his interview with Dr. John Millichap on recent updates regarding the Neurology Resident & Fellow section. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Werring has served on scientific advisory boards for Allergan, Bayer, IXICO, and Amgen; has received speaker honoraria from Bayer; has served on the editorial board of the European Stroke Journal; has received publishing royalties from Cambridge University Press; has been a consultant for Ixico Ltd.; and has received research support from Pfizer, the Department of Health/Higher Education Funding Council For England, the Stroke Association/British Heart Foundation, and the Rosetrees Trust. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 18 2017 Issue

Epidemiology and Prognosis of Mild Traumatic Brain Injury in Returning Soldiers: A Cohort Study

Published: Monday, 24 Apr 2017 17:00:00 CDT

Show description/summary: 1) Epidemiology and Prognosis of Mild Traumatic Brain Injury in Returning Soldiers: A Cohort Study 2) What's Trending: Alemtuzumab treatment and multiple sclerosis This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 18, 2017 issue of Neurology. In the first segment, Dr. Michael Jaffee talks with Dr. Karen Schwab about her paper on mild traumatic brain injury in returning soldiers. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Gavin Giovannoni about his paper on alemtuzumab treatment and multiple sclerosis. For more information on traumatic brain injury services for active duty military and veterans, please visit the Defense and Veterans Brain Injury Center website at http://dvbic.dcoe.mil. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Jaffee serves on the scientific advisory board for Neurohabitation, Inc., and has received research support from the Florida State Department of Elderly Affairs. Dr. Schwab receives research support from Congressionally Directed Medical Research Programs (Grant #W81XWH-08-2-0105). Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; served as eMedicine Chief Editor from 2009 to 2015; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press 2016); consults for Novartis, Bristol Meyers Squibb, and Bionest; and received research support from Biogen for the ARISE study. Dr. Giovannoni consulted and served on scientific advisory boards for Biogen-Idec, Fiveprime, Genzyme, GW Pharma, Ironwood, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex Pharmaceuticals, Abbvie, and Canbex; receives speaker honoraria from Biogen-Idec, Genzyme, GW Pharma, Merck-Serono, Novartis, Roche, and Teva Pharmaceuticals; serves as an editor for Multiple Sclerosis and Related Disorders; served on speaker's bureaus for Novartis and Teva; and received research support from Genzyme and Merck.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 25 2017 Issue

Practice guideline summary: Sudden unexpected death in epilepsy

Published: Monday, 24 Apr 2017 17:00:00 CDT

Show description/summary: 1) Practice guideline summary: Sudden unexpected death in epilepsy 2) What's Trending: 21st Century Cures Act This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 25, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer interviews Dr. Cynthia Harden about the AAN practice summary guideline on sudden unexpected death in epilepsy (SUDEP). Then, for our “What's Trending” feature of the week, Dr. Jason Crowell talks with Dr. Nicholas Johnson about the 21st Century Cures Act. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Johnson serves as Associate Editor for Neurology: Genetics; receives research support from Ionis Pharmaceuticals, Biogen Idec, Balerion Therapeutics, Cytokinetics, Acceleron, NINDS (grant 1K23NS091511-01), Muscular Dystrophy Association, and Myotonic Dystrophy Foundation; and consults for AMO Pharma and AveXis. Dr. Schomer, Harden, and Crowell report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 11 2017 Issue

Intracerebral hemorrhage location and outcome among INTERACT2 participants

Published: Monday, 10 Apr 2017 17:00:00 CDT

Show description/summary: 1) Intracerebral hemorrhage location and outcome among clinical trial participants 2) What's Trending: childhood amnesia This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 11, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer talks with Dr. Craig Anderson about his paper on intracerebral hemorrhage location and outcome among clinical trial participants. Then, for our “What's Trending” feature of the week, Dr. Ted Burns talks with Dr. Cristina Alberini about her paper on childhood amnesia. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Anderson served on scientific advisory boards for Astra Zeneca and Medtronic; receives honoraria and travel funding from Takeda China and Boehringer Ingelheim; serves on editorial boards for Stroke, Cerebrovascular Diseases, and International Journal of Stroke; and receives research support from the National Medical Research Council of Australia (grants 1052555, 1020462, and 1081356). Dr. Alberini serves on editorial boards for Neural Plasticity, Journal of Cell Science, Frontiers in Neuroscience, Neurobiology of Learning and Memory, Behavioral Neuroscience, Learning and Memory, European Brain Research Institute (EBRI) International Scientific Council (ISC), and Cellular and Molecular Neuroscience of Hippocampus. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - April 2017

Motor neuron disorders

Published: Tuesday, 04 Apr 2017 14:30:00 CDT

Motor neuron disorders

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 4 2017 Issue

Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis

Published: Monday, 03 Apr 2017 17:00:00 CDT

Show description/summary: 1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis 2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson disease Our podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today. This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 28 2017 Issue

Early Decompressive Craniectomy for Malignant Cerebral Infarction: Meta-analysis and Clinical Decision Algorithm [NCP]

Published: Monday, 27 Mar 2017 17:00:00 CDT

1) Early Decompressive Craniectomy for Malignant Cerebral Infarction: Meta-analysis and Clinical Decision Algorithm 2) What's Trending: Update on the Resident and Fellows section 3) Topic of the Month: Brain tumors - gliomas This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 28, 2017 issue of Neurology. In the first segment, Dr. Bryan Eckerle talks with Dr. Bradley Molyneaux and Dr. Christopher Streib about their Neurology® Clinical Practice paper on early decompressive craniectomy for malignant cerebral infarction. Dr. Ted Burns talks with Dr. Roy Strowd about recent updates regarding the Neurology® Resident & Fellows section for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Kait Nevel focuses her interview with Dr. David Schiff on gliomas. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Molyneaux has received research support from Remedy Pharmaceuticals, Inc. Dr. Streib has served on the Institute for Clinical Systems Improvement (ICSI) Stroke Guidelines Committee (no reimbursement). Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology. Dr. Schiff has served on the scientific advisory boards of Genetech, Celldex, Orbus, and Vascular Biogenics Oxigene; has received travel funding/speaker honoraria from Merck; serves on the editorial boards of Neurology, Neurosurgery, Neuro-Oncology, and Lancet Neurology; receives publishing royalties from UpToDate, and has been a consultant for Cavion. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 21 2017 Issue

Pure autonomic failure: Predictors of conversion to clinical CNS involvement

Published: Monday, 20 Mar 2017 17:00:00 CDT

1) Pure autonomic failure: Predictors of conversion to clinical CNS involvement 2) What's Trending: ocrelizumab in multiple sclerosis 3) Topic of the Month: neuro-oncology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 21, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff interviews Dr. Wolfgang Singer about his paper on pure autonomic failure. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Stephen Hauser about his paper on ocrelizumab in multiple sclerosis. In the next part of the podcast Dr. Kait Nevel focuses her interview with Dr. Lisa DeAngelis on metastatic disease. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Singer serves as Associate Editor for Clinical Autonomic Research; serves on the Autonomic Neuroscience: Basic and Clinical editorial board; holds a patent for use of 3,4 diaminopyridine in the treatment of orthostatic hypotension and postural tachycardia syndrome; received research support from NH, FDA, Cure MSA Foundation, Dysautonomia International, and American Dysautonomia Institute. Dr. Keegan serves on editorial boards for eMedicine (Chief Editor 2009-2015) and Multiple Sclerosis and Related Disorders; receives publishing royalties from Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning Cambridge University Press 2016; consulted for Novartis, Bristol Meyers Squibb, and Bionest Partners; and received research support from Terumo Corporation and BCT International Ltd. Dr. Hauser serves on scientific advisory boards for Bionure, Annexon, Symbiotix, Neurona, and Molecular Telescope; receives publishing royalties from Harrison's Principles of Intervnal Medicine (McGraw Hill 1994); holds stock options in Bionure, Annexon, Symbtiotix, all of which were transferred to University of California – San Francisco; and received funding from NIH, National Multiple Sclerosis Society, and the Conrad Hilton Foundation. Dr. DeAngelis serves on scientific advisory board for Celgene and CarThera; serves on editorial boards for Neurology, Neuro-Oncology, Journal of Neuro-oncology, and Neuro-Oncology Practice; receives publishing royalties from The Neurologic Complications of Cancer (Oxford University Press 2008); and receives research support from NIH. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 14 2017 Issue

Moderators and Predictors of Response to Behavior Therapy for Tics in Children and Adults with Tourette’s Disorder

Published: Monday, 13 Mar 2017 17:00:00 CDT

1) Moderators and Predictors of Response to Behavior Therapy for Tics in Children and Adults with Tourette's Disorder 2) What's Trending: Exercise and VCI 3) Topic of the Month: Neuro-oncology and ICP This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 14, 2017 issue of Neurology®. In the first segment, Dr. John Mytinger talks with Dr. Denis Sukhodolsky and Dr. Lawrence Scahill about their paper on therapy for tics in children and adults with Tourette's Disorder. For our “What's Trending” feature of the week, Dr. Ted Burns talks with Dr. Teresa Liu-Ambrose about her paper on exercise and vascular cognitive impairment. In the next part of the podcast, Dr. Kait Nevel focuses her interview with Dr. Mariza Daras on neuro-oncology and intracranial pressure. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Sukhodolsky has received travel funding/speaker honoraria from the Tourette Association of America; has served on the editorial board of the Journal of Autism and Developmental Disabilities; receives publishing royalties from Guilford Press; notes that 5% of his effort is dedicated to providing clinical care at the Yale TS clinic (including the form of behavior therapy for tics (CBIT) that was tested in the study reported in the previously noted paper); and has received research support from NMH. Dr. Scahill has served on the scientific advisory boards of Roche, Neuren, and Supernus; has received gifts from Bracket; has served on the editorial boards of the Journal of Child & Adolescent Psychopharmacology and the International Journal of Developmental Disabilities; receives publishing royalties from Oxford and Guilford; and has received research support from the Department of Defense and NIMH. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Liu-Ambrose has received travel funding and speaker honoraria from the Resistance Training Conference and the Traumatic Brain Injury Conference; serves on the editorial boards of the British Journal of Sports Medicine, the Physical Therapy Journal, and the Journal of Cognitive Enhancement; has been a consultant for a project entitled The Average Human (funded by Wellcome Trust); has been involved with operations for Synaptitude Inc.; and has received research support from the Canadian Stroke Network. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 7 2017 Issue

Neurology® Genetics: Clinical and Genetic Study of Hereditary Spastic Paraplegia in Canada

Published: Monday, 06 Mar 2017 17:00:00 CDT

1) Neurology® Genetics: Clinical and Genetic Study of Hereditary Spastic Paraplegia in Canada 2) What's Trending: Subarachnoid hemorrhage and smoking rates 3) Topic of the Month: Neuro-oncology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 7, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Nicolas Chrestian about his Neurology® Genetics paper on hereditary spastic paraplegia in Canada. For our “What's Trending” feature of the week, Dr. Ted Burns talks with Dr. Miikka Korja about his paper on subarachnoid hemorrhage and smoking rates. In the next part of the podcast Dr. Kathryn Nevel focuses her interview with Dr. Jennie Taylor on seizure management in neuro-oncology patients. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - March 2017

Movement Disorders

Published: Tuesday, 28 Feb 2017 17:00:00 CDT

The first interview is with Dr. Michelle Fullard and Dr. John Winkleman on the topic of RLS and RLS treatment. The second is with Dr. Jeff Ratliff and Dr. Anhar Hassan on orthostatic tremor. These interviews originally appeared on December 13, 2016 and February 2, 2016, respectively. In the third week's interview, originally released on June 7, 2016, Dr. Fullard talks with Dr. Mark LeDoux on the topic of cervical dystonia. In the fourth and final interview, from September 27, 2016, Dr. Ted Burns speaks with Mrs. Susan Schneider Williams about her late husband Robin Williams's Lewy Body Disease.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 28 2017 Issue

Symptoms from Repeated Intentional and Unintentional Head Impact in Soccer Players

Published: Monday, 27 Feb 2017 17:00:00 CDT

1) Symptoms from Repeated Intentional and Unintentional Head Impact in Soccer Players 2) What's Trending: Infantile amnesia and hippocampal learning 3) Topic of the Month: Neurology Today® paper on pulmonary embolism This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 28, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Michael Lipton about his paper on repeated head impact in soccer players. Dr. Ted Burns talks with Dr. Cristina Alberini about her Nature Neuroscience paper on infantile amnesia and hippocampal learning for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Sofia Barbar on a Neurology Today story about her article on pulmonary embolism. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Lipton has served on the scientific advisory boards of Guerbet and Bracco; has served on the editorial boards of the American Journal of Neuroimaging and Brain Imaging and Behavior; holds a patent on EZ-MAP image processing software; receives publishing royalties from Springer; has been a consultant for Bracco; and has received research support from Philips Medical Systems, NIH/NINDS, NIH/NIA, NIH/NICHD, the Dana Foundation, and the Resurrecting Lives Foundation. Dr. Finkel has served on the scientific advisory boards of Families of SMA, Nationwide Children's Hospital, SMA Europe, Pediatric Neuromuscular Clinical Research Network, and SMA REACH (UK); has received travel funding from Families of SMA, SMA Foundation, and the Muscular Dystrophy Association; has received travel funding and speaker honoraria from Ionis Pharmaceuticals; serves on the editorial boards of Neuromuscular Disorders and the Journal of Neuromuscular Diseases (additionally, spouse serves on editorial board of Arthritis Research and Therapy); his spouse holds patents for Mouse Anti-TCR Zeta Antibody to Southern Biotechnology Associate, Anti-Human TCR Zeta mAb to Upstate Pharmaceuticals, and Anti-Human TCR Zeta mAb to Santa Cruz Biotechnology; he receives publishing royalties from Elsevier; has been a consultant for Ionis Pharmaceuticals, Biogen, Roche, Novartis, Motobridge, Capricor, Lilly, and Summit; spends approximately 30% of his time working with spinal muscular atrophy patients; has received research support from Isis Pharmaceuticals, Biogen, Eli Lilly Pharmaceuticals, Cytokinetics, RevereGen, BMS, Summit, Sarepta, NIH, the Spinal Muscular Atrophy Foundation, Families of Spinal Muscular Atrophy, the Muscular Dystrophy Association, and the Charcot-Marie-Tooth Association; and his spouse receives licensing fee payments for aforementioned patents. All other participants have no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 21 2017 Issue

Neurology® Neuroimmunology & Neuroinflammation: Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes

Published: Monday, 20 Feb 2017 17:00:00 CDT

1) Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes 2) What's Trending: video gaming in children 3) Topic of the Month: Neurology Today® paper on mitochondrial replacement This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Hugh Willison about his Neurology® Neuroimmunology & Neuroinflammation paper on microarray screening of autoantibodies to glycolipid complexes in Guillain-Barre syndrome. Dr. Ted Burns talks with Dr. Gerard Martínez Vilavella about video gaming in children for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Shoukhrat Mitalipov on mitochondrial replacement for genetic diseases. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Willison serves on the scientific advisory board for Wellcome Trust; serves on editorial boards for Nature Clinical Practice Neurology; Journal of Neuroimmunology, Muscle and Nerve, J Peripheral Nervous System, BMC Neurology (Associate Editor), Clinical and Experimental Neuroimmunology, and Experimental Neurology; holds a patent for combinatorial glycoarray technology; and receives research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., Medical Research Council, and Wellcome Trust. Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer” (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 14 2017

Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review

Published: Monday, 13 Feb 2017 17:00:00 CDT

1) Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review 2) What's Trending: CRISPR gene editing in neuromuscular diseases 3) Neurology Today® paper – spotlight on Dr. John Noseworthy This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 14, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Hugh Markus about his paper on the prognosis of carotid dissecting aneurysms. For our "What's Trending" feature of the week, Dr. Ted Burns interviews Dr. Eric Olson regarding CRISPR at the 2016 AANEM meeting. In the next part of the podcast, Dr. Ted Burns speaks with Mayo Clinic CEO Dr. John Noseworthy about his meeting with President Trump and his experience as Editor-in-Chief of Neurology. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Markus has served on the editorial boards of the International Journal of Stroke, Clinical Neurology and Neurosurgery, BMC Medicine, and Frontiers in Neurology; receives publishing royalties from Oxford University Press; has received reimbursement from Astra Zeneca for teaching a session to employees; and has received research support from NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing. Dr. Noseworthy receives publishing royalties for the following publications: Fifty Neurologic Cases, Oxford, 2004, Multiple Sclerosis 2, Blue Books; Butterworth, 2003, Neurologic Therapeutics, Edition 1, Martin Dunitz, 2003, Neurologic Therapeutices, Edtion 2, Informa, 2006, McAlpine's Multiple Sclerosis, 4th Edition, 2006. All other participants have no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 7 2017 Issue

Dystonia treatment: patterns of medication use in an international cohort

Published: Monday, 06 Feb 2017 17:00:00 CDT

1) Dystonia treatment: patterns of medication use in an international cohort 2) What's Trending: Without Borders global neurology site 3) Topic of the Month: Neurology Today® paper on the expansion of teleneurology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 7, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Sarah Pirio Richardson about her paper on patterns of medication use in dystonia treatment. Dr. Ted Burns talks with Dr. Gretchen Birbeck about the Without Borders global neurology site for our “What's Trending” feature of the week. In the next part of the podcast Dr. Andy Southerland focuses his interview with Dr. Larry Wechsler on a Neurology Today® story about the expansion of teleneurology. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Willison serves on a scientific advisory board and receives research support from Wellcome Trust; possesses a patent for combinatorial glycoarray technology; and has received research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., and the Medical Research Council. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Pirio Richardson receives research support from the NIH. Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Birbeck serves on scientific advisory board for Lift the Burden Global Campaign against Headache Board; curates the Neurology®: Without Borders site; and receives research support from the NIH. Dr. Wechsler serves on scientific advisory boards for Remedy Pharmaceuticals, Inc., Forest Devices, and Silk Road Medical, Inc.; receives research support from NIH/NINDS and Athersys, Inc., and SanBio Co. Ltd.; provides telestroke services through UPMC Telemedicine network; and holds stock options in Silk Road Medical, Inc. Remedy Pharmaceuticals, Inc., and Forest Devices. Dr. Ratliff reports no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall February 2017

Delayed Recall February 2017

Published: Tuesday, 31 Jan 2017 17:00:00 CDT

CDC guidelines on prescribing opioids

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 31 2017 Issue

Progressive rural-urban disparity in acute stroke care

Published: Monday, 30 Jan 2017 17:00:00 CDT

Show description/summary: 1) Progressive rural-urban disparity in acute stroke care 2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topics This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 31, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Allison Willis about her paper on disparities in stroke care between rural and urban areas. Dr. Ted Burns talks with Dr. Eric Olsen regarding CRISPR at the 2016 AANEM meeting for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Merit Cudkowicz on amyotrophic lateral sclerosis (ALS). Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Allison Willis has served on the editorial board of Pharmacoepidemiology and Drug Safety; and has received research support from NIH/NINDS. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing. Dr. Merit Cudkowicz has served on the editorial board of DSMB AstraZenica (through Clintrex); has served on the editorial boards of Neurotherapeutics and JAMA Neurology; holds a patent for Metabolomics in ALS; receives publishing royalties from UpToDate; has been a consultant for Cytokinetics, Biogen-Idec, Voyager, Biohaven, Astrazenica, Genentech, Karyopharm, and Neuraltis; has received research support from NINDS, the Muscular Dystrophy Association, the ALS Association, and the ALS Finding a Cure Association; and has provided expert witness for defense (TEVA). All other participants have no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 24 2017 Issue

Relationship between Risk Factor Control and Vascular Events in the SAMMPRIS Trial

Published: Monday, 23 Jan 2017 17:00:00 CDT

1) Relationship between Risk Factor Control and Vascular Events in the SAMMPRIS Trial 2) What's Trending: 2017 AAN Annual Meeting 3) Topic of the Month: neuromuscular medicine This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 24, 2017 issue of Neurology. In the first segment, Dr. Joseph Carrera talks with Dr. Tanya Turan about her paper on risk factor control and vascular events in the SAMMPRIS trial. Dr. Ted Burns talks with Christy Phelps about the 2017 AAN Annual Meeting for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Anthony Amato on myositis. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Turan serves on a scientific advisory board for Boehringer Ingelheim; serves on blinded Neurological Events Adjudication Committees for Boehringer Ingelheim and W.L. Gore and Associates; is Review Editor for Frontiers in Endovascular and Interventional Neurology and specialty editor of Frontiers in Neurology; serves on editorial boards for World Journal of Neurology, Brain and Behavior, and Annals of Translational Medicine; and received research support from NIH/NINDS K23 award for activities in the SAMMPRIS trial. Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Amato serves on medical advisory boards for MedImmune, Amgen, Novartis, DART, Biogen, Acceleron, and DSMB for NIH; is Associate Editor for Neurology and Muscle & Nerve; possesses publishing royalties for Neuromuscular Disease (McGraw-Hill 2016); serves as medical consultant for MedImmune, Amgen, Biogen, Novartis, Acceleron, Analgesic Solutions, Up-to-Date, and Best Doctors; and receives research support from Novartis, Alexion, and Amgen. Christy Phelps serves as Deputy Executive Director for the AAN. Dr. Carrera reports no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 17 207 Issue

Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome

Published: Monday, 16 Jan 2017 17:00:00 CDT

1) Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome 2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topics This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 17, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Aneesh Singhal about his paper on glucocorticoid-associated worsening of reversible cerebral vasoconstriction syndrome. Dr. Ted Burns talks with Dr. Roy Strowd about upcoming changes regarding the Neurology Resident & Fellow section for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Volker Straub on limb-girdle dystrophy. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Aneesh Singhal has served on the scientific advisory boards of Biogen and DSMB; has served on the editorial board of Medical Gas Research; has received publishing royalties for the book Reversible Cerebral Vasoconstriction Syndromes; has been a consultant to Biogen; has acted as an event adjudicator for the Thrombolysis in Myocardial Infarction (TIMI) Trial Group; has received research support from Boehringer Ingelheim, NIH-NINDS, the American Academy of Neurology, UpToDate, and Medlink; and has served as a medicolegal expert witness for individual cases concerning stroke. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Straub has served on the scientific advisory boards for Pfizer, Italfarmaco, Audentes Therapeutics, Bristol-Myer Squibb, Summit Therapeutics, Tivorsan, and the Nationwide Children's Hospital; has received travel funding and speaker honoraria from Sanofi Genzyme; has served on the editorial boards of Neuromuscular Disorders, the Journal of Neuromuscular Diseases, and PLoS Currents Muscular Dystrophy; has been a consultant for Sanofi Genzyme; and has received research support from Sanofi Genzyme, BioMarin, Ionis Pharmaceuticals, Sarepta Therapeutics, Ultragenyx, the European Commission, the UK Medical Research Council, Newcastle University, the Parent Project Muscular Dystrophy, the Association Fracaise Contre les Myopathies, the LGMD2I Research Fund, the Wellcome Trust, the Sylvia Aitken Charitable Trust, Muscular Dystrophy UK, and Action Medical Research. All other participants have no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 10 2017 Issue

A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington’s Disease

Published: Monday, 09 Jan 2017 17:00:00 CDT

1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy 3) Topic of the Month: Neuromuscular medicine This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Gil Wolfe on myasthenia gravis. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. McGarry serves on an advisory board for Teva Pharmaceutical Industries, Ltd.; receives speaker honoraria for Teva Pharmaceutical Industries, Ltd. and ACADIA Pharmaceuticals, Inc.; and has received research support from Teva Pharmaceutical Industries, Ltd. and NINDS. Dr. Ramchandren received research support from the NIH. Dr. Wolfe advises for Grifols, Baxalta, Argenx, and UCB; receives speaker honoraria for Grifols and Baxalta; receives research support from CSL Behring; and serves as Associate Editor for Muscle and Nerve. Dr. Fullard reports no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 3 2017 Issue

The Effects of Orthostatic Hypotension on Cognition in Parkinson's Disease

Published: Monday, 02 Jan 2017 17:00:00 CDT

1) The Effects of Orthostatic Hypotension on Cognition in Parkinson's Disease 2) What's Trending: Carotid surgery trials 3) Topic of the Month: Neuromuscular topics This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Justin Centi about his paper on the effects of orthostatic hypotension on cognition in Parkinson disease. Dr. Andy Southerland is interviewing Dr. Seemant Chaturvedi for our “What's Trending” feature of the week about urgency for carotid surgery trials. In the next part of the podcast, Dr. Ted Burns interviews Dr. Michelle Mauermann about neuromuscular topics. Disclosures can be found at www.neurology.org. DISCLOSURES: Dr. Barrett has received research support from Axovant Sciences, Inc., the Virginia Center of Alzheimer's and Related Diseases, and the Department of Defense. Dr. Centi has been an employee of Commonwealth Psychology Associates LLC and Harvard Medical School/Partners Consortium in Neuropsychology; and has received research support from NIH-NINDS. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Chaturvedi has been a consultant for Merck; has served on the executive committee of ACT I study and CREST 2 study; serves on the editorial boards of Neurology, the Journal of Stroke & Cerebrovascular Disease, Stroke, and NEJM Journal Watch Neurology; has received research support from Boehringer-Ingelheim, NINDS, and the FDA; and has received compensation for expert witness testimony. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties for book Autonomic Neurology; and receives research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals. All other participants have no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall January 2017

Movement Disorders

Published: Saturday, 31 Dec 2016 17:00:00 CDT

The first interview is with Dr. Jeff Ratliff and Dr. Kailash Bhatia on the topic of dystonia. The second is with Dr. Alberto Espay and Dr. Roger Elble on tremor. These interviews were first released on November 1 and November 8, 2016. In the third week's interview, originally released on November 15, 2016, Dr. Alberto Espay interviews Don Gilbert on tics. In the fourth interview, from November 22, 2016, Dr. Ratliff speaks with Dr. Ruth Walker about chorea. The fifth and final interview, originally released on November 29, 2016, is an interview with Dr. Espay and Dr. Steven Frucht on the topic of myoclonus.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 13 2016 Issue

Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Published: Monday, 12 Dec 2016 17:00:00 CDT

1) AAN guideline summary: Treatment of restless legs syndrome in adults 2) What's Trending: Interview with Dr. Steven Messé on why acute ischemic stroke patients are not receiving IV tPA 3) Topic of the month: Neurology Today story about cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out for This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. John Winkelman about the AAN guideline summary on the treatment of restless legs syndrome in adults. Dr. Andy Southerland is interviewing Dr. Steven Messé for our “What's Trending” feature of the week about his paper on why are acute ischemic stroke patients not receiving IV tPA. In the next part of the podcast Dr. Ted Burns interviews Drs. Kevin Messacar and Ken Tyler about a Neurology Today story on the topic on cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out for. DISCLOSURES: Dr. Winkelman serves as Associate Editor for Sleep; serves as an editorial board member of Sleep Medicine and CNS Drugs; received honoraria from serving on the scientific advisory board of Merck Serono, Flex Pharma, UCB, Impax Pharmaceuticals, Pfizer Inc, Lacrima, Luitpold Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Xenoport, Zeo Inc., Sunovion, Insys, Takeda Pharmaceutical Company Limited, Jazz and Neurogen; receives royalties from the publication of the books: Foundations of Psychiatric Sleep Medicine and Nocturnal Leg Cramps; holds stock options in Flex Pharma; provided expert witness work for ArentFox and CantorColburn; received funding for travel from Novartis and Otsuka; currently performs neurophysiology studies as part of his practice;receives research support from Xenoport, GlaxoSmithKline, UCB, Sepracor, Pfizer Inc, Impax Pharmaceuticals, Purdue, Neurometrix and the NIH. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Messé received publishing royalties from UpToDate; received compensation from GlaxoSmithKline for consulting on protocol development for a trial of a neuroprotectant in high risk surgery; received research support from GlaxoSmithKline, Bayer Schering Pharma, WL Gore and the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for PML Consortium; is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from the NIH. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 6 2016 Issue

Systematic review and statistical analysis of the integrity of 33 randomized controlled trials

Published: Monday, 05 Dec 2016 17:00:00 CDT

1) Systematic review and statistical analysis of the integrity of 33 randomized controlled trials 2) What's Trending: Interview with Dr. Neil Garrett about his Nature Neuroscience article on dishonesty. 3) Topic of the month: Neurology Today story about Zika virus and Guillain Barre syndrome detected in Columbia This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Mark Bolland about his paper on the systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Dr. Ted Burns is also interviewing Dr. Neil Garrett for our “What's Trending” feature of the week about his Nature Neuroscience paper on dishonesty. In the next part of the podcast Dr. Ted Burns interviews Dr. Carlos Pardo about a Neurology Today story on the topic of Zika virus and Guillain Barre syndrome detected in Columbia. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Bolland receives research support from the Health Research Council of New Zealand. Dr. Pardo receives research support from Bart McLean Fund for Neuroimmunology Research-Project Restore and the NIH. All other participants report no disclosures.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - December 2016

Neurological topics related to genetics

Published: Thursday, 01 Dec 2016 12:25:00 CDT

Neurological topics related to genetics

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 29 2016 Issue

Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis

Published: Monday, 28 Nov 2016 17:00:00 CDT

1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis 2) e-Pearl topic: Hemiplegic migraine 3) Topic of the month: How to examine and approach movement disorders This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus. DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards. Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 22 2016 Issue

Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project

Published: Monday, 21 Nov 2016 17:00:00 CDT

1) Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project 2) e-Pearl topic: Transthyretin familial amyloid polyneuropathy 3) Topic of the month: How to examine and approach movement disorders This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Lynda Lisabeth about her paper on temporal trends in tissue plasminogen activator administration for acute ischemic stroke. Dr. Ilena George is reading our e-Pearl of the week about transthyretin familial amyloid polyneuropathy. In the next part of the podcast Dr. Jeff Ratliff interviews Dr. Ruth Walker on the topic of chorea. DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publication of the book Stroke and editing the book Neurology in Practice; and receives research support from the NIH. Dr. Lisabeth receives research support from the NIH. Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Walker is a consultant for Neurocrine Biosciences, Inc.; assists with Audio-Digest Board Reviews; received funding for travel from Korean Movement Disorders Society and honoraria from Neurocrine Biosciences, Inc.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 15 2016 Issue

Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy

Published: Monday, 14 Nov 2016 17:00:00 CDT

1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy 2) e-Pearl topic: Alien limb phenomenon 3) Topic of the month: How to examine and approach movement disorders This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics. DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH. Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 8 2016 Issue

Progression of brain atrophy in PSP and CBS over six months and one year

Published: Monday, 07 Nov 2016 17:00:00 CDT

1) Progression of brain atrophy in PSP and CBS over six months and one year 2) What's Trending: Interview with Mike Amery about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act 3) Topic of the month: How to examine and approach movement disorders This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Adam Boxer about his paper about on progression of brain atrophy in progressive supranuclear palsy and corticobasal syndrome. Dr. Ted Burns is interviewing Mike Amery for our “What's Trending” feature of the week about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act. In the next part of the podcast Dr. Alberto Espay interviews Dr. Rodger Elble on the topic of “how to approach” tremor disorders. DISCLOSURES: Dr. Morgan is a consultant for Impax, Lundbeck Inc., National Parkinson Foundation, Teva Pharmaceutical Industries Ltd., and Veloxis; serves on the speakers' bureau of Impax and Teva Pharmaceutical Industries Ltd.; received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic co; receives research support from National Parkinson Foundation, Parkinson's Outcome Project Grant and the NIH. Dr. Boxer serves on the scientific advisory board for Alector, Asceneuron and Delos; received funding for travel from the International Society for CNS Clinical Trials Methodology, the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium; is a consultant for Abbvie, Ionis, Janssen and Merck Serono; holds stock options in Alector and Delos; receives research support from Avid, Biogen Idec, BMS, C2N, Cortice, Forum, Genentech, Inc., Janssen, Pfizer Inc, Eli Lilly and Company, Roche, TauRx, The Tau Research Consortium, the Bluefield Project, Corticobasal Degeneration Solutions, the Alzheimer's Association and the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Amery is employed as Legislative Counsel for the American Academy of Neurology. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Elble receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Phytopharm, Pfizer Inc, Ortho-McNeil, Spastic Paralysis Research Foundation of Kiwanis International, Illinois-Eastern Iowa District and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall November 2016

Neurology Today articles on the topic of stroke.

Published: Tuesday, 01 Nov 2016 13:00:00 CDT

Neurology Today articles on the topic of stroke.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 1 2016 Issue

School aged cognition in children exposed to levetiracetam, topiramate or sodium valproate

Published: Monday, 31 Oct 2016 17:00:00 CDT

1) School aged cognition in children exposed to levetiracetam, topiramate or sodium valproate 2) What's Trending: Interview with David Spencer about his book titled: “Navigating life with epilepsy” 3) Topic of the month: How to examine and approach movement disorders This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Rebecca Bromley about her paper about school aged cognition in children exposed to levetiracetam, topiramate or sodium valproate. Dr. Ted Burns is interviewing Dr. David Spencer for our “What's Trending” feature of the week about his recently published Neurology Now book titled: “Navigating life with epilepsy.” In the next part of the podcast Dr. Jeff Ratliff interviews Prof. Kailash Bhatia on the topic of “how to approach” dystonia. DISCLOSURES: Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort). Dr. Bromley provided expert testimony regarding fetal valproate syndrome in the UK; although this case did not go to court and received research support from Epilepsy Research UK. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Spencer serves as Patient Page Editor for Neurology®, including past 2 years EMedicine, Chief Editor, Journal of Behavior and Brain Science, Associate Editor Neurology Now, Professional Advisory Board, including past 2 years Epilepsy Currents: Contributing editor; received honorariafrom NeuroPace Inc.; receives research support from NeuroPace, Inc., Upsher-Smith Laboratories, Inc., and Acorda; and was a consultant in a legal case. Prof. Bhatia serves as Co-Editor in Chief for Movement disorders Clinical Practice, serves as an Associate Editor for Movement Disorders, serves as an editorial board member of Therapeutic Advances in Neurological Disorders; received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceuticals Ltd, received honoraria from GlaxoSmithKline, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Ipsen Pharmaceuticals, Inc., MerzPharmaceuticals, LLC; receives royalties from the publication of Oxford Specialist Handbook of Parkinson's Disease and Other Movement Disorders, Marsdens book of Movement disorder, Lancet Neurology review article; receives research support from Wellcome Trust MRC strategic neurodegenerative disease initiative award, Parkinson's UK, Dystonia Coalition and The Bachmann-Strauss Foundation.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 25 2016 Issue

HIV associated motor neuron disease: HERV-K activation and response to anti-retroviral therapy

Published: Monday, 24 Oct 2016 17:00:00 CDT

1) HIV associated motor neuron disease: HERV-K activation and response to anti-retroviral therapy 2) e-Pearl topic: Ataxia with vitamin E deficiency 3) Topic of the month: Neurology Today story on functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Avindra Nath about his paper on human endogenous retrovirus-K in amyotrophic lateral sclerosis with HIV infection and response to treatment with anti-retroviral drugs. Dr. Sarah Wesley is reading our e-Pearl of the week about ataxia with vitamin E deficiency. In the next part of the podcast Dr. Andy Southerland interviews Prof. Heinrich Audebert about a Neurology Today story on the topic of functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Nath serves as Associate Editor for Journal of Neurovirology; has patents for Tat as an immunogen, Diosgenin for Treatment of Neurodegenerative Diseases; Role of Kv Channels in Neuroregeneration and Protection; Role of Lominoid compounds as neuroprotective agents; Tat ELISA; and receives research support from the NIH. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Prof. Audebert serves as Associate Editor for Frontiers of Teleneurology; is a consultant for Lundbeck Inc., Roche, Bayer Schering Pharma, Pfizer Inc; received speaker honoraria from Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Lundbeck Inc., Bayer Schering Pharma, UCB, Sanofi-aventis, Pfizer Inc, Bristol-Myers Squibb and EverNeuropharma; participated in an expert meeting launched by Lundbeck Inc. in order to estimate the target population for Desmoteplase; receives research support from the Technology Foundation Berlin and the Berlin Investment Bank with co-financing by the European Union, and Center for Stroke Research Berlin, funded by the German Federal Ministry of Education and Research.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 18 2016 Issue

Calcium supplementation and risk of dementia in women with cerebrovascular disease

Published: Monday, 17 Oct 2016 17:00:00 CDT

1) Calcium supplementation and risk of dementia in women with cerebrovascular disease 2) e-Pearl topic: MGMT promoter methylation in glioblastoma 3) Topic of the month: Neurology Today story on a new brain map identifying previously unidentified brain areas and what it means for neurology This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Silke Kern about her paper on whether calcium supplementation was associated with the development of dementia in women with cerebrovascular disease. Dr. Sarah Wesley is reading our e-Pearl of the week about MGMT promoter methylation in glioblastoma. In the next part of the podcast Dr. Ted Burns interviews Dr. Matthew Glasser about a Neurology Today story on the topic about a new brain map identifying previously unidentified brain areas and what it means for neurology. DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Kern serves as Associate Editor for Journal of Alzheimer`s disease. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 11 2016 Issue

Reducing costs while enhancing quality of care in MS

Published: Monday, 10 Oct 2016 17:00:00 CDT

1) Reducing costs while enhancing quality of care in MS 2) What's Trending: Interview with Lyell Jones about the topic of the Axon Registry and how it interfaces with practice and reimbursement this is part 2 with part 1 appearing last month 3) Topic of the month: Neurology Today story on the AAN Guideline published in Neurology on the topic of recurrent stroke with patent foramen ovale This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ilya Kister about his paper on the various approaches neurologists may contribute to cost containment while maintaining and enhancing the quality of MS care. Dr. Andy Southerland is interviewing Dr. Lyell Jones for our “What's Trending” feature of the week about the topic of the Axon Registry and how it interfaces with practice and reimbursement. This is part 2 with part 1 appearing last month. In the next part of the podcast Dr. Bryan Eckerle interviews Dr. Steven Messe about a Neurology Today story on the AAN Guideline published in Neurology on the topic of recurrent stroke with patent foramen ovale. DISCLOSURES: Dr. Keegan serves as an editorial board member of Multiple Sclerosis and Related Disorders; served as Chief Editor of eMedicine; receives royalties from the publication of the book: Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning; is a consultant for Novartis, Bristol-Meyers Squibb and Bionest; receives research support from Terumo BCT. Dr. Kister serves on the MS Franchise Data Generation advisory board for Biogen Idec and advisory board for Genentech, Inc.; received a one-time consulting fee from Biogen Idec; received research support from Biogen-Idec, Merck Serono, Novartis, Genzyme Corporation; Guthy-Jackson Charitable Foundation and National Multiple Sclerosis Society. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Messe received publishing royalties from UpToDate; received compensation from GlaxoSmithKline for consulting on protocol development for a trial of a neuroprotectant in high risk surgery; received research support from GlaxoSmithKline, Bayer Schering Pharma, WL Gore and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 4 2016

Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up

Published: Monday, 03 Oct 2016 17:00:00 CDT

1) Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up 2) What's Trending: Interview with Ben Utecht about his recently published book titled: Counting the Days While My Mind Slips Away: A Love Letter to My Family 3) Topic of the month: Neurology Today story about NEJM published paper on thymectomy for patients with myasthenia gravis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Maarten Titulaer about his paper on the clinical features and long-term follow-up of anti-LGI1 encephalitis. Dr. Ted Burns is interviewing Mr. Ben Utecht for our “What's Trending” feature of the week about his recently published book titled: “Counting the Days While My Mind Slips Away: A Love Letter to My Family.” In the next part of the podcast Dr. Ted Burns interviews Dr. Gil Wolfe about a Neurology Today story on the topic of thymectomy for patients with myasthenia gravis. DISCLOSURES: Dr. Titulaer serves on the scientific advisory board for MedImmune; serves as an editorial board member for Neurology®: Neuroimmunology & Neuroinflammation; received funding for travel from Sun Pharma; receives research support from Netherlands Organization for Scientific Research, Dutch Epilepsy Foundations and ErasmusMC fellowship. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Mr. Ben Utecht receives honoraria from the American Academy of Neurology and the American Brain Foundation, Spokesperson Agreement. Dr. Wolfe serves as an Associate Editor of Muscle and Nerve; serves on the scientific advisory board for Grifols, Baxalta, Argen X and UCB; receives honoraria for serving on the speakers' bureau of Grifols and Baxalta; receives research support from CSL Behring.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall October 2016

Evaluation of the anoxic brain injury patient

Published: Monday, 03 Oct 2016 09:52:00 CDT

Evaluation of the anoxic brain injury patient

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 27 2016 Issue

Editorial Titled: The Terrorist inside My Husband’s Brain

Published: Monday, 26 Sep 2016 17:00:00 CDT

1) Editorial Titled: The Terrorist inside My Husband's Brain 2) e-Pearl topic: X-linked myopathy with excessive autophagy 3) Topic of the month: Neurologic prognosis following cardiac arrest This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mrs. Susan Schneider Williams about her editorial on learning to deal with her husband's (Robin Williams) Lewy Body disease. Dr. Adam Numis is reading our e-Pearl of the week about X-linked myopathy with excessive autophagy. In the next part of the podcast Dr. Andy Schomer concludes his interview with Dr. Eelco Wijdicks about prognostic models and clinical findings of myoclonus. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Mrs. Schneider Williams serves on the board of directors for the American Brain Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 20 2016 Issue

Influence of sodium consumption and associated knowledge on post-stroke hypertension in Uganda

Published: Monday, 19 Sep 2016 17:00:00 CDT

1) Influence of sodium consumption and associated knowledge on post-stroke hypertension in Uganda 2) e-Pearl topic: Transient cerebral arteriopathy 3) Topic of the month: Neurologic prognosis following cardiac arrest This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Larry Goldstein about his paper on the influence of sodium consumption and its associated knowledge on post-stroke patients with and without a history of hypertension in Uganda. Dr. Adam Numis is reading our e-Pearl of the week about transient cerebral arteriopathy. In the next part of the podcast Dr. Andy Schomer continues his interview with Dr. Eelco Wijdicks about the ancillary testing that is done in patients with cardiac arrest. DISCLOSURES: Dr. Goldstein serves as an editorial board member of Neurology®, Emergency Medicine, Cardiology Today and Stroke; serves as an Associate Editor for Cerebrovascular Diseases; serves on the scientific advisory board for Daichi Sanyo, Merz, Roche and Pfizer Inc; is a consultant for Artemida, Nestle and Stroke Hospitalization in Elderly with Medicare; receives honoraria from serving on the scientific advisory board of Pfizer Inc; receives royalties from the publication of the books: Screening for Asymptomatic Carotid Stenosis, Use and Utility of Stroke Scales and Grading Sysytems and Henry Stewart Talks, Secondary Stroke Prevention; receives research support from Stroke Hospitalization in Elderly with Medicare and the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks receives royalties from the publication of several books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 13 2016 Issue

Cortical superficial siderosis: Prevalence and biomarker profile in a memory clinic population

Published: Monday, 12 Sep 2016 17:00:00 CDT

1) Cortical superficial siderosis: Prevalence and biomarker profile in a memory clinic population 2) What's Trending: Interview with Lyell Jones about Axon Registry and how it interfaces with practice and reimbursement (Part 1) 3) Topic of the month: Neurologic prognosis following cardiac arrest This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chris Tarolli interviews Dr. Sara Shams about her paper on the prevalence and biomarker profile of cortical superficial siderosis in a consecutive memory clinic population. Dr. Andy Southerland is interviewing Dr. Lyell Jones for our “What's Trending” feature of the week about the topic of the Axon Registry and how it interfaces with practice and reimbursement. This is part 1 with part 2 appearing next month. In the next part of the podcast Dr. Andy Schomer continues his interview with Dr. Eelco Wijdicks about the timing of the clinical examination of a patient following cardiac arrest. DISCLOSURES: Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Wijdicks receives royalties from the publication of several books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 6 2016 Issue

Neurology® Clinical Practice: Incidence of meningeal enhancement on brain MRI secondary to lumbar puncture

Published: Monday, 05 Sep 2016 17:00:00 CDT

1) Neurology® Clinical Practice: Incidence of meningeal enhancement on brain MRI secondary to lumbar puncture 2) What's Trending: Interview with Robert Gross about his editorial on the trial article format being published this week 3) Topic of the month: Neurologic prognosis following cardiac arrest This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jonathan Perk interviews Dr. Sarah Wesley about her Neurology® Clinical Practice paper on the unexplained meningeal enhancement after lumbar puncture. Dr. Ted Burns is interviewing Dr. Robert Gross for our “What's Trending” feature of the week about his editorial on the trial article format being published this week in Neurology. In the next part of the podcast Dr. Andy Schomer interviews Dr. Eelco Wijdicks about the treatment of cardiac arrest and hypothermia management. DISCLOSURES: Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Gross receives support for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH, since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus; receives an honorarium from AAN as Editor-in-Chief of Neurology®. Dr. Wijdicks receives royalties from the publication of several books. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall September 2016

Zika virus interviews

Published: Thursday, 01 Sep 2016 13:15:00 CDT

Zika virus interviews

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 30 2016 Issue

Predictive value of ABCD2 and ABCD3-1 scores in TIA and minor stroke in the Stroke Unit Setting

Published: Monday, 29 Aug 2016 17:00:00 CDT

1) Predictive value of ABCD2 and ABCD3-1 scores in TIA and minor stroke in the Stroke Unit Setting 2) e-Pearl topic: Alternating hemiplegia of childhood 3) Topic of the month: Neurology Today story about his book review on: “The Laws of Medicine: Field Notes from an Uncertain Science.” This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Anna Ranta interviews Dr. Michael Knoflach about his paper on the predictive value of ABCD2 and ABCD3-1 scores in transient ischemic attack and minor stroke in the Stroke Unit Setting. Dr. Steve O'Donnell is reading our e-Pearl of the week about alternating hemiplegia of childhood. Dr. Ted Burns interviews Jose Merino about a Neurology Today story about his book review on: “The Laws of Medicine: Field Notes from an Uncertain Science.” DISCLOSURES: Dr. Ranta receives research support from the New Zealand Health Research Council. Dr. O'Donnell serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Merino serves as US Clinical Research Editor for the BMJ; serves as Co-editor, blogging stroke (A Stroke journal blog); receives stroke outcomes adjudicator for the WHI study (NIH-funded); and DSMB of a PCORI-funded trial to evaluate depression in caregivers of patients with Alzheimer disease.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 23 2016 Issue

Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome

Published: Monday, 22 Aug 2016 17:00:00 CDT

1) Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome 2) e-Pearl topic: Moyamoya disease and syndrome 3) Topic of the month: Neurology Today story on a published paper titled: Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Drs. Francesc Graus and Josep Dalmau about their paper on the presentation and long-term outcome of anti-LGI1-associated cognitive impairment. Dr. Steve O'Donnell is reading our e-Pearl of the week about Moyamoya disease and syndrome. Dr. Javier Provencio interviews Dr. Adnan Qureshi about a Neurology Today story on his published paper titled: Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. DISCLOSURES: Dr. Graus serves as an editorial board member of Lancet; receives license fee Payments from Euroimmun for the use of IgLON5 as a diagnostic test; holds a patent for the use of IgLON5 as a diagnostic test. Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test. Dr. O'Donnell serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Provencio serves as an editorial board member of Journal of Neuroimmunology, serves on the scientific advisory board for Minnetronix, INC. (travel related expenses) and Advanced Circulatory, Inc (travel related expenses); received honoraria from Bard, Inc.; receives royalties from the publication of the book “Family Guide to Surviving the ICU”; receives research support from Bard Inc., Cryothermics INC. and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 16 2016 Issue

Neurology® Neuroimmunology & Neuroinflammation: Next-generation sequencing in neuropathological diagnosis of infections of the nervous system

Published: Monday, 15 Aug 2016 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation: Next-generation sequencing in neuropathological diagnosis of infections of the nervous system 2) e-Pearl topic: GABAb receptor encephalitis 3) Topic of the month: Neurology Today story about the global burden of stroke This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Carlo Pardo about his Neurology® Neuroimmunology & Neuroinflammation paper on next-generation sequencing in neuropathological diagnosis of infections of the nervous system. Dr. Steve O'Donnell is reading our e-Pearl of the week about GABAb receptor encephalitis. Dr. Andy Southerland interviews Dr. Vladimir Hachinski about a Neurology Today story on the topic of the global burden of stroke. DISCLOSURES: Dr. Pardo receive research support from the Bart McLean Fund for Neuroimmunology Research-Project Restore and the NIH. Dr. O'Donnell serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 9 2016 Issue

Impaired self-agency in functional movement disorders: A resting-state fMRI study

Published: Monday, 08 Aug 2016 17:00:00 CDT

1) Impaired self-agency in functional movement disorders 2) What's Trending: Interview with James Sejvar about possible links between Zika virus, microcephaly, and Guillain–Barre syndrome 3) Topic of the month: Neurology Today story about where advances are revolutionizing stroke treatment This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Carine Maurer about her paper on impaired self-agency in functional movement disorders Dr. Andy Southerland is interviewing Dr. James Sejvar for our “What's Trending” feature of the week on the topic of possible links between Zika virus, microcephaly, and Guillain–Barre syndrome. Dr. Andy Southerland interviews Dr. Ralph Sacco about a Neurology Today story on the topic of where advances are revolutionizing stroke treatment. DISCLOSURES: Dr. Maurer receives research support from the NINDS Intramural Program. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Sacco serves as an editorial board member of Stroke and Neuroepidemiology; serves on the scientific advisory board for DSMB for SOCRATES Trial through UCSF(indirect sponsor Astra Zeneca) and EUCLID trial through Duke Clinical Research Institute (indirect sponsor Astra Zeneca); receives research support from Boehringer Ingelheim, Evelyn McKnight Brain Institute, American Heart Association Burgher Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 2 2016 Issue

The clinical spectrum of Caspr2-antibody associated disease

Published: Monday, 01 Aug 2016 17:00:00 CDT

1) The clinical spectrum of Caspr2-antibody associated disease 2) What's Trending: Interview with Lenore Launer about how hostile attitudes and effortful coping in young adulthood can predict cognition in later life 3) Topic of the month: Neurology Today story about five mentally stimulating activities associated with a lower risk for mild cognitive impairment This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Maarten Titulaer about his paper on the clinical spectrum of Caspr2-antibody associated disease. Dr. Ted Burns is interviewing Dr. Lenore Launer for our “What's Trending” feature of the week about her paper on how hostile attitudes and effortful coping in young adulthood can predict cognition in later life. Dr. Ted Burns interviews Drs. Janina Krell-Roesch and Gregg Day about a Neurology Today story on the topic of five mentally stimulating activities associated with a lower risk for mild cognitive impairment. DISCLOSURES: Dr. Titulaer serves on the scientific advisory board for MedImmune; serves as an editorial board member for Neurology®: Neuroimmunology & Neuroinflammation; received funding for travel from Sun Pharma; receives research support from Netherlands Organization for Scientific Research, Dutch Epilepsy Foundations and ErasmusMC fellowship. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Launer receives research support from the National Institute on Aging Intramural Research Program. Dr. Day received funding for travel from Pfizer, Canada for Future Leader in Dementia award; receives Research support from Avid Pharmaceuticals, American Brain Foundation, Clinical Research Training Fellowship, Eugene M Johnson Jr, Weston Brain Institute Postdoctoral Fellowship; and holds stock options in ANI Pharmaceuticals (2014-2015).

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 26 2016 issue

Executive Summary: International consensus guidance for management of myasthenia gravis

Published: Monday, 25 Jul 2016 17:00:00 CDT

1) International consensus guidance for management of myasthenia gravis 2) e-Pearl topic: Progressive multifocal leukoencephalopathy 3) Topic of the month: Neurology Year in Review Plenary Session at the AAN meeting on the topic of headache This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Donald Sanders about the executive summary on the international consensus guidance for management of myasthenia gravis. Dr. Ilena George is reading our e-Pearl of the week about progressive multifocal leukoencephalopathy. Dr. Tesha Monteith interviews Dr. Richard Lipton about his Neurology Year in Review Plenary Session at the AAN meeting on the topic of headache. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Sanders receives royalties from the publication of the book: Single Fiber EMG; serves on the medical advisory board for Accordant Health Services; is a consultant for ArGen-X, Jacobus Pharmaceutical Co., Inc, Modus Outcomes, Momenta Pharmaceuticals, Inc. and UCB Celltech. Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Lipton receives royalties for books published from Oxford University Press and Baxter Publishing; Receives honoraria for serving on the scientific advisory board for Alder, Allergan, Inc., American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly and Company, eNeura Therapeutics, Informa, Merck Serono, Novartis, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Vedanta; is a consultant for Alder, Allergan, Inc., American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly and Company, eNeura Therapeutics, Informa, Merck Serono, Novartis, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Vedanta; holds stock options in eNeura Pharma; receives research support from Bristol-Myers Squibb, Vedanta Research Migraine epidemiology and Progression. Boston Scientific Occipital Nerve Stimulation in Migraine, ElectroCore Vagal Nerve Stimulation for Migraine and Cluster, Novartis Sleep and Migraine, Allergan Botox in Migraine, Allergan Chronic Migraine Epidemiology and Outcome Study, S & L Marx Foundation Alzheimer's Research and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 19 2016 Issue

Zika virus-associated Guillain-Barre Syndrome Variant in Haiti

Published: Monday, 18 Jul 2016 17:00:00 CDT

1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti 2 e-Pearl topic: Juvenile Huntington Disease 3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease. DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture. Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 12 Issue

Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review

Published: Monday, 11 Jul 2016 17:00:00 CDT

1) Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review 2) What's Trending: Interview with Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline 3) Topic of the month: Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Lapides interviews Dr. Jan Dirk Blom about his Neurology: Clinical Practice paper on the Alice in Wonderland syndrome. Dr. Ted Burns is interviewing Dr. Clinton Wright for our “What's Trending” feature of the week about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome. DISCLOSURES: Dr. Blom receives royalties from the publication of the book Hallucinations, Research and Practice and the book A Dictionary of Hallucinations. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Wright receives royalties from UpToDate website for two chapters on vascular dementia; receives research support from American Stroke Association-Bugher Foundation Centers of Excellence project and the NIH. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Schmahmann serves as an editorial board member of The Cerebellum and its sister journal, Cerebellum and Ataxias; serves on the scientific advisory board for Ataxion, Inc. and Atlas Ventures; Receives royalties from the publications of the books: The Cerebellum and Cognition: International Review of Neurobiology, MRI Atlas of the Human Cerebellum, Pathways of the Brain, Cerebellar Disorders in Children: Clinics in Development Medicine, and Handbook of the Cerebellum and Cerebellar Disorders; is a consultant for Takeda Pharmaceutical Company Limited; holds stock option in Ataxion, Inc. and Atlas Ventures; receives research support from Birmingham Foundation, MINDlink Foundation, Sidney R. Baer Jr., Foundation, National Ataxia Foundation, Ataxia Telangiectasia Children's Project and the NIH. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Migraine updates and what we have learned - July 2016

Migraine updates and what we have learned - July 2016

Published: Tuesday, 05 Jul 2016 17:00:00 CDT

Migraine updates and discussion on the topics of migraine genetics, science behind lifestyle factors, science behind lifestyle factors and clinical trials - July 2016

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Plenary Session Interviews - May 2016

Plenary Session Interviews - May 2016

Published: Tuesday, 05 Jul 2016 17:00:00 CDT

Plenary Session Interviews - May 2016

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 5 2016 Issue

A low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study

Published: Monday, 04 Jul 2016 17:00:00 CDT

1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study 2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection 3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our “What's Trending” feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia. DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India. Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 14 Issue

Quality improvement in neurology: Parkinson disease update quality measurement set

Published: Monday, 13 Jun 2016 17:00:00 CDT

1) Quality improvement in neurology: Parkinson disease update quality measurement set 2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: George C. Cotzias Lecture at the AAN Meeting on antibody mediated disorders of the synapse This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Drs. Janis Miyasaki and Stewart Factor about the AAN paper on new quality measures developed to improve outcomes for patients with Parkinson disease. Dr. Ted Burns is interviewing Dr. Ansgar Furst for our “What's Trending” feature of the week about his editorial on incidental findings for what's to come in amyloid plaques in traumatic brain injury. Dr. Alberto Espay interviews Dr. Josep Dalmau about his George C. Cotzias Lecture at the AAN Meeting on the topic of antibody mediated disorders of the synapse. DISCLOSURES: Dr. Miyasaki received honoraria and funding for travel from Teva Pharmaceutical Industries Ltd.; received funding for travel from Merz Pharmaceuticals, LLC; received travel honoraria from The International Parkinson Disease and Movement Disorders Society; is a consultant for Merz Pharmaceuticals, LLC; receives royalties from the publication of the book “Psychogenic Movement Disorders;” receives research support from PCORI: 2015-2018 and Parkinson Alberta. Dr. Factor served as an editorial board member of Neurotherapeutics; serves on the data safety monitoring board for Lundbeck, Inc; is a consultant for UCB; is a consultant and video reviewer for clinical trials for Avanir, Neurocrine and Auspex/Teva Pharmaceutical Industries Ltd.; receives royalties from the publications of the books “Parkinson's disease diagnosis and clinical management” and “Drug induced movement disorders;” gave expert testimony in Kmart trial (2014-2016); receives research support from Ceregene, Cynapsus, Sangamo, Teva Pharmaceutical Industries Ltd., Ipsen Pharmaceuticals, Inc., USWorldMeds, Allergen, Inc., Medtronics, Inc., Auspex, Genzyme Corporation, Michael J. Fox Foundation and the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH. Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 7 2016 Issue

Neurology® Genetics: Clinical and genetic features of cervical dystonia in a large multi-center cohort

Published: Monday, 06 Jun 2016 17:00:00 CDT

1) Neurology® Genetics: Clinical and genetic features of cervical dystonia in a large multi-center cohort 2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: Abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Mark LeDoux about his Neurology: Genetics paper on the clinical and genetic features of cervical dystonia. Dr. Ted Burns is interviewing Dr. Dave Sharp for our “What's Trending” feature of the week about his paper on amyloid pathology and axonal injury after brain trauma. Dr. Andy Southerland interviews Dr. Andy Solomon about his abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria. DISCLOSURES: Dr. LeDoux serves on the scientific advisory boards of Spastic Paraplegia Foundation; serves as Chairman on the board of medical advisors of the National Spasmodic Torticollis Association; serves as an editorial board member of Parkinsonism and Related Disorders, Tremor and other hyperkinetic movement disorders, PLOS ONE and Neurology®; is a consultant for Azilect Advisory Board, Mayo Clinic, Teva Pharmaceutical Industries Ltd., Lundbeck Inc.; serves on the speakers' bureau of Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives funding for travel from Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives royalties from the publication of the books “Animal models of movement disorders” and “Movement disorders: Genetics and models;” receives research support from Benign Essential Blepharospasm Research FDN, CHDI, Enroll HD, Omeros, Phase 2, Auspex, US WorldMeds, Mysticol, Protocol, Accorda and the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Sharp receives research support from UK Medical Research Council, European Union, Wellcome Trust, Rosetrees Trust, Action Medical Research, Public engagement grant from The Physiological Society, The Royal Society Summer Science Exhibition and the NIH (UK). Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Solomon received research support from the Portland Veterans Affairs Medical Center Fellowship in Multiple Sclerosis and Neuroimmunology and Partners Multiple Sclerosis Fellowship Award. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 31 2016 Issue

APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline

Published: Monday, 30 May 2016 17:00:00 CDT

1) APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline 2) e-Pearl topic: Ocular neuromyotonia 3) Topic of the month: Neurology Today story about Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 2) This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Prof. Martha Morris about her paper on APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Dr. Adam Numis is reading our e-Pearl of the week about ocular neuromyotonia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 2). DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Prof. Morris is a consultant for Neurotrack; serves on the scientific advisory board for the University of Chicago; received funding for travel from the University of California; receives research support from the Abbott Fund and the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 24 2016 Issue

Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies

Published: Monday, 23 May 2016 17:00:00 CDT

1) Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies 2) e-Pearl topic: Neurologic manifestations of hereditary hemorrhagic telangiectasia 3) Topic of the month: Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 1) This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Flaherty interviews Dr. Loch Macdonald about his paper on review and meta-analysis of 25 studies about the natural history of cavernous malformation. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of hereditary hemorrhagic telangiectasia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 1). DISCLOSURES: Dr. Flaherty serves on the scientific advisory board for DSMB member, I-DEF Trial (NINDS sponsored ICH treatment trial); has a patent pending, non-invasive CNS monitor; owns company stock as co-founder of SENSE Diagnostics, LLC (our product is currently investigational and not on the market); serves on the speakers' bureau of CSL Behring and Janssen; receives research support from American Heart Association, Pfizer Inc, Bristol-Myers Squibb, NIH and as Principal Investigator of a phase II, NINDS funded trial testing recombinant activated factor VII for treatment of intracerebral hemorrhage where study drug is supplied by Novo Nordisk. Dr. Macdonald serves as an editorial board member of Stroke, Journal of Neurosurgery, Neurosurgery, Journal of cerebral blood flow and metabolism, Neurocritical care, World Neurosurgery, Surgical Neurology International, Translational stroke research and Cerebrovascular diseases; treats unruptured aneurysm patients (1% effort); holds stock options in Edge Therapeutics, Inc; has a patent for treatment of delayed cerebral ischemia and subdural hemorrhage, intracranial drug delivery systems; receives research support from Canadian Institutes of Health Research, Brain Aneurysm Foundation, Heart and Stroke Foundation of Canada and Physicians Services Incorporated Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 17 2016 Issue

Variability in Physician Prognosis and Recommendations after Intracerebral Hemorrhage

Published: Monday, 16 May 2016 17:00:00 CDT

1) Variability in Physician Prognosis and Recommendations after Intracerebral Hemorrhage 2) e-Pearl topic: Eye and facial findings in psychogenic non-epileptic seizures 3) Topic of the month: Neurology Today story about lead crisis in Flint exposing continuing risk to children nationwide This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Javier Provencio interviews Dr. Darin Zahuranec about his paper on variability in physician prognosis and recommendations after intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about eye and facial findings in psychogenic non-epileptic seizures. Dr. Ted Burns interviews Dr. Chris Holstege about a Neurology Today story on the topic of lead crisis in Flint exposes continuing risk to children nationwide: What neurologists should know and what they can do about it. DISCLOSURES: Dr. Provencio serves on the scientific advisory boards for Minnetronix, INC., Advanced Circulatory, Inc; serves on the data safety monitoring board for the ASTROH trial; Received honoraria and funding for travel from Bard, Inc.; serves as an editorial board member of Journal of Neuroimmunology; receives royalties from the publication of the book Family guide to Surviving the ICU; served on the board of directors of the Neurocritical Care Society; serves as President for the Ohio Chapter of the Society of Critical Care Medicine; receives research support From Bard Inc., Systemic Normothermia in ICH (SNICH), Crothermics INC. and the NIH. Dr. Zahuranec receives research support from Medtronic, Inc. and the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 10 2016 Issue

Neurology® Clinical Practice: Clinical Exome Sequencing in Neurologic Disease

Published: Monday, 09 May 2016 17:00:00 CDT

1) Neurology® Clinical Practice: Clinical Exome Sequencing in Neurologic Disease 2) What's Trending: Interview with Natalia del Campo about her paper on relationship of regional brain beta-amyloid to gait speed 3) Topic of the month: Neurology Today story about pioglitazone found to be associated with a lower risk of secondary stroke in Non-diabetic patients with insulin resistance This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Brent Fogel about his Neurology: Clinical Practice paper on clinical exome sequencing in neurologic disease. Dr. Ted Burns is interviewing Dr. Natalia del Campo for our “What's Trending” feature of the week about her paper on relationship of regional brain beta-amyloid to gait speed. Dr. Andy Southerland interviews Dr. Walter Kernan about a Neurology Today story on the topic of pioglitazone found to be associated with a lower risk of secondary stroke in Non-diabetic patients with insulin resistance. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Fogel received speaker honoraria from the American Academy of Neurology and American Physician Institute for Advanced Professional Studies; received funding for travel from American Physician Institute for Advanced Professional Studies and National Ataxia Foundation; receives research support from American Physician Institute for Advance Professional Studies, National Ataxia Foundation and the NIH. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Kernan academic institution receives research support from Takeda Pharmaceutical Company Limited and the NIH. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 3 2016 Issue

Neurology® Neuroimmunology & Neuroinflammation: VZV in biopsy-positive and -negative giant cell arteritis: analysis of 100+ temporal arteries

Published: Monday, 02 May 2016 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation: VZV in biopsy-positive and -negative giant cell arteritis: analysis of 100+ temporal arteries 2) What's Trending: Interview with Kimberley R. Barker about “altmetrics” 3) Topic of the month: Neurology Today story about epidemiologists tracking possible links between Zika virus, microcephaly, and Guillain–Barre syndrome This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Don Gilden about his Neurology: Neuroimmunology & Neuroinflammation paper on varicella zoster virus in over 100 temporal arteries that showed clinical features of giant cell arteritis. Dr. Andy Southerland is interviewing Kimberley R. Barker for our “What's Trending” feature of the week about “altmetrics.” Dr. Ted Burns interviews Dr. James Sejvar about a Neurology Today story on the topic of epidemiologists tracking possible links between Zika virus, microcephaly, and Guillain–Barre syndrome. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Gilden serves as Senior Associate Editor for Journal of NeuroVirology, serves as an editorial Board member of In Vivo, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology®, and the Journal of the Nuerological Sciences; receives research support from the NIH. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium ofr improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 26 2016 Issue

The association between hospitalization and care after transient ischemic attack or minor stroke

Published: Monday, 25 Apr 2016 17:00:00 CDT

1) The association between hospitalization and care after transient ischemic attack or minor stroke 2) e-Pearl topic: Neuroretinitis 3) Topic of the month: Migraine awareness series This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Moira Kapral about her paper on the association between hospitalization and care after transient ischemic attack or minor stroke. Dr. Sarah Wesley is reading our e-Pearl of the week about neuroretinitis. Dr. Tesha Monteith interviews Dr. Stephen Silberstein about the topic of migraine clinical trials: A drug therapy and neuromodulation update. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Kapral serves as Guest Editor for Cardiovascular Quality and Outcomes; serves as an editorial board member of Circulation; receives research support from the Heart and Stroke Foundation of Canada. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Silberstein serves as an editorial board member of Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management and Neurology®; serves on the scientific advisory board for Alder, Allergan, Inc., Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Inc., Mitsubishi Tanabe Pharma Corporation, Neuralieve, NINDS, Pfizer Inc, Supernus and Teva Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Inc., Neuralieve, Pfizer, Inc, Supernus and Teva Pharmaceutical Industries Ltd.; receives research support from American Headache Society®, International Headache Society and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 19 2016 Issue

Standardized EEG interpretation accurately predicts prognosis after cardiac arrest

Published: Monday, 18 Apr 2016 17:00:00 CDT

1) Standardized EEG interpretation accurately predicts prognosis after cardiac arrest 2) e-Pearl topic: Panayiotopoulos syndrome 3) Topic of the month: Migraine awareness series This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Fugate interviews Dr. Tobias Cronberg about his paper on standardized EEG interpretation and how it predicts prognosis after cardiac arrest. Dr. Sarah Wesley is reading our e-Pearl of the week about Panayiotopoulos syndrome. Dr. Tesha Monteith interviews Dr. Messoud Ashina about the topic of neuroimaging biomarkers and human models for new drug targets: Lessons from PACAP38. DISCLOSURES: Dr. Cronberg receives research support from the Regional Research Support, Region Skane, The Swedish Heart and Lung Association, The Skane University Hospital Foundations, The Gyllenstierna-Krapperup Foundation, The Swedish Society of Medicine, The Koch Foundation and The Segerfalk Foundation. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Ashina serves as an associate editor of Cephalgia Member of advisory board: The Journal of Headache and Pain; is a consultant or scientific adviser for the ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received an honoraria for lecturing from Allergan, Inc.; receivesresearch support from the Research Foundation of the Capital Region of Denmark, the Danish Council for Independent Research-Medical Sciences, the Novo Nordisk Foundation, IMK Almene Foundation, and the Cool Sorption Foundation.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 12 2016 Issue

Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis

Published: Monday, 11 Apr 2016 17:00:00 CDT

1) Dichlorphenamide in periodic paralysis 2) What's Trending: Editorial on the Zika Virus and what the neurologist wants to know 3) Topic of the month: Migraine awareness series This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Valeria Sansone about her paper on dichlorphenamide in periodic paralysis. Dr. Ted Burns is interviewing Dr. Gretchen Birbeck for our “What's Trending” feature of the week about her editorial on the Zika Virus and what the neurologist wants to know. Dr. Tesha Monteith interviews Dr. Peter Goadsby about the topic of science behind lifestyle factors: Our basic instincts and the migraine brain. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Birbeck serves as Section Editor and Curator for Without Borders mini-site Neurology®; receives research support from the NIH and Dana Foundation Neuroimaging Grant. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Goadsby serves as an editorial board member for Journal Watch Neurology; receives royalties from the publication of Mechanism and Management of Headache. (7th ed.); was a consultant for Alder Bio, Allergan, Inc., Amgen, ATI, Boehringer Ingelheim, BMS, Boston Scientific, Colucid, Coherex, DrReddy, Eli Lilly and Company, Gammacore, GlaxoSmithKline, Impax, J&J Linde Gases, Lundbeck Inc., MAP Pharmaceuticals, Medtronic, Inc., MSD, Neuralieve, Nevrocorp, Pfizer Inc, Zogenix; receives research support from Amgen and Allergan, Inc.; has worked with legal firms handling patent matters.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 5 2016 Issue

Mid-life exercise blood pressure, heart rate and fitness relate to brain volume two decades later

Published: Monday, 04 Apr 2016 17:00:00 CDT

1) Mid-life exercise blood pressure, heart rate and fitness relate to brain volume two decades later 2) What's Trending: Antibiotic-associated encephalopathy 3) Topic of the month: Migraine awareness series This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Nicole Spartano about her paper on the mid-life exercise blood pressure, heart rate and fitness and how it relates to brain volume two decades later. Dr. Ted Burns is interviewing Dr. Shamik Bhattacharyya for our “What's Trending” feature of the week about his paper on antibiotic-associated encephalopathy. Dr. Tesha Monteith interviews Dr. Aarno Palotie about the topic of migraine genetics: What have we learned. DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Spartano receives research support from the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Palotie serves as a member of the Pfizer Genetics Scientific Advisory Panel; receives research support from Finnish Academy, European Union NIH, NINDS, Juselius Foundation and Finnish Foundation for Cardiovascular Research.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 29 2016 Issue

Neurology® Clinical Practice article titled: How do you treat anti-NMDA receptor encephalitis?

Published: Monday, 28 Mar 2016 17:00:00 CDT

1) Neurology® Clinical Practice article titled: How do you treat anti-NMDA receptor encephalitis? 2) e-Pearl topic: Primary lateral sclerosis 3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Luca Bartolini about his Neurology: Clinical Practice paper on how you treat anti-NMDA receptor encephalitis. Dr. Steve O'Donnell is reading our e-Pearl of the week about primary lateral sclerosis. In the next part of the podcast Dr. Nick Brenton interviews Dr. Leigh Charvet about the topic of cognitive, emotional and behavioral outcomes in pediatric multiple sclerosis. DISCLOSURES: Dr. Bartolini serves as Section Editor for Neurology Clinical Practice. Dr. O'Donnell serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Charvet has received research support from Novartis. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 22 2016 Issue

Statin pretreatment is associated with better outcomes in large-artery atherosclerotic stroke

Published: Monday, 21 Mar 2016 17:00:00 CDT

1) Statin pretreatment is associated with better outcomes in large-artery atherosclerotic stroke 2) e-Pearl topic: Fatal familial insomnia 3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Georgios Tsivgoulis about his paper on how statin pretreatment is associated with better outcome in large-artery atherosclerotic stroke. Dr. Steve O'Donnell is reading our e-Pearl of the week about fatal familial insomnia. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Emmanuelle Waubant about the topic of vitamin D in pediatric multiple sclerosis. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Tsivgoulis serves as Associate Editor for Neurosonology; serves as an editorial board member of Journal of Neuroimaging; and receives research support from the European Regional Development Fund. Dr. O'Donnell serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada. Dr. Waubant serves on the scientific advisory board for Novartis; serves as an editorial board member of Annals of Clinical and Translational Neurology; is an ad hoc consultant for Roche and MedDay; received funding for travel for one educational physician lecture from Genentech, Inc.; receives royalties from the publication of the book Demyelinating disorders of the central nervous system in childhood; receives research support for trials of ocrelizumab in PPMS (Roche), and fingolimod in pediatric MS (Novartis); receives research support from the National Multiple Sclerosis Society, the Race to Erase MS and NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 15 2016 Issue

Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes

Published: Monday, 14 Mar 2016 17:00:00 CDT

1) Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes 2) What's Trending: Editorial on if stress could cause a stroke 3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kathryn Nevel interviews Dr. Andrew McKeon about his paper on clinical features and treatment outcomes of metabotropic glutamate receptor type 1 autoimmunity. Dr. Ted Burns is interviewing Dr. Jennifer Majersik for our “What's Trending” feature of the week about her editorial on if stress could cause a stroke. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Ann Yeh about the topic of exercise in pediatric multiple sclerosis. DISCLOSURES: Dr. McKeon receives research support from Medimmune, Inc. Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Majersik serves as an editorial board member of Neurology; and receives research support from the NIH. Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada. Dr. Yeh perform multiple sclerosis relapse adjudication for ACI services on a fee-for-service basis; serves as an editorial board member of Neurology; receives research support from the Canadian Institutes of Health Research, Patient-Centered Outcomes Research Institute, MS Monitoring system pilot funding, National MS Society, MS Society, Dairy Farmers of Ontario, SickKids Innovation Fund, MS Research Foundation (Canada), and Rare Diseases Foundation.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 8 2016 Issue

Transient ischemic attack service provision: A review of available service models

Published: Monday, 07 Mar 2016 17:00:00 CDT

1) Transient ischemic attack service provision: A review of available service models 2) What's Trending: Mediterranean diet and brain structure in a multiethnic elderly cohort 3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Anna Ranta about her paper on transient ischemic attacks as predictors of high risk for subsequent strokes. Dr. Ted Burns is interviewing Dr. Yian Gu for our “What's Trending” feature of the week about his paper on the Mediterranean diet and brain structure in a multiethnic elderly cohort. In the next part of the podcast Dr. Nick Brenton interviews Dr. Daniela Pohl about the topic of disease-modifying therapy management in pediatric multiple sclerosis. DISCLOSURES: Dr. Ranta receives research support from the New Zealand Health Research Council. Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Pohl received funding for travel from Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, ENS, Merck Serono, Consortium of Multiple Sclerosis Center, LACTRIMS and National Multiple Sclerosis Society; received speaker honoraria from Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, Merck Serono and Consortium of Multiple Sclerosis Center; serves on the scientific advisory board for Biogen Idec and Merck Serono.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - March 2016

Tele-neurology: reimbursement, credentialing, quality measures and applications in tele-stroke and other neurological diseases

Published: Monday, 29 Feb 2016 17:00:00 CDT

Tele-neurology and tele-stroke - from September 2015 LOTWs

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 1 2016 Issue

Neurology® Neuroimmunology & Neuroinflammation: Therapy with natalizumab is associated with high JCV sero-conversion and rising JCV index values

Published: Monday, 29 Feb 2016 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation: Therapy with natalizumab is associated with high JCV sero-conversion and rising JCV index values 2) What's Trending: Interviews with Sandi Moriarity and Andy Lucas about their positions and responsibilities with the Neurology podcasts 3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Nicholas Schwab about his Neurology: Neuroimmunology & Neuroinflammation paper on therapy with natalizumab and how it is associated with high JCV sero-conversion and rising JCV index values. Dr. Ted Burns is interviewing Sandi Moriarity and Andy Lucas for our “What's Trending” feature of the week about their positions and responsibilities with the Neurology podcast. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Brenda Banwell about the topic of diagnosis of pediatric multiple sclerosis and acute disseminated encephalomyelitis. DISCLOSURES: Dr. Schwab received funding for travel expenses from Biogen Idec; received speaking honoraria from Novartis; has a patent for Usage of L-selectin as predictive marker for progressive multifocal leukoencephalopathy; and receives research support from the Deutsche Forschungsgemeinschaft German Research Foundation and University Münster, IMF. Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Sandi Moriarity is Senior Production Editor, Neurology. Andy Lucas is Audio-Visual Administrator, American Academy of Neurology. Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada. Dr. Banwell serves as an editorial board member of Neurology and Multiple Sclerosis and Related Disorders; serves on the scientific advisory board for Biogen Idec, Sanofi-aventis, Eli Lilly and Company, Novartis; served as a consultant to Biogen Idec, Eli Lilly and Company, Sanofi-aventis; spoken at an event supported by the Consortium of MS Centers; receives research support from the Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Research Foundation, and the National Multiple Sclerosis Society. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 23 2016 Issue

Neurology® Genetics: Late diagnosis of cerebral folate deficiency: Fewer seizures with folinic acid in adult siblings

Published: Monday, 22 Feb 2016 17:00:00 CDT

1) Neurology® Genetics: Late diagnosis of cerebral folate deficiency: Fewer seizures with folinic acid in adult siblings 2) e-Pearl topic: Stroke-like migraine attacks after radiation therapy (SMART) Syndrome 3) Topic of the month: Neurology Today story about unraveling the genetics of Alzheimer disease and attending the ‘Oscars of Science' This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Dave Dyment about his Neurology: Genetics paper on late diagnosis of cerebral folate deficiency. Dr. Ilena George is reading our e-Pearl of the week about stroke-like migraine attacks after radiation therapy (SMART) syndrome. Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of unraveling the genetics of Alzheimer disease and attending the ‘Oscars of Science.' DISCLOSURES: Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. George serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Hardy serves on the scientific advisory boards for Eisai Inc. and Eli Lilly and Company; is a Consultant for Eisai Inc. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Feburary 16 2016 Issue

Neurology® Neuroimmunology & Neuroinflammation: Vasculitis neuropathy following exposure to minocycline

Published: Monday, 15 Feb 2016 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation: Vasculitis neuropathy following exposure to minocycline 2) e-Pearl topic: Primary progressive aphasia 3) Topic of the month: Neurology Today story about a wearable EEG device This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Chafic Karam about his Neurology: Neuroimmunology & Neuroinflammation paper on vasculitis neuropathy following exposure to minocycline. Dr. Ilena George is reading our e-Pearl of the week about primary progressive aphasia. Dr. Ted Burns interviews Dr. Jacqueline French about a Neurology Today story on the topic of a wearable EEG device. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Karam serves as Deputy Editor for Neurology Write Click; served on the editorial team for the Neurology® Resident and Fellow Section; received speaker honoraria from Nufactor, Inc.; received consulting honoraria from Lundbeck Inc. Dr. George serves on the editorial team for the Neurology Resident and Fellow Section. Dr. French is a consultant for Acorda Therapeutics, Anavex, Brabant Pharma, Bio-Pharm Solutions, Eisai Inc., GlaxoSmithKline, GW Pharma, Impax, Johnson and Johnson, Marinus Pharmaceuticals, Inc., Neusentis, Novartis, Pfizer Inc, Sage, Sunovion Pharmaceuticals Inc., SK Life Sciences, Supernus, Takeda, UCB Pharma, Upsher-Smith Laboratories, Inc., Ultragenyx, Vertex, Zogenix, and Zynerba, all consulting was on behalf of the Epilepsy Study Consortium, and fees are paid to the consortium and New York University receives salary support from the consortium; serves as Associate Editor for Epilepsia; serves as an Editorial board member for Lancet Neurology, Neurology Today and Epilepsy Currents; research support from Acorda Therapeutics, Alexza, LCGH, Eisai Inc., Lundbeck Inc, Pfizer Inc, SK Life Sciences, UCB Pharma, Upsher-Smith Laboratories, Vertex, NIH, and the Epilepsy Foundation. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 9 2016 Issue

Mid-life milk consumption and substantia nigra neuron density at death

Published: Monday, 08 Feb 2016 17:00:00 CDT

1) Mid-life milk consumption and substantia nigra neuron density at death 2) What's Trending: Interview with Dr. Ray Dorsey about new Neurology site, which will be called Innovations in Care Delivery 3) Topic of the month: Neurology Today story about should there be a moratorium on human germline editing This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Robert Abbott about his paper on mid-life milk consumption and substantia nigra neuro density at death. Dr. Robert Gross is interviewing Dr. Ray Dorsey for our “What's Trending” feature of the week about being the section editor and curator of our new Neurology site, which will be called Innovations in Care Delivery. In the next part of the podcast Dr. Ted Burns interviews Dr. Thomas Bird about a Neurology Today story on the topic of should there be a moratorium on human germline editing. DISCLOSURES: Dr. Abbott serves as an editorial board member of Keio Journal of Medicine Journal of Epidemiology, and receives non-profit research support from Pacific Health Research and Education Institute. Dr. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH; since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus and receives an honorarium from AAN as Editor-in-Chief of Neurology. Dr. Dorsey serves on the scientific advisory board of Shire Pharmaceuticals, Huntington's Disease Society of America and NINDS; serves as Editor for HD Insights; serves as an editorial board member of the Journal of Huntington's Disease; serves as Section Editor and Curator for Innovations in Care Delivery mini-site Neurology; received travel funding and honoraria from the American Academy of Neurology; has a patent application related to telemedicine; includes telemedicine in his clinical practice as a movement disorder neurologist (20% effort); has received compensation for expert testimony; is a consultant for 23andME, Amgen, Avid radiopharmaceuticals, Clintrex, Lundbeck Inc, MC10, Inc., Shire Pharmaceuticals, MedAvante, Transpanency Life Sciences and NINDS; receives research support from AMC Health, Avid Radiopharmaceuticals, Biogen Idec, Great Lakes Neurotechnologies, Lundbeck Inc, Medtronic, Inc., Prana Biotechnology, Agency for Health Care Research and Quality; NINDS, National Science Foundation, Patient-Centered Outcomes Research Institute; Davis Phinney Foundation, Michael J. Fox Foundation, Sage Bionetworks. Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Bird serves as an editorial board member of GeneReviews.org; has a patent for Genetic testing technology for CMT1C and SCA14 and receives research support from the Department of Veterans' Affairs, Merit Research Grant.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 2 2016 Issue

Orthostatic tremor: Clinical, electrophysiologic and treatment findings in 184 patients

Published: Monday, 01 Feb 2016 17:00:00 CDT

1) Orthostatic tremor: Clinical, electrophysiologic and treatment findings in 184 patients 2) What's Trending: Interview with Dr. Gretchen Birbeck about Global Neurology site, which will be called Without Borders 3) Topic of the month: Neurology Today story about the SPRINT trial and lowering of blood pressure and stroke This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Anhar Hassan about her paper on the clinical, electrophysiologic and treatment findings in 184 patients with orthostatic tremor. Dr. Robert Gross is interviewing Dr. Gretchen Birbeck for our “What's Trending” feature of the week about being the section editor and curator of our Global Neurology site, which will be called Without Borders. Dr. Ted Burns interviews Dr. James Grotta about a Neurology Today story on the topic of the SPRINT trial and lowering of blood pressure and stroke. DISCLOSURES: Dr. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH; since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus and receives an honorarium from AAN as Editor-in-Chief of Neurology. Dr. Birbeck serves as Section Editor and Curator for Without Borders mini-site Neurology; receives research support from the NIH and Dana Foundation Neuroimaging Grant. Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Grotta serves as an editorial board member for International Journal of Stroke, serves as Consulting editor for Stroke; serves on the steering committee for a clinical trial, Lundbeck Inc.; is a consultant for Specialists on Call, Frazer ambulance and Haemonetics Corporation; has a patent for a composition and method for treatment of cerebral ischemia; receives royalties from the publication of the books Acute Stroke Care and Stroke: Pathology, Diagnosis, and Management; receives research support from Genentech, Inc., Haemonetics Corporation, Coviden, Halle Family/Discount Tire Fund, Alexander Foundation and Mobile Stroke Unit Fund (various donors).

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 26 2016 Issue

Overdiagnosis of idiopathic intracranial hypertension

Published: Monday, 25 Jan 2016 17:00:00 CDT

1) Overdiagnosis of idiopathic intracranial hypertension 2) e-Pearl topic: Neurologic manifestations of Hemolytic Uremic syndrome 3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Valerie Biousse about her paper on overdiagnosis of idiopathic intracranial hypertension. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of Hemolytic Uremic syndrome. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. James F. Meschia about the topic of what's on the horizon in endovascular stroke therapy. DISCLOSURES: Dr. Biousse serves as an editorial board member of American Journal of Ophthalmology and Journal of Neuro-ophthalmology; is a consultant for GenSight; receives royalties from the publication of the books Walsh and Hoyt's Clinical Neuro-Ophthalmology, Neuro-Ophthalmology Illustrated and from Up-to-Date; and receives research support for Research to Prevent Blindness. Dr. Numis serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Meschia serves as an editorial board member of Mayo Clinic Proceedings, Stroke and the European Journal of Neurology; receives research support from the NINDS for efforts devoted to the SiGN study.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 19 2016 Issue

Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF

Published: Monday, 18 Jan 2016 17:00:00 CDT

1) Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF 2) e-Pearl topic: Treatment of pediatric onset neuromyelitis optica 3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Vincent Thijs about his paper on predictors for atrial fibrillation detection after cryptogenic stroke. Dr. Adam Numis is reading our e-Pearl of the week about treatment of pediatric onset neuromyelitis optica. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Lee H. Schwamm about the topic of implications for stroke systems of care in endovascular stroke therapy. DISCLOSURES: Dr. Thijs serves as an Associate Editor for Acta Neurologica Belgica; serves as an editorial board member of Stroke and European Journal of Emergency Medicine; serves on the scientific advisory board for Sygnis Ax200 steering committee, Boehringer Ingelheim Belgium advisory board, Boehringer Ingelheim international advisory board, Medtronic steering committee of the REACT-AF trial; is a consultant for Boehringer Ingelheim, Pfizer Inc, Bayer Schering Pharma, AstraZeneca. Medtronic, Inc.; serves on the speakers bureau of Pfizer Inc, Boehringer Ingelheim and Medtronic, Inc.; received funding for travel or speaker honoraria from Medtronic, Inc.; Boehringer Ingelheim, Pfizer Inc, and Bayer Schering Pharma; receives research support from SYGNIS AG, Medtronic, Inc., Pfizer Inc, AstraZeneca, Boehringer Ingelheim and VIB Flanders Research Fund (FWO). Dr. Numis serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Schwamm serves on the scientific advisory board for CoAxia, Lundbeck Inc. DIAS 4 steering Committee, LifeImage and Medtronic, Inc.; serves as an editorial board member for Neurocritical Care, Stroke and Frontiers in TeleNeurology; receives royalties from the publication of the book Acute Ischemic Stroke: Imaging and Intervention, 2nd Edition; is a consultant for Lundbeck Inc. DIAS 4 steering Committee, LifeImage, Medtronic, Inc., and Massachusetts Department of Public Health; has a patent for Imaging system for obtaining quantitative perfusion indices. US Patent 6,542,769. 2003 Apr 1, The General Hospital Corporation assignee, Inventors: Schwamm LH and Sorensen AG; is the principal investigator of an investigator-initiated study of extended-window intravenous thrombolysis funded by the National Institutes of Neurological Disorders and Stroke (clinicaltrials.gov/show/NCT01282242) for which Genentech provides alteplase free of charge to Massachusetts General Hospital as well as supplemental per-patient payments to participating sites; is the chair of the AHA/ASA GWTG stroke clinical work group.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 12 2016 Issue

Neurology® Clinical Practice article titled: Anti-GAD antibody syndrome with concomitant cerebellar ataxia, stiff-person syndrome, and limbic encephalitis

Published: Monday, 11 Jan 2016 17:00:00 CDT

1) Neurology® Clinical Practice: Anti-GAD syndrome with concomitant cerebellar ataxia, stiff-person syndrome, and limbic encephalitis 2) What's Trending: Current exciting projects at the AAN 3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Sara Schaefer about her Neurology: Clinical Practice paper on anti-GAD syndrome with concomitant cerebellar ataxia, stiff-person syndrome, and limbic encephalitis. Dr. Ted Burns is interviewing Cathy Rydell for our “What's Trending” feature of the week about current exciting projects happening at the AAN. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Max Wintermark about the topic of imaging modalities used as selection criteria in endovascular stroke therapy. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Catherine M. Rydell is Executive Director & Chief Executive Officer, American Academy of Neurology. Dr. Wintermark serves as an editorial board member of American Journal of Neuroradiology and American Journal of Roentgenology; serves on the scientific advisory board for the GE-NFL board. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Physician Burnout; a primer for neurologists

Physician Burnout; a primer for neurologists

Published: Tuesday, 05 Jan 2016 11:13:00 CDT

Physician Burnout; a primer for neurologists

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 5 2016 Issue

Pregnancy outcomes in aquaporin-4 positive neuromyelitis optica

Published: Monday, 28 Dec 2015 17:00:00 CDT

1) Pregnancy outcomes in aquaporin-4 positive neuromyelitis optica 2) What's Trending: Safety and tolerability of resveratrol for Alzheimer disease 3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Maria Isabel S. Leite about her paper on pregnancy outcomes in aquaporin-4 positive neuromyelitis optica. Dr. Ted Burns is interviewing Dr. R. Scott Turner for our “What's Trending” feature of the week about his paper on a randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Pooja Khatri about the topic of broad overview of the new clinical trials in endovascular stroke therapy. DISCLOSURES: Dr. Leite serves as an editorial board member for Neuromuscular Disorders; has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis; is supported by NHS National Specialized Commissioning Group for Neuromyelitis Optica, UK and by NIHR Oxford Biomedical Research Centre. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Turner serves on the data safety and monitoring board for the National Institute on Aging; serves as an editorial board Member for Frontiers in Neuroscience and Neuropsychology and Cognition; receives research support from the National Institute on Aging. Dr. Khatri provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc, Genentech, Inc. and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 15 2015 Issue

Neurology® Neuroimmunology & Neuroinflammation Journal: Basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures

Published: Monday, 14 Dec 2015 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation Journal: Basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Dr. Eoin Flanagan about his Neurology: Neuroimmunology & Neuroinflammation paper on basal ganglia T1-hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in facioscapulohumeral dystrophy. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of immunotherapy for autoimmune cerebellar ataxia. The participants had nothing to disclose except Drs. Numis, Burns and Ringel. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Ringel serves as editor of Neurology Today. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 8 2015 Issue

Practice Guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response

Published: Monday, 07 Dec 2015 17:00:00 CDT

1) Response to shunting and predictors of response in idiopathic normal pressure hydrocephalus and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. John Halperin about the AAN guideline on response to shunting and predictors of response in idiopathic normal pressure hydrocephalus. Dr. Ted Burns is interviewing Dr. Qadeer Arshad for our “What's Trending” feature of the week about his paper on electrocortical therapy for motion sickness. In the next part of the podcast Dr. Ted Burns interviews Dr. Lorenz Studer about a Neurology Today story on the topic of stem cell therapy in Parkinson disease. The participants had nothing to disclose except Drs. Mateen, Halperin, Burns and Studer. Dr. Mateen received research support from the Canadian Institute of Health Research. Dr. Halperin serves as an editorial board member of The Neurologist, ACP PIER, Current Neurology & Neuroscience Reports; serves on the evidence-based medicine group for Neurology®; receives speakers' honoraria from the American Academy of Neurology, Flemish Neurological Society, University of Maryland, Winthrop University Hospital and Inova Health System; receives royalties from the publication of the book Lyme disease-An evidence-based approach and from Up-to-Date; gave expert testimony in medical malpractice cases defending physicians related to Lyme disease; received research support from Centers for Disease Control & Prevention, Lyme disease vs. MS. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Studer serves on the scientific advisory board for Allen Brain Institute and Neurona Irc.; received travel of compensation Allen Brain Institute and Neurona Irc.; is a consultant for Allen BrainInstitute and Neurona Irc.; is a consultant for Allen Brain Institute and Neurona Irc.; has a patent for dopaminergic neuron.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 1 2015 Issue

Endovascular versus medical management of acute ischemic stroke

Published: Monday, 30 Nov 2015 17:00:00 CDT

1) Endovascular versus medical management of acute ischemic stroke and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Brad Worrall about his paper on endovascular versus medical management of acute ischemic stroke. Dr. Ted Burns is interviewing Dr. Daniel Kaufer for our “What's Trending” feature of the week about the AAN Behavioral Neurology Section Workgroup paper on improving clinical cognitive testing. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of defective nuclear transport and endogenous retrovirus in ALS. The participants had nothing to disclose except Drs. Barrett, Worrall, Burns, Kaufer and Ringel. Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH. Dr. Worrall serves as Associate Editor for Neurology®; receives royalties as Chapter Author for Merritt's Neurology editions 10, 11, and 12; and receives research support from the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Kaufer is a consultant for Janssen Research and Development; receives research support from TauRx Therapeutics Ltd, Navidea Biopharmaceuticals, Inc., Guardian Angel Thrift Fund, National Football League Players Association and the NIH. Dr. Ringel serves as editor of Neurology Today.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 24 2015 Issue

Stroke risk stratification in acute dizziness presentations: A prospective imaging-based study

Published: Monday, 23 Nov 2015 17:00:00 CDT

1) Stroke risk stratification in acute dizziness presentations and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Kevin Kerber about his paper on stroke risk stratification in acute dizziness presentations. Dr. Sarah Wesley is reading our e-Pearl of the week about focal cortical dysplasia. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jacqueline Palace about the topic of aquaporin-4 molecular mimicry/pathogenesis/research developments. The participants had nothing to disclose except Drs. Southerland, Kerber, Wesley, Clardy and Palace. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clardy receives research support from the Western Institute for Biomedical Research. Dr. Palace serves as on the scientific advisory board for Merck Serono, Bayer Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis Pharmaceuticals UK Ltd., Sanofi-aventis, Alexion; received support for attending ECTRIMS Merck Serono Novartis and Biogen Idec Talks at scientific meetings (majority have CME) Bayer Schering Pharma, Biogen Idec, Merck Serono, Medimmune; is a consultant for Ono Pharmaceuticals Ltd., Chugai Pharma Ltd., CI Consulting, Biogen Idec, GlaxoSmithKline, Alexion; serves on the speakers' bureau of Teva The CMSC, U. S.; receives research support from Bayer Schering Pharma, Merck Serono, Novartis Teva Pharmaceutical Industries Ltd., MS Society UK, Guthy Jackson Foundation and Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service; receives revenue from a patent from ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 17 2015 Issue

Autoimmune post-herpes simplex encephalitis of adults and teenagers

Published: Monday, 16 Nov 2015 17:00:00 CDT

1) Autoimmune post-herpes simplex encephalitis in adults and teenagers and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Josep Dalmau about his paper on autoimmune post-herpes simplex encephalitis in adults and teenagers. Dr. Sarah Wesley is reading our e-Pearl of the week about immunotherapy-responsive seizures. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Dean Wingerchuk about the topic of new guidelines for neuromyelitis optica. The participants had nothing to disclose except Drs. Dalmau, Wesley, Clardy and Wingerchuk. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clardy receives research support from the Western Institute for Biomedical Research. Dr. Wingerchuk serves as an editorial advisory board member for Current Medical Research and Opinion and Drugs in Context; serves as an editorial board member for Journal of Clinical Apheresis; serves as Co-Editor-in-Chief of The Neurologist; served on the adjudication committee for therapeutic trial for MedImmune; is a consultant for Alexion and MedImmune; receives research support from Alexion, TerumoBCT and Guthy-Jackson Charitable Foundation.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 10 2015 Issue

Spectrum of cognition short of dementia: Framingham heart study and Mayo Clinic study of aging

Published: Monday, 09 Nov 2015 17:00:00 CDT

1) Spectrum of cognition short of dementia and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. David Knopman about his paper on the spectrum of cognition short of dementia. Dr. Ted Burns is interviewing Dr. Terrence Cascino for our “What's Trending” feature of the week about what AAN is doing to combat the trend of physician burnout. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Sean Pittock about the topic of neuromyelitis optica assay development, treatments and mimics, including MOG antibodies. The participants had nothing to disclose except Drs. Jeff Burns, Knopman, Burns, Cascino, Clardy and Pittock. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Knopman served as Deputy Editor for Neurology®; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; serves as a consultant to the Bluefield Project to Cure Frontotemporal Dementia; and receives research support from the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Cascino serves as President for the American Academy of Neurology. Dr. Clardy receives research support from the Western Institute for Biomedical Research. Dr. Pittock receives research support from Alexion, Guthy Jackson Charitable Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 3 2015 Issue

Neurology® Neuroimmunology & Neuroinflammation article titled: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

Published: Monday, 02 Nov 2015 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Isabel Illa about her Neurology: Neuroimmunology & Neuroinflammation paper on rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Dr. Ted Burns is interviewing Dr. Murray Grossman for our “What's Trending” feature of the week about his paper on the classification of primary progressive aphasia and its variants. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jeff Bennett about the topic of latest developments in neuromyelitis optica using his antibody library. The participants had nothing to disclose except Drs. Illa, Burns, Grossman, Clardy and Bennett. Dr. Illa received a travel grant from Genzyme; serves as an editorial board member of Neurologia; holds a patent for Dysferlin detection in monocytes; has consulted for Grifols; received research support from Fondo de Investigaciones Sanitarias and ISCIII, Ministry of Health (Spain), Fundacion Gemio. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Grossman serves on the scientific advisory board for Forum; serves as an editorial board member of Neurology®, Journal of Neurolinguistics, Journal of Alzheimer's Disease; serves on the editorial advisory board for Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration; receives research support from Wyncote Foundation, ALS Association and the NIH; received travel funding for a site visit from Max-Planck Society. Dr. Clardy receives research support from the Western Institute for Biomedical Research. Dr. Bennett serves on the scientific advisory board for Apsara Therapeutics; serves as an editorial board member of Journal of Neuro-ophthalmology, Multiple Sclerosis Journal and Neurology® Neuroimmunology and Neuroimflammation; has patents for compositions and methods for the treatment of neuromyelitis optica and novel blocking monoclonal therapy for neuromyelitis optica; is a consultant for EMD-Serono, Questcor Pharmaceuticals, Alnaylam Pharmaceuticals, Medimmune, Abbvie, Novartis, Chugai Pharmaceuticals Co., Ltd., Genzyme Corporation, Genentech, Inc.; receives license fee payments from Aquaporumab; has rights for future royalty payments from Aquaporumab; holds stock options in Apsara Therapeutics; receives research support from Questcor Pharmaceuticals, Novartis, NIH and Guthy-Jackson Foundation. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 27 2015 Issue

Infection, vaccination and childhood arterial ischemic stroke: Results of the VIPS study

Published: Monday, 26 Oct 2015 17:00:00 CDT

1) Infection, vaccination and childhood arterial ischemic stroke and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark McAllister interviews Dr. Heather Fullerton about her paper on infection, vaccination and childhood arterial ischemic stroke. Dr. Adam Numis is reading our e-Pearl of the week about Lafora body disease. In the next part of the podcast Dr. Ted Burns interviews Dr. Jim Bernat about his Neurology Today book review about “The Digital Doctor.” The participants had nothing to disclose except Drs. Fullerton, Numis, Burns and Bernat. Dr. Fullerton serves as an editorial board member of Stroke; serves on a DSMB for the NIH for clinical trials related to sickle cell disease and stroke; and receives research support from American Heart Association Established Investigator Award. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Bernat serves as an editorial board member of Neurocritical Care, Neurology Today, The Physician's Index for Ethics and Medicine and Multiple Sclerosis and Related Diseases; receives royalties from the publication of the books Ethical and Legal Issues in Neurology, Ethical Issues in Neurology, 3rd ed. and Palliative Care in Neurology.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 20 2015 Issue

Neurology® Genetics: Phenotypic and molecular analyses of primary lateral sclerosis

Published: Monday, 19 Oct 2015 17:00:00 CDT

1) Neurology® Genetics: Phenotypic and molecular analyses of primary lateral sclerosis and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Hitoshi Mitsumoto about his Neurology: Genetics paper on the phenotypic and molecular analyses of primary lateral sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about cerebral amyloid angiopathy-related inflammation. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of systemic exertion intolerance disease. The participants had nothing to disclose except Drs. Dimberg, Mitsumoto, Numis, Burns and Ringel. Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast. Dr. Mitsumoto is a consultant for Biogen Idec; receives research support from Avanir Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Biogen Idec and the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Ringel serves as editor of Neurology Today. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 13 2015 Issue

Longitudinal study of normal cognition in Parkinson disease

Published: Monday, 12 Oct 2015 17:00:00 CDT

1) Longitudinal study of normal cognition in Parkinson disease and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Daniel Weintraub about his paper on studying normal cognition in Parkinson disease. Dr. Ted Burns is interviewing Mike Avery for our “What's Trending” feature of the week about things happening in the Beltway of interest to neurologists. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of uptick in cases of narcolepsy. The participants had nothing to disclose except Drs. Barrett, Weintraub, Burns and Ringel. Dr. Barrett received research support from the Virginia Center of Alzheimer´s and Related Diseases Research Award Fund. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's Disease; serves on the scientific advisory boards for Pfizer, Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc. UCB, Bristol-Myers Squibb, Novartis, Clintrex, LLC, Theravance Biopharma, Medivation, Inc. Non-profit-CHDI, ADCS; receives licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; receives research support from Novartis, Michael J. Fox Foundation and the NIH; gave expert testimony for defense in 2012-2014 in two lawsuits related to impulse control disorders in Parkinson disease. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Ringel serves as editor of Neurology Today.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 6 2015 Issue

Evaluation of outcome measures for neurogenic claudication: A patient-centered approach

Published: Monday, 05 Oct 2015 17:00:00 CDT

1) Evaluation of outcome measures for neurogenic claudication and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. John Markman about his paper on a patient-centered approach for evaluation of outcome measures for neurogenic claudication. Dr. Ted Burns is interviewing Dr. Robert Gross for our “What's Trending” feature of the week about Neurology's spoke journals. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of acute flaccid myelitis. The participants had nothing to disclose except Drs. Burns, Markman and Ringel. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Markman serves on the scientific advisory board for Allergan, Inc., Pfizer Inc, Purdue Pharma L. P., Chromocell Corporation, Plasma Surgical, Nektar, Depomed, Inc., Regeneron Pharmaceuticals; serves as an editorial board member of Merck Serono; is a consultant for Xian Janssen Pharmaceutical Ltd. and Nektar; receives research support from Depomed, Inc., Pfizer Inc and as a special government employee of the Food and Drug Administration. Dr. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH, since his appointment as Editor-in-Chief in 2009, he has ceased participation in industry-sponsored clinical trials and speakers' bureaus, receives an honorarium from AAN as Editor-in-Chief of Neurology. Dr. Ringel serves as editor of Neurology Today.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 29 2015 Issue

Hemorrhagic stroke following use of the synthetic marijuana "spice"

Published: Monday, 28 Sep 2015 17:00:00 CDT

1) Hemorrhagic stroke following use of the synthetic marijuana "spice" and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. David Rose about his paper on hemorrhagic stroke following use of the synthetic marijuana "spice." Dr. Sarah Wesley is reading our e-Pearl of the week about Hirayama disease. In the next part of the podcast Dr. Andy Southerland interviews Dr. Jennifer Majersik about the topic of tele-neurology quality measures. The participants had nothing to disclose except Drs. Rose, Wesley, Southerland and Majersik. Dr. Rose serves as an editorial board member of Neurohospitalist Journal and serves on the Speakers' bureau of Boehringer Ingelheim. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Majersik receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 22 2015 Issue

Acute headache diagnosis in pregnant women: A hospital-based study

Published: Monday, 21 Sep 2015 17:00:00 CDT

1) Acute headache diagnosis in pregnant women and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Teshamae Monteith interviews Dr. Matthew Robbins about his paper on acute headache diagnosis in pregnant women. Dr. Sarah Wesley is reading our e-Pearl of the week about primary lateral sclerosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Jack Tsao about the topic of reimbursement, credentialing, and policy updates. The participants had nothing to disclose except Drs. Monteith, Robbins, Wesley, Southerland and Tsao. Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH. Dr. Robbins serves as an editorial board member of Headache and The Einstein Journal of Biology and Medicine; received honoraria for educational content and presentation American Headache Society and Prova Education and receives royalties from the publication of the book Headache (Neurology in Practice series). Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Tsao receives royalties from the publication of the book Traumatic Brain Injury: A Clinician's Guide to Diagnosis, Management, and Rehabilitation and receives research support from the US Army Medical Research and Materiel Command and the Wounded, Ill & Injured Directorate, US Navy Bureau of Medicine and Surgery.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 15 2015 Issue

Neurology® Clinical Practice: Medical marijuana: Between a plant and a hard place

Published: Monday, 14 Sep 2015 17:00:00 CDT

1) Neurology® Clinical Practice: Medical Marijuana: Between a plant and a hard place and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Wong interviews Dr. David Gloss about his Neurology Clinical Practice paper on medical marijuana: Between a plant and a hard place. Dr. Sarah Wesley is reading our e-Pearl of the week about arterial retinal ischemic disease. In the next part of the podcast Dr. Andy Southerland interviews Dr. Bert Vargas about the topic of teleconcussion. The participants had nothing to disclose except Drs. Gloss, Wesley, Southerland and Vargas. Dr. Gloss serves as an evidence-based medicine consultant for the American Academy of Neurology; serves as an LOE associate editor for Neurology® and receives royalties from the publicationof the book Neurology for the Specialty Boards. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Vargas serves on the scientific advisory boards Allergan, Inc and Zogenix, Inc.; receives honoraria for travel from the American Headache Society. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 8 2015 Issue

Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons

Published: Monday, 07 Sep 2015 17:00:00 CDT

1) Pathogenic effects of antibodies on gut and brain neurons in anti-DPPX encephalitis and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Johannes Piepgras about his paper on pathogenic effects of antibodies on gut and brain neurons in anti-DPPX encephalitis. Dr. Ted Burns is interviewing Morgan Sorenson for our "What's Trending" feature of the week about twitter handles. In the next part of the podcast Dr. Andy Southerland interviews Dr. Kevin Barrett about the topic of teleneurology (non-stroke applications). The participants had nothing to disclose except Drs. Burns, Sorenson, Southerland and Barrett. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Morgan Sorenson is Managing Editor, Neurology® Neuroimmunology & Neuroinflammation. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Oliver Sacks Tribute

Oliver Sacks Tribute

Published: Tuesday, 01 Sep 2015 03:00:00 CDT

Interviews with Oliver Sacks. Lesson of the week interviews from January 2011.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 1 2015 Issue

Neurology® Neuroimmunology & Neuroinflammation article titled: Aquaporin-4 autoimmunity, a review

Published: Monday, 31 Aug 2015 17:00:00 CDT

1) Neurology® Neuroimmunology & Neuroinflammation: Aquaporin-4 autoimmunity and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Vanda Lennon about her Neurology: Neuroimmunology & Neuroinflammation paper on aquaporin-4 autoimmunity. Dr. Ted Burns is interviewing Kathy Pieper for our "What's Trending" feature of the week about you tube videos. In the next part of the podcast Dr. Andy Southerland interviews Dr. Kevin Barrett about the topic of updates in telestroke. The participants had nothing to disclose except Drs. Lennon, Burns, Pieper, Southerland and Barrett. Dr. Lennon receives research support from the NIH. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Kathy Pieper is Managing Editor, Neurology®. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH. NO CME WILL BE OFFERED THIS WEEK.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 25 2015 Issue

Migraine and risk of stroke in older adults: Northern Manhattan Study

Published: Monday, 24 Aug 2015 17:00:00 CDT

1) Migraine and risk of stroke in older adults and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Teshamae Monteith about her paper on migraine and risk of stroke in older adults. Dr. Adam Numis is reading our e-Pearl of the week about neurosyphilis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of antemortem signatures of neurodegenerative proteinopathies. The participants had nothing to disclose except Drs. Southerland, Monteith, Numis, Espay and Josephs. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 18 2015 Issue

Opioids for chronic noncancer pain: To prescribe or not to prescribe-What is the question? and Opioids for chronic, non-cancer pain: Science, policy and best practice in a rapidly changing landscape: A position paper of the American Academy of Neurology

Published: Monday, 17 Aug 2015 17:00:00 CDT

1) Opioids for chronic non-cancer pain and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen Nadeau and Gary Franklin about their papers on opioids for chronic non-cancer pain and the policy behind prescribing them. Dr. Adam Numis is reading our e-Pearl of the week about vaccinations and seizures. In the next part of the podcast Dr. Alberto Espay interviews Dr. Virginia Lee about her Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of transmission of alpha-Synuclein in Parkinson disease: Pathogenesis and implications for therapy. The participants had nothing to disclose except Drs. Burns, Nadeau, Franklin, Numis, Espay and Lee. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Nadeau served on the DSMB for the National Institute of Neurological Disorders and Stroke and National Institute of Child Health and Human Development funded Interdisciplinary Comprehensive Arm Rehab Evaluation, DSMB ; served as an Associate Editor of the Journal of the International Neuropsychological Society; received honoraria and funding for travel for an International Neuropsychological Society meeting; received funding for travel for an American Neuropsychiatric Association meeting; receives royalties from the publication of the book The Neural Architecture of Grammar ; and receives research support from a VA Rehabilitation R&D Grant and University of Florida McKnight Brain Institute Brain and Spinal Cord Injury Research Trust Fund Grant. Dr. Franklin serves as an editorial board member of Neurology® Levels of Evidence Team and Neuroepidemiology; is a consultant for the California State Compensation Insurance Fund and receives research support from the Centers for Disease Control and Prevention (CDC). Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Lee serves as an editorial board member of Laboratory Investigation, Neurorehabilitation and Neural Repair, NeuroSignals, Neuron, Experimental Neurology, Science Magazine; receives research support from Ware Benaroya and the NIH; receives revenue for the following patent: "Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants" Penn G1120, Patent # 5,792,900.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 11 2015 Issue

CIDP diagnostic pit-falls and perception of treatment benefits

Published: Monday, 10 Aug 2015 17:00:00 CDT

1) CIDP diagnostic pit-falls and perception of treatment benefits and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interviews Dr. Jeffrey Allen about his paper on chronic inflammatory demyelinating polyneuropathy diagnostic pit-falls and perception of treatment benefits. Dr. Adam Numis is reading our e-Pearl of the week about exam findings in hemifacial spasms. In the next part of the podcast Dr. Alberto Espay interviews Dr. Howard Weiner about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of immune mechanisms in neurologic diseases. The participants had nothing to disclose except Drs. Mauermann, Allen, Numis, Espay and Weiner. Dr. Mauermann receives research support from ISIS Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and the NIH. Dr. Allen is a consultant for AxelaCare and CSL Behring. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Weiner is a consultant for Biogen Idec, Novartis, Merck Serono, Sanofi-aventis, Teva Pharmaceutical Industries Ltd. and Therapix Biosciences Ltd.; served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis; receives research support from EMD, Merck Serono, National Multiple Sclerosis Society, and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

N2 August 2015 Issue

Widespread arterial infection by varicella zoster virus explains refractory giant cell arteritis

Published: Thursday, 06 Aug 2015 17:00:00 CDT

Josep O. Dalmau, Editor of Neurology: Neuroimmunology & Neuroinfammation introduces the podcast inverview. Dr. Laura Benjamin interviews Dr. Don Gilden about his paper Widespread arterial infection by varicella zoster virus explains refractory giant cell arteritis. J. Damlau is the editor of Neurology: Neuroimmunology & Neuroinflammation, is on the editorial board for Neurology UpToDate, holds patents for and receives royalties from Ma2 autoantibody test, NMDA receptor autoantibody test, GABA(B) receptor autoantibody test, GABA(A) receptor autoantibody test, DPPX autoantibody test, IgLON5 autoantibody test, received research support from Euroimmun, NIH, Fondo de Investigaciones Sanitarias de la Seguridad Social (Spanish Government); L. Benjamin reports no disclosures; D. Gilden is a senior Associate editor for Journal of NeuroVirology, is on the editorial board for In Vivio, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology, Journal of the Neurological Sciences, received research support from NIH;

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 4 2015 Issue

Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy

Published: Monday, 03 Aug 2015 17:00:00 CDT

1) Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Grete Andersen about her paper on aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy. Dr. Adam Numis is reading our e-Pearl of the week about non-invasive imaging of arterial dissection with MRI. In the next part of the podcast Dr. Alberto Espay interviews Dr. Stefan Pulst about his George C. Cotzias Lecture at the AAN Meeting about the topic of degenerative ataxias: From genes to therapies. The participants had nothing to disclose except Drs. Ensrud, Numis, Espay and Pulst. Dr. Ensrud serves on the data safety monitoring board for phase II trial of methotrexate in myastenia gravis; is a consultant for Skulpt/Convergence Medical Devices and FDA; received honoraria and funding for travel from Osler Institute; received funding for travel from American Association of Physical Medicine and Rehabilitation; and received honoraria from American Association of Neuromuscular and Electrodiagnostic Medicine. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Pulst serves as Editor-in-Chief of Current Genomics; serves as Editor of Neurology® Genetics; serves as an editorial board member of Journal of Cerebellum, NeuroMolecular Medicine, Continuum, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology; is author on patents re: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; and Compositions and methods for spinocerebellar ataxia; receives royalties from the publications of the books The Ataxias, Genetics in Neurology, Genetics of Movement Disorders, Neurogenetics, and Molecular Genetic Testing in Neurology, 2nd–5th ed.; serves on the speakers' bureau for Athena Diagnostics; receives research support from the NIH and the National Ataxia Foundation; receives license fee payments from Cedars-Sinai Medical Center; and has provided expert testimony in a medico-legal case.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - August 2015

Inflammatory Myopathy

Published: Saturday, 01 Aug 2015 03:00:00 CDT

Inflammatory myopathy. Lesson of the week interviews from May 2015.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 28 2015 Issue

Evidence-based guideline: Evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy

Published: Monday, 27 Jul 2015 17:00:00 CDT

1) Evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Rabi Tawil about his paper on the evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy. Dr. Sarah Wesley is reading our e-Pearl of the week about vertical nystagmus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Helen Mayberg about her Robert Wartenberg Lecture at the AAN Meeting on the topic of what deep brain stimulation has taught us about the neurology of depression. The participants had nothing to disclose except Drs. Burns, Tawil, Wesley and Espay. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Tawil serves as an editorial board member of Journal of Neuromuscular Diseases; serves on the safety monitoring board of Novartis; receives royalties from the publication of the books Neuromuscular Disorders (Rabi N. Tawil & Shannon Venance, Editors) and Neurology in Practice Series; receives research support from the NIH and Spinal Muscular Atrophy Foundation. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 21 2015 Issue

Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study

Published: Monday, 20 Jul 2015 17:00:00 CDT

1) Paraneoplastic neurologic disorders in small cell lung carcinoma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Paul Gozzard about his paper on paraneoplastic neurologic disorders in small cell lung carcinoma. Dr. Sarah Wesley is reading our e-Pearl of the week about Balint Syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Lloyd Kasper about his Hot Topic Lecture at the AAN Meeting on the topic of digesting the gut microbiome: role in CNS demyelinating disease. The participants had nothing to disclose except Drs. Dimberg, Wesley and Espay. Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 14 2015 Issue

Early EEG contributes to multimodal outcome prediction of postanoxic coma

Published: Monday, 13 Jul 2015 17:00:00 CDT

1) Early EEG contributing to multimodal outcome prediction of postanoxic coma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Schomer interviews Dr. Jeannette Hofmeijer about her paper on early EEG contributing to multimodal outcome prediction of postanoxic coma. Dr. Sarah Wesley is reading our e-Pearl of the week about Susac syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Daniel Lowenstein about his H. Houston Merritt Lecture at the AAN Meeting on the topic of advances in the treatments for epilepsy. The participants had nothing to disclose except Drs. Wesley, Espay and Lowenstein. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Lowenstein receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 7 2015 Issue

Switching from natalizumab to fingolimod: a randomized, placebo-controlled study of patients with RRMS

Published: Monday, 06 Jul 2015 17:00:00 CDT

1) Switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ludwig Kappos about his paper on switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis. Dr. Sarah Wesley is reading our e-Pearl of the week about dopamine-responsive dystonia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Timothy Pedley about his Presidential Lecture at the AAN Meeting about the topics of neurologists' burnout, cost and quality of healthcare, value of neurology to congress and payers along with maintenance of certification. The participants had nothing to disclose except Drs. Keegan, Kappos, Wesley, Espay and Pedley. Dr. Keegan serves as Chief Editor of eMedicine; serves as an editorial board member of Multiple Sclerosis and Related Disorders; is a consultant for Novartis, Bristol-Meyers Squibb, Bionest Partners and receives research support from Terumo BCT and Caridian BCT. Dr. Kappos serves as an editorial board member of Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders and Journal of Neurology; receives research support from Actelion Pharmaceuticals Ltd, Addex, Bayer Schering Pharma, Biogen Idec, Biotica, CSL Behring, Genzyme Corporation, Eli Lilly and Company, Merck Serono, Mitsubishi, Novartis, Ono Pharma, Pfizer Inc, Receptos, Roche, Sanofi-aventis, Santhera, Siemens, Teva Pharmaceutical Industries Ltd., UCB, Xenoport, Swiss National Research Foundation and the European Union and The Swiss MS Society; honoraria and other payments for all these activities have been exclusively used for funding of research of his department. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Pedley serves as an editorial board member of Journal of Clinical Neurophysiology and Nature Reviews Neurology and as Editor-in-Chief (Neurology) for UpToDate; serves as President for the American Academy of Neurology; receives royalties form the publication of the books Current Practice of Clinical Electroencephalography, Epilepsy: A comprehensive Textbook and Merritt's Neurology.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - July 2015

Autoimmune & Paraneoplastic Encephalitis

Published: Wednesday, 01 Jul 2015 03:00:00 CDT

Stroke in Systemic Disease. Lesson of the week interviews from March 2015.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 16 2015 Issue

SMART: Screening with MRI for accurate and rapid stroke treatment

Published: Monday, 15 Jun 2015 17:00:00 CDT

1) Screening with MRI for accurate and rapid stroke treatment and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Amie Hsia about her paper on screening with MRI for accurate and rapid stroke treatment. Dr. James Addington is reading our e-Pearl of the week about intracranial hypotension. In the next part of the podcast Dr. Lara Marcuse interviews Mia about the topic of Anti-N-methyl-D-aspartate. The participants had nothing to disclose except Dr. Loddenkemper and Addington. Dr. Barrett serves as an Associate Editor for Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 9 2015 Issue

Time from convulsive status epilepticus onset to anticonvulsant administration in children

Published: Monday, 08 Jun 2015 17:00:00 CDT

1) Time from convulsive status epilepticus onset to anticonvulsant administration in children and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Tobias Loddenkemper about his paper on time from convulsive status epilepticus onset to anticonvulsant administration in children. Dr. James Addington is reading our e-Pearl of the week about cannabis in epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Stephen Haslett about the topic of herpes simplex virus encephalitis. The participants had nothing to disclose except Dr. Loddenkemper and Addington. Dr. Loddenkemper performs video EEG long term monitoring, EEGs and other electrophysiological studies at Boston Children's Hospital (20% effort); evaluates pediatric neurology patients; serves on the Laboratory Accreditation Board for Long Term (Epilepsy and Intensive Care Unit) Monitoring, on the Council of the American Clinical Neurophysiology Society, on the American Board of Clinical Neurophysiology; serves as an Associate Editor for Seizure serves as Contributing Editor for Epilepsy Currents; serves as an Associate Editor for Wyllie's Treatment of Epilepsy 6th edition; is part of pending patent applications to detect seizures and to diagnose epilepsy; receives research support from the American Epilepsy Society, the Epilepsy Foundation of America, the Epilepsy Therapy Project, PCORI, the Pediatric Epilepsy Research Foundation, Cure, Danny-Did Foundation, HHV-6 Foundation, Lundbeck Inc., Eisai Inc., and Upsher-Smith Laboratories, Inc. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 2 2015 Issue

Emerging Subspecialties in Neurology: Tele-stroke & tele-neurology

Published: Monday, 01 Jun 2015 17:00:00 CDT

1) Tele-stroke and tele-neurology and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nina Solenski interviews Dr. Sunil Mutgi about his paper on tele-stroke and tele-neurology. Dr. James Addington is reading our e-Pearl of the week about cerebral vasospasm in subarachnoid hemorrhage. In the next part of the podcast Dr. Lara Marcuse interviews Kenneth Kearins and his wife Patricia Kennedy about the topic of autoimmune encephalitis with antibodies to LGI-1. The participants had nothing to disclose except Dr. Addington. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - June 2015

Implementation of Genetic Testing

Published: Monday, 01 Jun 2015 03:00:00 CDT

Implementation of Genetic Testing. Lesson of the week interviews from April 2015.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 26 2015 Issue

The rising cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Published: Monday, 25 May 2015 17:00:00 CDT

1) Rising cost of multiple sclerosis drugs in the U. S. and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Jones interviews Dr. Daniel Hartung about his paper on the rising cost of multiple sclerosis drugs in the U. S. Dr. Adam Numis is reading our e-Pearl of the week about Walker-Warburg syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of treatment overview of immunotherapy for the immune-mediated myopathies. The participants had nothing to disclose except Drs. Jones, Hartung, Numis, Burns and Mammen. Dr. Jones has received personal compensation for attending consultant meetings for Biogen Idec, Novartis and Genzyme Corporation. Dr. Hartung serves on the data safety monitoring board for Kaiser Permanente Center for Health Research; is a consultant for Alkermes Inc.; receives research support from Alkermes Inc. and the Center for Disease Control and National Institute on Drug Abuse. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 19 2015 Issue

The practice of neurology: Looking ahead by looking back

Published: Monday, 18 May 2015 17:00:00 CDT

1) Looking ahead by looking back at practicing neurology and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Steven Ringel about his paper on looking ahead by looking back at practicing neurology. Dr. Adam Numis is reading our e-Pearl of the week about neurologic complications of heroin inhalation. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of inclusion body myositis. The participants had nothing to disclose except Drs. Ringel, Numis, Burns and Mammen. Dr. Ringel serves as Editor of Neurology Today. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 12 2015 Issue

Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis

Published: Monday, 11 May 2015 17:00:00 CDT

1) Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Don Gilden about his paper on the prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Dr. Adam Numis is reading our e-Pearl of the week about unresponsive CIDP: Is it POEMS? In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of dermatomyositis. The participants had nothing to disclose except Drs. Gilden, Numis, Burns and Mammen. Dr. Gilden serves as an Senior Associate Editor for Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology and Journal of the Neurological Sciences; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 5 2015 Issue

Dystonia: Five new things

Published: Monday, 04 May 2015 17:00:00 CDT

1) Dystonia: Five new things and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Brian Berman about his paper on five new things about dystonia. Dr. Adam Numis is reading our e-Pearl of the week about hereditary hemorrhagic telangectasia. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of immune-mediated necrotizing myopathy. The participants had nothing to disclose except Drs. Berman, Numis, Burns and Mammen. Dr. Berman serves on the Medical Advisory Boards for the Benign Essential Blepharospasm Research Foundation and the National Spasmodic Torticollis Association; has received funding for travel to conferences from Parkinson Study Group, American Neurological Association, Movement Disorder Society, Dystonia Medical Research Foundation, Benign Essential Blepharospasm Research Foundation; serves on the editorial board of Journal of Neurology and Neurophysiology; receives research support from the NIH, Dystonia Coalition, Dystonia Medical Research Foundation, Colorado Translational Research Imaging Center, University of Colorado Center for Neuroscience, The Dana Foundation, and the Benign Essential Blepharospasm Research Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - May 2015

Autoimmune & Paraneoplastic Encephalitis

Published: Friday, 01 May 2015 03:00:00 CDT

Autoimmune & Paraneoplastic Encephalitis. Lesson of the week interviews from February 2015.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 28 2015 Issue

Medicare payments to the Neurology workforce in 2012

Published: Monday, 27 Apr 2015 17:00:00 CDT

1) Medicare payments to the Neurology workforce in 2012 and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews with Drs. Lesli Skolarus and Kevin Kerber about their paper on Medicare payments to the Neurology workforce in 2012. Dr. Sarah Wesley is reading our e-Pearl of the week about dural arteriovenous fistulas. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel MacArthur about other issues related to genetic testing. The participants had nothing to disclose except Drs. Southerland, Kerber, Skolarus, Wesley and Burns. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Kerber received honoraria from Elsevier Inc., Michigan Academy of Family Physicians and American Academy of Neurology; is a consultant for University of California San Francisco, Best Doctors, Inc. and American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; participated in legal proceedings by reviewing legal records of Phil Pearsons, MD, JD; and receives research support from NIH. Dr. Skolarus received funding for travel to AUPN meeting; receives institutional support from the University of Michigan for stroke-related research projects; and receives research support from the NIH. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 21 2015 Issue

C90orf72 promotor hypermethylation is neuroprotective: Neuroimaging and neuropathological evidence

Published: Monday, 20 Apr 2015 17:00:00 CDT

1) How C90orf72 promotor hypermethylation is neuroprotective and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Corey McMillan about his paper on how C90orf72 promotor hypermethylation is neuroprotective. Dr. Sarah Wesley is reading our e-Pearl of the week about paraneoplastic cerebellar degeneration. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel MacArthur about the variants of unknown significance. The participants had nothing to disclose except Drs. Burns, McMillan and Wesley. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. McMillan received payment for being plenary speaker at the 2015 International Conference on Frontotemporal Degeneration; and receives research support from the NIH. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 14 2015 Issue

Being diagnosed with multiple sclerosis, her story and focus on life with the disease

Published: Monday, 13 Apr 2015 17:00:00 CDT

1) Being diagnosed with multiple sclerosis and how she has focused on living with the disease and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Ms. Janice Dean about being diagnosed with multiple sclerosis and how she has focused on living with the disease. Dr. Sarah Wesley is reading our e-Pearl of the week about spinobulbar muscular atrophy. In the next part of the podcast Dr. Ted Burns interviews Drs. Radhika Dhamija and Christopher Klein about the reporting of sequence variants and also how the interpretability of the data is rapidly changing and what the implications of this change may be. The participants had nothing to disclose except Drs. Burns, Wesley and Klein. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Klein serves as an editorial board member of Journal of Peripheral Nerve Society; and receives research support from NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 7 2015 Issue

Quality improvement in neurology: Epilepsy update quality measurement set

Published: Monday, 06 Apr 2015 17:00:00 CDT

1) Update of quality measures in epilepsy and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Nathan Fountain about his paper on the update of quality measures in epilepsy. Dr. Sarah Wesley is reading our e-Pearl of the week about hemicrania continua. In the next part of the podcast Dr. Ted Burns interviews Drs. Radhika Dhamija and Christopher Klein about the topic of next generation sequencing. The participants had nothing to disclose except Drs. Fountain, Wesley, Burns and Klein. Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Klein serves as an editorial board member of Journal of Peripheral Nerve Society; and receives research support from NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - April 2015

Myelopathy Due to Systemic Disease

Published: Wednesday, 01 Apr 2015 03:00:00 CDT

Myelopathy Due to Systemic Disease. Lesson of the week interviews from January 2015.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 31 2015 Issue

When a serum test overrides the clinical assessment

Published: Monday, 30 Mar 2015 17:00:00 CDT

1) When a serum test overrides the clinical assessment and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Josep Dalmau about his paper on when a serum test overrides the clinical assessment. Dr. James Addington is reading our e-Pearl of the week about lissencephaly. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Mitch Elkind about the topic of stroke in the setting of systemic infection. The participants had nothing to disclose except Drs. Dalmau, Addington, Johansen and Elkind. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke. Dr. Elkind serves as Section editor for the Neurology® Resident and Fellow Section; serves on the scientific advisory board for Biogen IDEC, Boehringer Ingelheim, BMS-Pfizer Partnership, Janssen Pharmaceutical; is a consultant for Daiichi Sankyo, BMS-Pfizer Partnership and Biotelemetry; participated in legal proceedings for Organon/Merck Serono, NuvaRing and stroke litigation; receives research support from American Heart Association National Board of Directors, American Heart Association Founders Affiliate Board of Directors, American Heart Association NY City Board of Directors and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 24 2015 Issue

Antibodies to GABAA receptor a1 and y2 subunits: Clinical and serological characterization

Published: Monday, 23 Mar 2015 17:00:00 CDT

1) Clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Angela Vincent about her paper on the clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits. Dr. James Addington is reading our e-Pearl of the week about navigating painful neuropathies. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Steve Zeiler about the topic of stroke in the setting of CNS vasculitis. The participants had nothing to disclose except Drs. Vincent, Addington, Johansen and Zeiler. Dr. Vincent serves on the advisory editorial board Journal of Neurology; holds patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG; was a consultant with Athena Diagnostics; occasional small honoraria, travel and speaker honoraria from Baxter International Inc. and Biogen Idec; receives royalties from Athena Diagnostics (MuSK assays), from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010); and receives research support from the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke. Dr. Zeiler receives research support from Johns Hopkins Neurology and NIH; has provided expert legal testimony in 2013 and 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 17 2015 Issue

Age of first exposure to football and later-life cognitive impairment in former NFL players

Published: Monday, 16 Mar 2015 17:00:00 CDT

1) Age of first exposure to football and the effect of later-life cognitive impairment on former NFL players and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Robert Stern about his paper on the age of first exposure to football and the effect of later-life cognitive impairment on former NFL players. Dr. James Addington is reading our e-Pearl of the week about REM behavior disorder. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Endocrine disorders. The participants had nothing to disclose except Drs. Goodkin, Stern, Addington, Johansen and Barrett. Dr. Goodkin serves on the scientific advisory board for Tuberous Sclerosis Alliance and CURE Infantile Spasms; serves as an editorial board member of Neurology, Surgical Neurology International and Epilepsia; receive a royalty from UpToDate for co-authorship of an entry entitled The "choking game" and other strangulation activities in children and adolescents; will be receiving royalties for editing Epilepsy as part of the Neurology in Practice series and receives research support from the NIH. Dr. Stern serves as an Associate Editor of Journal of Neuropsychiatry and Clinical Neurosciences; serves as an editorial board member of Archives of Clinical Neuropsychology; serves as a Review Editor of Frontiers in Neurotrauma and Frontiers in Sports Neurology; serves as Series Editor of Alzheimer's Research and Therapy; serves on the Mackey-White Traumatic Brain Injury Committee of the National Football League Players Association; serves on the medical advisory board of Sports Legacy Institute, the National Graves' Disease Foundation and Amarantus Biosciences (paid advisor); serves on the Medical and Scientific Advisory Committee of the MA/NH Chapter of the Alzheimer's Association; is a consultant for Janssen Research & Development and Athena Diagnostics; receives publishing royalties from Psychological Assessment Resources, Inc. for the Visual Analog Mood Scales, the Boston Qualitative Scoring System for the Rey-Osterreith Complex Figure, and the Neuropsychological Assessment Battery; receives research support from Eisai Inc., Eli Lilly and Company, Amarantus Biosciences, Aethlon Medical, Avid Radiopharmaceuticals, the Department of Defense and the NIH; received honorariums from, Braintree Neurorehabilitation Conference, National Academy of Neuropsychology, Harvard Medical School, The German Center for Research and Innovation and Ludwig-Maximilians-Universitat Munchen, Medical University of South Carolina, Spaulding Rehabilitation Hospital and 8th Annual National Summit on Sports Concussion. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke. Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 10 2015 Issue

The PARK 10 locus is a major locus for sporadic, neuropathologically-confirmed Parkinson disease

Published: Monday, 09 Mar 2015 17:00:00 CDT

1) PARK 10 locus being a major locus for sporadic, neuropathologically-confirmed Parkinson disease and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Jeffrey Vance about his paper on the PARK 10 locus being a major locus for sporadic, neuropathologically-confirmed Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about a mnemonic for the clinical manifestations of CADASIL. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Renal disease. The participants had nothing to disclose except Drs. Vance, Addington, Johansen and Barrett. Dr. Vance serves as an editorial board member of American Journal of Neurodegenerative Diseases; speaker honoraria from Movement Disorders Society, Society of Neuroscience, Hussman Foundation, travel reimbursement for NIH for meeting on Parkinson Disease and NIH for study section; has patents for method of detecting Charcot-Marie-Tooth disease type 2A, TRPC6 involved in glomerulonephritis and methods for identifying an individual at increased risk of developing coronary artery disease; receives research support from NIH; receives royalties for invention from Duke University. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke. Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 3 2015 Issue

Utilization of antiepileptic drugs in pregnant women in Florida Medicaid

Published: Monday, 02 Mar 2015 17:00:00 CDT

1) Utilization of antiepileptic drugs in pregnant women in Florida Medicaid and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Xuerong Wen about her paper on the utilization of antiepileptic drugs in pregnant women in Florida Medicaid. Dr. James Addington is reading our e-Pearl of the week about primary orthostatic tremor. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Victor Urrutia about the topic of hemoglobinopathies and stroke. The participants had nothing to disclose except Drs. Fountain, Addington, Johansen and Urrutia. Dr. Fountain performs clinical procedures as epileptologist (100% effort) at the University of Virginia Comprehensive Epilepsy Program; receives research support from UCB, SK Life Sciences, Inc., Sunovion Pharmaceuticals, Inc., Medtronic, Inc., NeuroPace, Inc. and the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke. Dr. Urrutia serves as a Guest Editor for Frontiers; was asked to consult for New York University to conduct a stroke center certification mock survey; receives research support from Genentech, Inc. and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - March 2015

Therapeutics in Epilepsy

Published: Sunday, 01 Mar 2015 03:00:00 CDT

Therapeutics in Epilepsy. Lesson of the week interviews from April 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 24 2015 Issue

Aspirin and intracerebral hemorrhage: Where are we now?

Published: Monday, 23 Feb 2015 17:00:00 CDT

1) Aspirin and intracerebral hemorrhage: Where are we now and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Reza Behrouz about his paper on where we are regarding aspirin use in relation to intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about POLG mutations in neurologic disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about some of his recent discoveries regarding pathogenic mechanism in autoimmune encephalitis, as well as current challenges facing autoimmune neurology. The participants had nothing to disclose except Drs. Southerland, Behrouz, Numis and Dalmau. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Behrouz serves as a Contributing Editor to Practical Neurology and as an Associate Editor for BioMed Central Neurology; and has participated in medico-legal cases. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 17 2015 Issue

Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD

Published: Monday, 16 Feb 2015 17:00:00 CDT

1) Olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Werner Poewe about his paper on olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD. Dr. Adam Numis is reading our e-Pearl of the week about Fragile X tremor ataxia syndrome. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about other recently described antibodies associated with autoimmune encephalitis. The participants had nothing to disclose except Drs. Poewe, Numis and Dalmau. Dr. Poewe has received consultancy and lecture fees from Abbott, AstraZeneca, Teva Pharmaceutical Industries Ltd, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma Ltd., and Merck Serono in relation to clinical drug development programs for Parkinson disease; has received research support from the Michael J. Fox Foundation; receives royalties from the publications of the books: Therapeutics of Parkinson's disease and other movement disorders, Non-motor symptoms of Parkinson's disease and Parkinson-syndrome und andere Bewegungsstorungen. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 10 2015 Issue

"Non-cognitive" symptoms of early Alzheimer disease: A longitudinal analysis

Published: Monday, 09 Feb 2015 17:00:00 CDT

1) Non-cognitive symptoms of early Alzheimer disease and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Catherine Roe about her paper on non-cognitive symptoms of early Alzheimer disease. Dr. Adam Numis is reading our e-Pearl of the week about cannabidiol in the treatment of epilepsy. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of NMDA receptor encephalitis. The participants had nothing to disclose except Drs. Burns, Roe, Numis and Dalmau. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Roe receives salary support from the NIH, the Longer Life Foundation, the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, The Farrell Family Research Fund, and F. Simmons and O. Mohan; receives research support from the Charles and Joanne Knight Alzheimer Research Initiative of the Knight Alzheimer's disease Research Center, the Longer Life Foundation, The Farrell Family Research Fund, and F. Simmons and O. Mohan. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 3 2015 Issue

Optimal achieved blood pressure in acute intracerebral hemorrhage: INTERACT2

Published: Monday, 02 Feb 2015 17:00:00 CDT

1) Optimal achieved blood pressure in acute intracerebral hemorrhage and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Craig Anderson about his paper on the optimal achieved blood pressure in acute intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about neuropathy in Fabry disease. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about the topic of autoimmune and paraneoplastic encephalitis and how recent discoveries have changed our understanding of these disorders. The participants had nothing to disclose except Drs. Anderson, Numis and Dalmau. Dr. Anderson serves as an editorial board member of Stroke, Cerebrovascular Diseases, and Medical Journal of Australia; receives honoraria from serving on the scientific advisory board for Pfizer Inc and The Medicines Company; receives funding for travel from Takeda China and Covidien; and receives research support from the National Health and Medical Research Council (NHMRC) of Australia. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - February 2015

Movement Disorder Emergencies

Published: Sunday, 01 Feb 2015 03:00:00 CDT

Movement Disorder Emergencies. Lesson of the week interviews from November 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 27 2015 Issue

The spectrum of acute encephalitis: Causes, management and predictors of outcome

Published: Monday, 26 Jan 2015 17:00:00 CDT

1) Causes, management and predictors of outcome in acute encephalitis and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Alejandro Rabinstein about his paper on the causes, management and predictors of outcome in acute encephalitis. Dr. Sarah Wesley is reading our e-Pearl of the week about Charcot-Marie-Tooth. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: chemo, mets, AMN, organ/failure/dysfxn and extramed hemato. The participants had nothing to disclose except Drs. Canning, Wesley, Burns and Lewis. Dr. Rabinstein serves as an Associate Editor of Neurocritical Care, serves as an editorial board member of Neurology®, served on the safety monitoring board for the PREVAIL trial; receives royalties from the publication of the books Practical Neuroimaging in Stroke and What To Do? Neurocritical Care and receives research support from DJO Global. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 20 2015 Issue

Exercise for falls prevention in Parkinson disease: a randomized controlled trial

Published: Monday, 19 Jan 2015 17:00:00 CDT

1) Exercise for falls prevention in Parkinson disease and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michele Fullard interviews Dr. Colleen Canning about her paper on exercise for falls prevention in Parkinson disease. Dr. Sarah Wesley is reading our e-Pearl of the week about subacute sclerosing panencephalitis. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: drugs, toxins, vitamin and minerals. The participants had nothing to disclose except Drs. Canning, Wesley, Burns and Lewis. Dr. Canning received funding for travel expenses and honorarium from the Movement Disorders Society, Singapore General Hospital, Australian and New Zealand Falls Prevention Society; receives research support from the Australian Government National Health and Medical Research Council, Parkinson's NSW and Harry Secomb Foundation. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 13 2015 Issue

Reduced trigeminovascular cyclicity in patients with menstrually-related migraine

Published: Monday, 12 Jan 2015 17:00:00 CDT

1) Reduced trigeminovascular cyclicity in patients with menstrually-related migraine and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Antoinette Maassen van den Brink about her paper on reduced trigeminovascular cyclicity in patients with menstrually-related migraine. Dr. Sarah Wesley is reading our e-Pearl of the week about tauopathies. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: infections. The participants had nothing to disclose except Drs. Southerland, Maassen van den Brink, Wesley, Burns and Lewis. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Maassen van den Brink received support for congress visits from Menarini Group; receives research support from Netherlands Organization for Scientific Research, Dutch Brain Foundation, Netherlands Heart Foundation, MAP Pharmaceuticals, Inc. and Allergan, Inc. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 5 2016 Issue

Pregnancy outcomes in aquaporin-4 positive neuromyelitis optica

Published: Monday, 05 Jan 2015 17:00:00 CDT

1) Pregnancy outcomes in aquaporin-4 positive neuromyelitis optica 2) What's Trending: Safety and tolerability of resveratrol for Alzheimer disease 3) Topic of the month: Endovascular Stroke Therapy This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Maria Isabel S. Leite about her paper on pregnancy outcomes in aquaporin-4 positive neuromyelitis optica. Dr. Ted Burns is interviewing Dr. R. Scott Turner for our “What's Trending” feature of the week about his paper on a randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. In the next part of the podcast Dr. Prachi Mehndiratta interviews Dr. Pooja Khatri about the topic of broad overview of the new clinical trials in endovascular stroke therapy. DISCLOSURES: Dr. Leite serves as an editorial board member for Neuromuscular Disorders; has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis; is supported by NHS National Specialized Commissioning Group for Neuromyelitis Optica, UK and by NIHR Oxford Biomedical Research Centre. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Turner serves on the data safety and monitoring board for the National Institute on Aging; serves as an editorial board Member for Frontiers in Neuroscience and Neuropsychology and Cognition; receives research support from the National Institute on Aging. Dr. Khatri provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc, Genentech, Inc. and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - January 2015

Neuro-Infectious Diseases II

Published: Thursday, 01 Jan 2015 03:00:00 CDT

Neuro-infectious diseases part II. Lesson of the week interviews from October 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 6 2015 Issue

Optimal combination secondary prevention drug treatment and stroke outcomes

Published: Monday, 29 Dec 2014 17:00:00 CDT

1) Optimal combination of secondary prevention drug treatment and stroke outcomes and 2) Topic of the month: Myelopathy due to systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Bruce Ovbiagele about his paper on the optimal combination of secondary prevention drug treatment and stroke outcomes. Dr. Sarah Wesley is reading our e-Pearl of the week about persistent cryptococcal meningitis. In the next part of the podcast Dr. Ted Burns interviews Dr. Steven L. Lewis about the topic of myelopathy due to systemic disease: autoimmune disorders. The participants had nothing to disclose except Drs. Southerland, Ovbiagele, Wesley, Burns and Lewis. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Ovbiagele serves as an Assistant Editor of Stroke; serves as an Associate Editor of the Journal of Neurological Sciences; serves on the editorial board of the Journal of Stroke and Cerebrovascular Diseases and receives research support from the NIH. Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Editor in Chief for Continuum: Lifelong Learning in Neurology®; received royalties for book authorship and editorship from the publishers Wolters Kluwer and Wiley- Blackwell.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 9 2014 Issue

Physician burnout: A neurologic crisis

Published: Monday, 08 Dec 2014 17:00:00 CDT

1) Physician burnout: A neurologic crisis and 2) Topic of the month: Living legend interviews: A career as a neurologist. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bruce Sigsbee about his paper on physician burnout. Dr. James Addington is reading our e-Pearl of the week about colloid cysts. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Josep Dalmau about his career as a neurologist. The participants had nothing to disclose except Drs. Burns, Sigsbee, Addington and Dalmau. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Sigsbee is a consultant for a non-profit, the American Academy of Neurology, on healthcare policy and advocacy. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 2 2014 Issue

Results of two-year B-vitamin treatment on cognitive performance: Secondary data from an RCT

Published: Monday, 01 Dec 2014 17:00:00 CDT

1) Results of two-year B-vitamin treatment on cognitive performance and 2) Topic of the month: Living legend interviews: A career as a neurologist. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Ms. Nikita van der Zwaluw & Dr. Rosalie A. M. Dhonukshe-Rutten about their paper on the results of a two-year B-vitamin treatment for cognitive performance. Dr. James Addington is reading our e-Pearl of the week about Rasmussen encephalitis. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Philip Low about his career as a neurologist. The participants had nothing to disclose except Drs. Burns, Addington and Low. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Low serves as Clinical Editor for Autonomic Neuroscience; is a consultant for WR Medical Electronics, Inc. and receives research support from the NIH and FDA.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - December 2014

Concussion

Published: Monday, 01 Dec 2014 03:00:00 CDT

Topics on concussion. Interview with Ben Utecht and the lesson of the week interviews from September 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 25 2014 Issue

Her experiences and observations dealing with stroke recovery and rehabilitation

Published: Monday, 24 Nov 2014 17:00:00 CDT

1) Her experiences and observations dealing with stroke recovery and rehabilitation and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Ms. Esmeralda Santiago about her experiences and observations dealing with stroke recovery and rehabilitation. Dr. Adam Numis is reading our e-Pearl of the week about variants of sporadic Creutzfeld-Jakob disease. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: tic status. The participants had nothing to disclose except Drs. Southerland, Addington and Frucht. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 18 2014 Issue

Dietary treatment in adults with refractory epilepsy: A review

Published: Monday, 17 Nov 2014 17:00:00 CDT

1) Dietary treatment in adults with refractory epilepsy and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Pavel Klein about his paper on dietary treatment in adults with refractory epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about intraventricular neurocysticercosis. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: dystonic storm. The participants had nothing to disclose except Drs. Klein, Numis and Frucht. Dr. Klein serves on the scientific advisory board for Eisai Inc., Sunovion Pharmaceuticals, Inc., Acorda Therapeutics.; serves on the speakers' boards of UCB, Eisai Inc., Sunovion Pharmaceuticals, Inc.; receives research support from UCB, SK Life Science, Inc., Marinus Pharmaceuticals, Inc. and Lundbeck Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 11 2014 Issue

DPPX potassium channel antibody: Frequency, clinical accompaniments and outcomes in 20 patients

Published: Monday, 10 Nov 2014 17:00:00 CDT

1) DPPX potassium channel antibody and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Oliver Tobin about his paper on the DPPX potassium channel antibody. Dr. Adam Numis is reading our e-Pearl of the week about cortical vein thrombosis. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: neuroleptic malignant syndrome. The participants had nothing to disclose except Drs. Burns, Numis and Frucht. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 4 2014 Issue

Imaging Prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study

Published: Monday, 03 Nov 2014 17:00:00 CDT

1) Imaging prodromal Parkinson disease and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alberto Espay interviews Dr. Danna Jennings about her paper on imaging prodromal Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about distal hereditary neuropathies. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: serotonin syndrome. The participants had nothing to disclose except Drs. Espay, Jennings, Numis and Frucht. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Jennings received speaker honoraria from Novartis; serves on the speaker board of UCB; receives research funding from Michael J. Fox Foundation, FORUM Pharmaceuticals, Concert Pharmaceuticals, Inc.; Omeros, Amgen, Abbvie, Merck Serono, Eli Lilly and Company, Avid Radiopharmaceuticals, Inc.; Navidea Biopharmaceuticals, Inc.; Eisai Inc., TauRx Therapeutics Ltd and Biogen Idec. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - November 2014

Oral Anticoagulants in Stroke

Published: Saturday, 01 Nov 2014 03:00:00 CDT

Oral Anticoagulants in Stroke. Lesson of the week interviews from February 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 28 2014 Issue

Cerebral amyloid angiopathy-inflammation

Published: Monday, 27 Oct 2014 17:00:00 CDT

Cerebral amyloid angiopathy-related inflammation and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Prachi Mehndiratta interviews Dr. Aaron Berkowitz about his paper on cerebral amyloid angiopathy-related inflammation. Dr. Adam Numis is reading our e-Pearl of the week about nasociliary reflex. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurocysticercosis, its common manifestations, investigations and treatment. The participants had nothing to disclose except Drs. Numis and Roos. Dr. Berkowitz received speaker honoraria from Stevens Institute of Technology and receives royalties from the publications of the books Clinical Pathophysiology Made Ridiculously Simple, MedMaster and The Improvising Mind, Oxford. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 21 2014 Issue

Blood pressure management in stroke

Published: Monday, 20 Oct 2014 17:00:00 CDT

1) Blood pressure management in stroke and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Ritvij Bowry about his paper on blood pressure management in stroke. Dr. Adam Numis is reading our e-Pearl of the week about Ondine's curse. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about Creutzfeldt–Jakob disease, its clinical symptoms, signs, natural course and treatment. The participants had nothing to disclose except Drs. Numis and Roos. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 14 2014 Issue

Why brain death is considered death and why there should be no confusion

Published: Monday, 13 Oct 2014 17:00:00 CDT

1) Why brain death is considered death and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Drs. Chris Burkle and Eelco Wijdicks about their paper on why brain death is considered death. Dr. Adam Numis is reading our e-Pearl of the week about equine encephalitides. In the next part of the podcast Dr. Chenjie Xia interviews Dr. David Clifford about progressive multifocal leukoencephalopathy and neurologic care of patients with HIV/AIDS. The participants had nothing to disclose except Drs. Wijdicks, Numis and Clifford. Dr. Wijdicks served as Editor-in-Chief of Neurocritical Care and receives royalties from the publication of several books published by Oxford University Press. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clifford has served/serves on scientific advisory boards for Amgen, Biogen Idec/Quintiles, BMS, Genentech, Inc., Genzyme Corporation, Pfizer Inc, Millennium Pharmaceuticals, Inc. and Sanofi-aventis; received a speaker honorarium from Sun Pharmaceuticals; serves/has served as a consultant for Millennium Pharmaceuticals, Inc., Genzyme Corporation, Biogen Idec, IAS-USA, CMSC/ACTRIMS, ECTRIMS, Drinker, Biddle, Reath, Cytheris and Novartis; receives research support from Lilly, Roche, Alzheimer Association and the NIH (NIMH, NINR); and has provided consultation in medico-legal cases.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 7 2014 Issue

Clinical and ethical judgment: A profound dilemma

Published: Monday, 06 Oct 2014 17:00:00 CDT

1) Clinical and ethical judgment and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Dan Larriviere interviews Dr. Ciro Ramos-Estebanez about his paper on clinical and ethical judgment. Dr. Adam Numis is reading our e-Pearl of the week about Brun's nystagmus. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Justin McArthur about the salient and clinically relevant features of HIV and its neurologic complications. The participants had nothing to disclose except Drs. Larriviere, Numis and McArthur. Dr. Larriviere serves as an Associate Editor of Continuum Audio; serves on the editorial advisory board of Neurology Today and receives speaker honoraria from American Association for the Advancement of Science. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. McArthur serves on the scientific advisory board of Relevare Pharmaceuticals LTD.; holds stock options in Relevare Pharmaceuticals LTD.; holds a patent for a device for thermal stimulation of small neural fibers with the World Intellectual Property Organization, International Publication Number WO 03/040672 A2, medical device for treatment of ulnar neuropathy. UlnarGuard ™ (JHU Ref: 4545) and immunophilin ligand treatment of antiretroviral toxic neuropathy (Provisional application number 60/466,650).

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - October 2014

Mitochondrial Disorders

Published: Wednesday, 01 Oct 2014 03:00:00 CDT

Mitochondrial disorders. Lesson of the week interviews from March 2014

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 30 2014 Issue

The takeaway Frenzel goggles: a Fresnel-based device

Published: Monday, 29 Sep 2014 17:00:00 CDT

1) The takeaway Frenzel goggles: a Fresnel-based device and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Reza Seyedsadjadi interviews Dr. Michael Strupp about his paper on the takeaway Frenzel goggles: a Fresnel-based device. Dr. James Addington is reading our e-Pearl of the week about steroid-responsive encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the impact of concussion and traumatic brain injury in society. The participants had nothing to disclose except Drs. Strupp, Addington and Jaffee. Dr. Strupp serves as Joint-Chief Editor of the Journal of Neurology, Editor-in-Chief of Frontiers in Neuro-otology Section Editor of F1000; serves on the scientific advisory board for Abbott and Pierre-Fabre; receives royalties from the publication of the book Vertigo and dizziness - common complaints; received speaker honoraria from Abbott, GlaxoSmithKline, Merck Serono, Henning Arzneimittel GmbH & Co. KG, Pierre Fabre Laboratories, UCB and Eisai Inc. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 23 2014 Issue

Editorial: Concussed

Published: Monday, 22 Sep 2014 17:00:00 CDT

1) Editorial on his career-ending traumatic brain injury and his concerns about the consequence of such injuries for his future and for others affected and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. Ben Utecht about his editorial on his career-ending traumatic brain injury and his concerns about the consequence of such injuries for his future and for others affected. Dr. James Addington is reading our e-Pearl of the week about POTS syndrome. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of patients with chronic issues related to post concussive symptoms. The participants had nothing to disclose except Drs. Burns, Addington, Jaffee and Mr. Utecht. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Mr. Utecht serves as a spokesperson for the AAN/ABF. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 16 2014 Issue

Course of psychiatric symptoms and global cognition in early Parkinson disease

Published: Monday, 15 Sep 2014 17:00:00 CDT

1) Course of psychiatric symptoms and global cognition in early Parkinson disease and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Dan Weintraub about his paper on the course of psychiatric symptoms and global cognition in early Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about KCNQ2 in early onset epileptic encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of concussion after the diagnosis has been made and the recommendation for graduated return to play or normal activities. The participants had nothing to disclose except Drs. Barrett, Weintraub, Addington and Jaffee. Dr. Barrett receives research support from the Virginia Center of Alzheimer's and Related Diseases Research Award Fund. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's disease; serves on the scientific advisory boards of Pfizer Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc., UCB, Bristol-Myers Squibb, Novartis, Clintrex, Theravance, Medication Non-profit-CHDI, ADCS; receives license fee payments from the University of Pennsylvania for licensing of questionnaire for impulsive-compulsive disorders in Parkinson disease and QUIP and QUIP-RS; gave expert testimony for defense in two lawsuits related to impulse control disorders in Parkinson disease; receives research support from Michael J. Fox Foundation, Department of Veterans Affairs, Novartis and the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 9 2014 Issue

Mirror therapy in unilateral neglect after STroke (MUST trial)-A randomized controlled trial

Published: Monday, 08 Sep 2014 17:00:00 CDT

1) Mirror therapy in unilateral neglect after stroke and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Jeyaraj Pandian about his paper on mirror therapy in unilateral neglect after stroke. Dr. James Addington is reading our e-Pearl of the week about basilar-type migraine. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the acute diagnosis and management of concussion. The participants had nothing to disclose except Drs. Southerland, Pandian, Addington and Jaffee. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Pandian serves as Editor-in-Chief of CHRISMED J Health and Research; serves on the scientific advisory board of International J Stroke and serves as an Associate Editor for the Neurology India Journal. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 2 2014 Issue

Current practices in feeding tube placement for US acute ischemic stroke inpatients

Published: Monday, 01 Sep 2014 17:00:00 CDT

1) Current practices in feeding tube placement for US acute ischemic stroke inpatients and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Drs. Ben George and Adam Kelly about their paper on current practices in feeding tube placement for US acute ischemic stroke inpatients. Dr. James Addington is reading our e-Pearl of the week about childhood stroke: think metabolic. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the definition of concussion and how the grading has evolved over recent years. The participants had nothing to disclose except Drs. Barrett, George, Kelly, Addington and Jaffee. Dr. Barrett serves as an editorial board member of Neurology; serves as an Associate Editor of Neurohospitalist and receives research support from the NIH. Dr. George receives research support from the American Heart Association/American Stroke Association and the Parkinson's disease Foundation. Dr. Kelly serves as an editorial board member of Continuum; serves as Guest Editor for Cerebrovascular Disease issue, April 2014 and received research support from the Donald W. Reynolds Foundation. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - September 2014

Functional Symptoms & Conversion Disorders

Published: Monday, 01 Sep 2014 03:00:00 CDT

Area of functional symptoms & conversion disorders. Lesson of the Week interviews from November 2013.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 26 2014 Issue

Growth hormone treatment for childhood short stature and risk of stroke in early adulthood

Published: Monday, 25 Aug 2014 17:00:00 CDT

1) Growth hormone treatment for childhood short stature and risk of stroke in early adulthood and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Cyrus Boelman interviews Dr. Emmanuel Touze about his paper on growth hormone treatment for childhood short stature and risk of stroke in early childhood. Dr. Adam Numis is reading our e-Pearl of the week about LG-1 antibodies in limbic encephalitis. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Don Levy about approaches of Integrative Medicine practitioners to patient care. The participants had nothing to disclose except Dr. Numis. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 19 2014 Issue

A clinical pathologic study of depressive symptoms and cognitive decline in old age

Published: Monday, 18 Aug 2014 17:00:00 CDT

1) A clinical pathologic study of depressive symptoms and cognitive decline in old age and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Robert S. Wilson about his paper on depressive symptoms and cognitive decline in old age. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Tieraona Low Dog about complementary alternative medicine therapies using supplements for treatment of headaches. The participants had nothing to disclose except Drs. Burns, Wilson and Numis. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Wilson serves as a Consulting Editor of Aging, Neuropsychology and Cognition, Psychology and Aging, and Neuropsychology; is a consultant for Pain Therapeutics, Inc.; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 12 2014 Issue

Untreated brain arteriovenous malformations: Patient level meta-analysis of hemorrhage predictors

Published: Monday, 11 Aug 2014 17:00:00 CDT

1) Untreated brain arteriovenous malformations: Patient level meta-analysis of hemorrhage predictors and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Helen Kim about her paper on untreated brain arteriovenous malformations. Dr. Adam Numis is reading our e-Pearl of the week about spinal epidural abscesses. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Remy Coeytaux about complementary alternative medicine to chronic pain and integrative medicine approaches. The participants had nothing to disclose except Drs. Coeytaux and Numis. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Coeytaux is a consultant for Samueli Institute and receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 5 2014 Issue

Palliative care and neurology: Time for a paradigm shift

Published: Monday, 04 Aug 2014 17:00:00 CDT

1) Palliative care and neurology: Time for a paradigm shift and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Bragg interviews Dr. Benzi Kluger about his paper on palliative care and neurology: Time for a paradigm shift. Dr. Adam Numis is reading our e-Pearl of the week about intravascular B-cell lymphoma. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Pushpa Narayanaswami about complementary alternative medicine therapies for patients with multiple sclerosis. The participants had nothing to disclose except Drs. Kluger, Numis, and Narayanaswami. Dr. Kluger serves as an editorial board member of Frontiers in Movement Disorders; received speaker honoraria from Teva Pharmaceutical Industrials Ltd., Parkinson's Association of the Rockies and National Parkinson's Foundation; receives research support from the US Army Research Laboratory and US Army Research Office, Veterans Affairs Medical Center CRICC Program, Michael J. Fox Foundation, University of Colorado Hospital Clinical Effectiveness and Patient Safety Program and the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Narayanaswami serves as an editorial board member of Neurology® Level of Evidence Review Team; is a consultant for Blue Cross Blue Shield of Massachusetts, Pharmacy and Therapeutics Committee, Advanced Medical and Boston Clinical Research Institute; performs EMG in her clinical practice (35% effort); receives research support from Merz Pharmaceuticals, Inc., Solstice Pharma and AHRQ; received research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - August 2014

Neuro Infectious Diseases

Published: Friday, 01 Aug 2014 03:00:00 CDT

Viral meningoencephalitides, lyme disease, & bacterial meningoencephalitides. Lesson of the week interviews from June 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 29 2014 Issue

Evaluation and construction of diagnostic criteria for inclusion body myositis

Published: Monday, 28 Jul 2014 17:00:00 CDT

1) Evaluation and construction of diagnostic criteria for inclusion body myositis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steven A. Greenberg about his paper on evaluation and construction of diagnostic criteria for inclusion body myositis. Dr. James Addington is reading our e-Pearl of the week about Rapid-Onset Dystonia Parkinsonism. In the next part of the podcast Dr. Alberto Espay continues his interview with Dr. Jon Stone including questions about his Contemporary Clinical Issues Lecture about functional (psychogenic) disorders in neurology from the audience at Interview Central and his responses. The participants had nothing to disclose except Drs. Burns, Greenberg, Addington, Espay and Stone. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Greenberg is a consultant for MedImmune, aTyr Pharma; receives publishing royalties from the publication of the book EMG Pearls; receives license fee payments from Composition and Methods for Diagnosing and Assessing Inflammatory Myopathies, MedImmune; receives revenue for patents for composition and methods for diagnosing and assessing inflammatory myopathies, detecting inclusion body myositis; receives research support from MedImmune, Novartis and the NIH; serves on the scientific advisory board for MedImmune; received funding for travel from Biogen Idec and Genzyme Corporation. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 22 2014 Issue

Traumatic brain injury and risk of dementia in older veterans

Published: Monday, 21 Jul 2014 17:00:00 CDT

1) Traumatic brain injury and risk of dementia in older veterans and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Deborah Barnes about her paper on traumatic brain injury and risk of dementia in older veterans. Dr. James Addington is reading our e-Pearl of the week about chronic traumatic encephalopathy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jon Stone about his Contemporary Clinical Issues Lecture at the AAN Meeting about functional (psychogenic) disorders in neurology. The participants had nothing to disclose except Drs. Mateen, Barnes, Addington, Espay and Stone. Dr. Mateen received funding support from the Canadian Institute of Health Research. Dr. Barnes receives research support from UCB, Department of Defense, Department of Veterans Affairs, NARSAD (Brain & Behavior Research Foundation), S.D. Bechtel Jr. Foundation, philanthrophic support via Osher Center for Integrative Medicine, University of California, San Francisco, patient centered outcomes research institute and the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 15 2014 Issue

Defining the clinical course of multiple sclerosis: The 2013 revisions

Published: Monday, 14 Jul 2014 17:00:00 CDT

1) Defining the clinical course of multiple sclerosis: The 2013 revisions and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Fred Lublin about his paper on defining the clinical course of multiple sclerosis: The 2013 revisions. Dr. James Addington is reading our e-Pearl of the week about familial fatal insomnia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Eidelberg about his Hot Topics Lecture at the AAN Meeting about functional connectivity and functional imaging in movement disorders. The participants had nothing to disclose except Drs. Keegan, Lublin, Addington, Espay and Eidelberg. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Lublin serves as co-Chief Editor of Multiple Sclerosis and Related Disorders; serves on the scientific advisory boards and as a consultant for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals Ltd, Sanofi-aventis, Acorda Therapeutics Inc, Questcor Pharmaceuticals, Roche, Genentech, Inc., Celgene, Johnson & Johnson, Revalesio Corporation, Coronado Bioscience, Genzyme Corporation, MedImmune, Bristol-Myers Squibb, XenoPort, Inc., Receptos Inc, Forward Pharma, to- BBB technologies; receives research support from Biogen Idec, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc, Novartis, Genzyme Corporation, Sanofi-aventis, Celgene, National Multiple Sclerosis Society and the NIH; holds financial interests/stock options in Cognition Pharmaceuticals. Inc. and may discuss unapproved agents that are in the MS developmental pipeline with any recommendations on their use. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Eidelberg serves as an Associate Editor of Journal of Neuroscience; serves as an editorial board member of Journal of Nuclear Medicine, Current Opinion in Neurology, Annals of Neurology and NeuroImage; serves on the scientific advisory board for the Michael J. Fox Foundation, ; co-inventor of United States Patent No. 5, 632,276 and No. 5,873,823 without financial gain; receives research support from the Michael J. Fox Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 8 2014 Issue

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

Published: Monday, 07 Jul 2014 17:00:00 CDT

1) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Russell Dale about his paper on utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Dr. James Addington is reading our e-Pearl of the week about pseudo-internuclear ophthalmoplegia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Holtzman about his Robert Wartenberg Lecture at the AAN Meeting about Alzheimer's disease in 2014: Mapping a road forward. The participants had nothing to disclose except Drs. Dale, Addington, Espay and Holtzman. Dr. Dale serves on the scientific advisory board for Queensland Children's Medical Institute; serves as an editorial advisory board member of Multiple Sclerosis and Related Disorders Journal; received honoraria for lecturing from Biogen Idec; receives research support from the National Health and Medical Research Council. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Holtzman serves as an Associate Editor of Annuals of Neurology; serves as an editorial board member of Neurobiology of Disease, Experimental Neurology, Molecular Neurodegeneration, Science Translational Medicine and Journal of Experimental Medicine; co-founder of C2N Diagnostic LLC; is a consultant for AstraZeneca, Genentech, Inc., Bristol-Myers Squibb and Forum Pharmaceuticals; receives research support AstraZeneca, Eli Lilly and Company, Biogen Idec, C2N Diagnostic LLC, Cure Alzheimer's Disease, Tau Consortium, Ellison Medical Foundation and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - July 2014 - Critical Care Neurology

Critical Care Neurology

Published: Tuesday, 01 Jul 2014 03:00:00 CDT

Topics in critical care neurology. Lessons of the week from May 2014

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 1 2014 Issue

Long-term safety and effectiveness of natalizumab re-dosing and treatment in the STRATA MS study

Published: Monday, 30 Jun 2014 17:00:00 CDT

1) Long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ruth Ann Marrie interviews Dr. Paul O'Connor about his paper on long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about inclusion body myositis. In the next part of the podcast Dr. Alberto Espay interviews Dr. James Bernat about his Presidential Lecture at the AAN Meeting about challenges to ethics and professionalism facing the contemporary neurologist. The participants had nothing to disclose except Drs. Marrie, O'Connor, Addington, Espay and Bernat. Dr. Marrie serves on the editorial board for Neurology® and Multiple Sclerosis Journal; receives research support from Sanofi-aventis, Canadian Institutes of Health Research, Public Health Agency of Canada, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Multiple Sclerosis Scientific Foundation and Consortium of Multiple Sclerosis Centers. Dr. O'Connor served on the editorial advisory board of the MS Journal; serves on the scientific advisory board for Novartis, Sanofi-aventis, Bravo Pharmaceuticals, Genentech, Inc., Roche and Actelion Pharmaceuticals Ltd; is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Sanofi-aventis and Novartis; received funding for travel to advisory board meeting in Toronto; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec and as National Scientific and Clinical Advisor to the MS Society of Canada. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH. Dr. Bernat serves as an unpaid editorial board member of Neurocritical Care, Neurology Today, and Multiple Sclerosis and Related Diseases; a paid editorial board member of The Physician's Index for Ethics and Medicine; and receives royalties from the publication of the books Ethical Issues in Neurology, 3rd ed, Palliative Care in Neurology, and Ethical and Legal Issues in Neurology.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 17 2014 Issue

Factors associated with recovery from acute optic neuritis in multiple sclerosis

Published: Monday, 16 Jun 2014 17:00:00 CDT

1) Factors associated with recovery from acute optic neuritis in multiple sclerosis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Tanuja Chitnis about her paper on factors associated with recovery from acute optic neuritis in multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about tanycytic ependymal tumors. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Bacterial meningoencephalitides. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Chitnis is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis, Sanofi-aventis; receives research support from Merck Serono and Novartis in the form of Independent Investigator Awards, National Multiple Sclerosis Society. the Peabody Foundation and the Guthy-Jackson Charitable Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 10 2014 Issue

Abnormal thalamic function in patients with vestibular migraine

Published: Monday, 09 Jun 2014 17:00:00 CDT

1) Abnormal thalamic function in patients with vestibular migraine and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Jen interviews Dr. Gioacchino Tedeschi about his paper on abnormal thalamic function in patients with vestibular migraine. Dr. Adam Numis is reading our e-Pearl of the week about Gerstmann-Straussler-Scheinker syndrome. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Lyme disease. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos. Dr. Jen serves as a Section Editor for Experimental Brain Research; serves as an Associate Editor for Frontiers in Neuro-otology; receives research support from the FDA. Dr. Tedeschi receives speaker honoraria from Novartis, Schwarz Pharma AG, UCB, Lundbeck Inc., GlaxoSmithKline and AbbVie. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 3 2014 Issue

Anti-agrin autoantibodies in myasthenia gravis

Published: Monday, 02 Jun 2014 17:00:00 CDT

1) Anti-agrin autoantibodies in myasthenia gravis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Arthur Melms about his paper on anti-agrin autoantibodies in myasthenia gravis. Dr. Adam Numis is reading our e-Pearl of the week about myopathy masquerading as myasthenia. In the next part of the podcast Dr. Chenjie Xia interviews Drs. Maria Nagel and Don Gilden about neurology and infectious diseases: Viral meningoencephalitides. The participants had nothing to disclose except Drs. Burns, Melms, Numis, Nagel and Gilden. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals. Dr. Melms performs clinical procedures as Professor of Neurology and Neurorehabilitation at the University of Erlangen, Germany (20%) and is clinical director of a privately owned neurological rehabilitation hospital (80%); clinical research is supported by the Ernst Freiberger Foundation, Berlin, Germany; received speaker honoraria from GlaxoSmithKline; received research support from German Research Agency, Collaborative Research Center 685, Immunotherapy, and the Gemeinützige Hertie Foundation, Frankfurt/Main, Germany. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Nagel receives research support from the NIH. Dr. Gilden serves as Senior Associate Editor of Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology; Scientific American Medicine, Virus Genes, Neurology Journal, receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - June 2014 - Movement Disorders II

Parkinson's & Parkinsonism Disorders

Published: Sunday, 01 Jun 2014 03:00:00 CDT

Parkinson's & parkinsonism disorders. Lesson of the Week interviews from January 2014.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 27 2014 Issue

The effects of cannabis on cognition in MS patients: A psychometric and MRI study

Published: Monday, 26 May 2014 17:00:00 CDT

1) Effects of cannabis on cognition in patients with multiple sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Anthony Feinstein about his paper on the effects of cannabis on cognition in patients with multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about spinal dural arteriovenous fistula. In the next part of the podcast Dr. Mike Brogan interviews Dr. Claude Hemphill about the management of intracranial hypertension. The participants had nothing to disclose except Drs. Feinstein, Addington and Hemphill. Dr. Feinstein serves as an editorial board member of Multiple Sclerosis and African Journal of Psychiatry; receives royalties from the publication of the book The Clinical Neuropsychiatry of Multiple Sclerosis; performs neuropsychiatric evaluation, cognitive testing, brain imaging in neuropsychiatry clinical practice; receives research support from Biogen Idec, Canadian Institute of Health Research, Multiple Sclerosis Society of Canada and University of Toronto; received honoraria for lectures from Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Hemphill serves as an editorial board member of Neurocritical Care; holds stock options for serving on the scientific advisory board for Ornim Medical; receives research support from Cerebrotech Medical; funding as PI for hub site for Neurological Emergencies Treatment Trials Network; received a one-time speaking honorarium from Besins Critical Care, LLC and honoraria from Edge Therapeutics, Inc. for consulting; gave expert witness review and testimony on various cases related to stroke and neurocritical care.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 20 2014 Issue

Cerebrospinal fluid AB42 predicts early onset dementia in Parkinson disease

Published: Monday, 19 May 2014 17:00:00 CDT

1) Cerebrospinal fluid AB42 predicting early onset Parkinson disease and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Henrik Zetterberg about his paper on cerebrospinal fluid A?42 predicting early onset Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about Kennedy disease. In the next part of the podcast Dr. Mike Brogan interviews Dr. Laurie Gutmann about critical illness in polyneuropathy and myopathy. The participants had nothing to disclose except Drs. Zetterberg, Addington and Gutmann. Dr. Zetterberg serves as Senior Editor of the Journal of Alzheimer's disease; serves as Associate Editor of Alzheimer and Dementia; receives research support from the Swedish Research Council and Swedish State Support for Clinical Research. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gutmann receives royalties from Up-to-Date Online from the publication of Hypokalemic and Hyperkalemic Periodic Paralysis; receives research support from Alexion Pharmaceuticals, Inc. and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 13 2014 Issue

Venous thromboembolism in amyotrophic lateral sclerosis: A prospective study

Published: Monday, 12 May 2014 17:00:00 CDT

1) Venous thromboembolism in amyotrophic lateral sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Lorne Zinman about his paper on venous thromboembolism in amyotrophic lateral sclerosis. Dr. James Addington is reading our e-Pearl of the week about SCN4A mutations. In the next part of the podcast Dr. Mike Brogan interviews Dr. Thomas Bleck about the management of status epilepticus in critical care. The participants had nothing to disclose except Drs. Burns, Zinman, Addington and Bleck. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc. Dr. Zinman serves on the scientific advisory board for the Data and Safety Monitoring Board NIH sponsored Tamoxiphen/Creatine ALS Study (non-profit entity); receives research support from the Garfield Weston Foundation, Public Health Agency of Canada, Canadian Institute of Health Research, ALS Society of Canada and the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bleck serves on the data safety and monitoring boards of the NIH sponsored RAMPART and ProTECT trials.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

May 6 2014 Issue

Utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy

Published: Monday, 05 May 2014 17:00:00 CDT

Utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Sean Pittock about his paper on the utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy. Dr. James Addington is reading our e-Pearl of the week about logopenic-variant primary progressive aphasia. In the next part of the podcast Dr. Mike Brogan interviews Dr. Pratik Pandharipande about delirium in acute brain dysfunction in critically ill patients. The participants had nothing to disclose except Drs. Pandharipande, Pittock and Addington. Dr. Pandharipande received research support from Hospira Inc. and the NIH. Dr. Pittock received research support from Alexion Pharmaceuticals, Inc.; Guthy Jackson Charitable Foundation and the NIH. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - May 2014 - Movement Disorders I

Treatment of Movement disorders

Published: Thursday, 01 May 2014 03:00:00 CDT

Treatment of Movement disorders. Lesson of the Week interviews from May 2013

download this now episode segments

April 29 2014 Issue

Systematic Review: Efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology

Published: Monday, 28 Apr 2014 17:00:00 CDT

1) AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Barbara Koppel about the AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders. Dr. Adam Numis is reading our e-Pearl of the week about myoclonic astatic epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Greg Bergey about epilepsy therapeutics: Beyond medications for the refractory patient. The participants had nothing to disclose except Drs. Koppel, Numis and Bergey. Dr. Koppel serves as an editorial board member of Clinical Neurology. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bergey was an expert witness in medicolegal activity over the past two years and receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 22 2014 Issue

Migraine trait symptoms in migraine with and without aura

Published: Monday, 21 Apr 2014 17:00:00 CDT

1) Migraine trait symptoms in migraine with and without aura and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Sowell interviews Dr. Tim Jürgens about his paper on migraine trait symptoms in migraine with and without aura. Dr. Adam Numis is reading our e-Pearl of the week about idiopathic normal pressure hydrocephalus. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Elinor Ben-Menachem about epilepsy therapeutics: Vigabatrin. The participants had nothing to disclose except Drs. Jürgens, Numis and Ben-Menachem. Dr. Jurgens serves as an editorial board member of ISRN Pain, serves as Visiting Editor of the Journal of Headache and Pain; is a consultant for Autonomic Technologies, Inc.; received speaker honoraria from Allergan, Inc., Pfizer Inc, MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), received funding for Travel from MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), Deutsche Migrane- und Kopfschmerzgesellschaft (non-commercial),) Deutsche Schmerzgesellschaft (non-commercial); serves as a board member of Deutsche Migrane- und Kopfschmerzgesellschaft; receives research support from Allergan, Inc. and Deutsche Migrane- und Kopfschmerzgesellschaft. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ben-Menachem serves as Editor of Acta Neurologica Scanidnavica; receives funding for travel from Eisai Inc., UCB, ElectroCore Medical, LLC.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 15 2014 Issue

Skin nerve a-synuclein deposits: a biomarker for idiopathic Parkinson disease

Published: Monday, 14 Apr 2014 17:00:00 CDT

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 8 2014 Issue

Fingolimod after natalizumab and the risk of short-term relapse

Published: Monday, 07 Apr 2014 17:00:00 CDT

1) Fingolimod after natalizumab and the risk of short-term relapse and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Vilija Jokubaitis about her paper on fingolimod after natalizumab and the risk of short-term relapse. Dr. Adam Numis is reading our e-Pearl of the week about cardiac cephalgia. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Madeline Fields about epilepsy therapeutics: Clobazam. The participants had nothing to disclose except Drs. Keegan, Jokubaitis and Numis. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Jokubaitis received funding for travel to speak at a conference from Novartis, receives research support from MSBase Foundation and National Health and Medical Research Council. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - April 2014 - AAN AM Interviews II

Interviews from the 2013 AAN Annual Meeting

Published: Tuesday, 01 Apr 2014 03:00:00 CDT

Interviews from the 2013 AAN Annual Meeting

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

April 1 2014 Issue

Rolandic epilepsy has little effect on adult life 30 years later: A population-based study

Published: Monday, 31 Mar 2014 17:00:00 CDT

1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH. Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 25 2014 Issue

Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia

Published: Monday, 24 Mar 2014 17:00:00 CDT

1) Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. William Powers about his paper on lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Dr. Roy Strowd is reading our e-Pearl of the week about Déjà vu. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Doug Turnbull about the management of mitochondrial disorders. The participants had nothing to disclose except Drs. Southerland, Powers and Strowd. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Powers serves as an editorial board member of Stroke and Journal of Cerebral Blood Flow and Metabolism; serves on the scientific advisory board for Ontario Brain Institute Morehouse School of Medicine; receives research support from the NIH and UNC. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 18 2014 Issue

A randomized trial of intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine

Published: Monday, 17 Mar 2014 17:00:00 CDT

1) Intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Benjamin Friedman about his paper on intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine. Dr. Roy Strowd is reading our e-Pearl of the week about evaluating the exome. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Robert Taylor about the investigations for mitochondrial disorders. The participants had nothing to disclose except Drs. Friedman and Strowd. Dr. Friedman serves on the scientific advisory board for MAP Pharmaceuticals. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 11 2014 Issue

Submandibular Gland Needle Biopsy for the Diagnosis of Parkinson Disease

Published: Monday, 10 Mar 2014 17:00:00 CDT

1) Submandibular gland needle biopsy for diagnosis of Parkinson disease and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Brown interviews Dr. Charles Adler about his paper on submandibular gland needle biopsy for diagnosis of Parkinson disease. Dr. Roy Strowd is reading our e-Pearl of the week about nodes needing neurofascin. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Andrew Schaefer about syndromes of mitochondrial disorders. The participants had nothing to disclose except Drs. Adler and Strowd. Dr. Adler serves on the scientific advisory board of Bachmann Strauss Dystonia and Parkinson Foundation; is a consultant for Allergan, Inc., Novartis, Merz Pharmaceuticals, LLC, XenoPort, Inc.; receives royalties from the publication of the book Parkinson's Disease and Movement Disorders; receives research support from Avid Radiopharmaceuticals, Department of Defense, Michael J. Fox Foundation for Parkinson's Disease Research, National Parkinson's Foundation and NIH. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

March 4 2014 Issue

Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis

Published: Monday, 03 Mar 2014 17:00:00 CDT

1) Clinical characteristics and outcome of brain abscess and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Cupka interviews Dr. Matthijs Brouwer about his paper on clinical characteristics and outcome of brain abscess. Dr. Roy Strowd is reading our e-Pearl of the week about angioedema after tPA. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Grainne Gorman about the fundamental principles of mitochondrial disorders. The participants had nothing to disclose except Drs. Brouwer, Strowd and Gorman. Dr. Brouwer receives research support from the Dutch Scientific Organization; received research support from the European Federation of Neurological Sciences and European Society of Clinical Microbiology and Infectious Diseases. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gorman receives research support from the UK NIHR Biomedical Research Centre for Aging and Age-related disease, Research Fellow, awarded to the Newcastle upon Tyne Trust Foundation Hospitals NHS Trust.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - March 2014 - AAN AM Interviews I

Interviews from the 2013 AAN Annual Meeting

Published: Saturday, 01 Mar 2014 03:00:00 CDT

Interviews from the 2013 AAN Annual Meeting

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 25 2014 Issue

Summary of evidence-based guideline: Prevention of stroke in nonvalvular atrial fibrillation

Published: Monday, 24 Feb 2014 17:00:00 CDT

1) Guideline on prevention of stroke in nonvalvular atrial fibrillation. and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Gary Gronseth about AAN paper on prevention of stroke in nonvalvular atrial fibrillation. Dr. James Addington is reading our e-Pearl of the week about superficial siderosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about Edoxaban, non-pharmaceutical options for stroke prevention in afib: ablation, atrial appendage occluder devices and any other options. The participants had nothing to disclose except Drs. Kissela, Gronseth, Addington, Southerland and Chaturvedi. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring and provides medico-legal reviews. Dr. Gronseth serves as Associate Editor for for Neurology®; serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 18 2014 Issue

Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis

Published: Monday, 17 Feb 2014 17:00:00 CDT

1) Clinical specificities of patients with NMDA receptor antibodies encephalitis and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Jerome Honnorat about his paper on the clinical specificities of patients with NMDA receptor antibodies encephalitis. Dr. James Addington is reading our e-Pearl of the week about posterior interosseous nerve syndrome. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Apixaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Addington and Chaturvedi. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 11 2014 Issue

Guillain-Barre syndrome associated with processing hepatitis E virus infection

Published: Monday, 10 Feb 2014 17:00:00 CDT

1) Guillain-Barre syndrome being associated with hepatitis E virus infection and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barre syndrome being associated with hepatitis E virus infection. Dr. James Addington is reading our e-Pearl of the week about myelin-oligodendrocyte glycoprotein antibody. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Rivaroxaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Burns, Jacobs, Addington and Chaturvedi. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals. Dr. Jacobs serves as an editorial board member for Journal of the Peripheral Nerve System; received funding for travel from Baxter International Inc. for a scientific meeting; received research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

February 4 2014 Issue

ASA failure: Does the combination ASA/clopidogrel confer better long term vascular protection?

Published: Monday, 03 Feb 2014 17:00:00 CDT

1) ASA/clopidogrel combination confers better long term vascular protection in ASA failure and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Robert Cote about his paper on whether the combination of ASA/clopidogrel confers better long term vascular protection in ASA failure. Dr. James Addington is reading our e-Pearl of the week about hypoglycorrhachia. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Dabigatran), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Cote, Addington, Southerland and Chaturvedi. Dr. Cote served on the scientific advisory board for Bayer Schering Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer Inc; serves on the scientific advisory board for DSMB for National Institute of Health (Point Study), Steering committee for the National Institute of Health (SPS3 study); is a consultant for Otsuka Pharmaceutical Co., Ltd.; received speaker honoraria from Boehringer Ingelheim, Merck Serono, Sanofi-aventis. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - February 2014

Frontotemporal Dementia

Published: Saturday, 01 Feb 2014 03:00:00 CDT

Interviews with Bill Seely on frontotemporal dementia. Clinical presentations & bedside evaluation, diagnostic testing & genetics, therapeutics & future directions.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 28 2014 Issue

High dose midazolam infusion for refractory status epilepticus

Published: Monday, 27 Jan 2014 17:00:00 CDT

1) High dose midazolam infusion for refractory status epilepticus and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Jan Claassen about his paper on high dose midazolam infusion for refractory status epilepticus. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in early onset epileptic encephalopathies. In the next part of the podcast Dr. Matt Barrett interviews Dr. Vicki Shanker about clinical approach to non-Parkinson disease tremor. The participants had nothing to disclose except Drs. Claassen and Numis. Dr. Claassen serves as an editorial board member of Neurocritical Care. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 21 2014 Issue

Age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women

Published: Monday, 20 Jan 2014 17:00:00 CDT

1) Influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Drs. Riley Bove and Philip De Jager about their paper on the influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women. Dr. Adam Numis is reading our e-Pearl of the week about parechovirus and neurologic disease. In the next part of the podcast Dr. Binit Shah interviews Dr. Anthony Lang about non-neurodegenerative causes of parkinsonism - drug-induced; structural: NPH, stroke, tumor; psychogenic. The participants had nothing to disclose except Drs. Burns, Bove, De Jager, Numis and Lang. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Bove receives research support from Partners Healthcare, National Multiple Sclerosis Society and the NIH. Dr. De Jager serves as an editorial board member of the Journal of Neuroimmunology; serves on the scientific advisory board for Teva Neuroscience, Genzyme/Sanofi; receives speakers' honoraria from Biogen Idec and Source Healthcare Analytics, LLC; receives research support from Biogen Idec, GlaxoSmithKline, Genzyme/Sanofi, Vertex Pharmaceuticals and the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lang served as an advisor for Abbott, Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Medtronic, Inc, Merck Serono, Novartis, NeuroPhage Pharmaceuticals, Teva Pharmaceutical Industries Ltd, UCB.; received research support from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press; served as an expert witness in cases related to the welding industry.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 14 2014

Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with multiple sclerosis

Published: Monday, 13 Jan 2014 17:00:00 CDT

1) Guideline on assessment and management of psychiatric disorders in individuals with multiple sclerosis and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Sarah Minden about AAN paper on assessment and management of psychiatric disorders in individuals with multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about airplane headache. In the next part of the podcast Dr. Binit Shah interviews Dr. Melissa Armstrong about diagnosis, management and prognosis of atypical parkinsonian disorders. The participants had nothing to disclose except Drs. Keegan, Minden, Numis and Armstrong. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Minden received honoraria and travel reimbursement for meetings from Pfizer Inc, Merck Serono, Genentech, Inc., Novartis, and Avanir Pharmaceuticals; received research support from the National Multiple Sclerosis Society, the Center for Mental Health Services, and the Substance Abuse and Mental Health Services Administration; holds stock options in Merck Serono, Schering-Plough Corp, and GlaxoSmithKline. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Armstrong serves on the Level of Evidence Review Team for Neurology®; is an evidence-based guideline methodology consultant for the AAN; receives research support from Abbvie as local sub-investigator; received a 2011 Movement Disorders Society travel Scholarship to the MDS International Congress; and in 2010-2011 was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - January 2014

The New MS Drugs

Published: Wednesday, 01 Jan 2014 03:00:00 CDT

The New MS Drugs

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

January 7 2014

Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletes

Published: Monday, 30 Dec 2013 17:00:00 CDT

1) Effect of head impacts on diffusivity measures in collegiate contact sport athletes and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Noah Kolb interviews Dr. Thomas McAllister about his paper on effect of head impacts on diffusivity measures in collegiate contact sport athletes. Dr. Adam Numis is reading our e-Pearl of the week about recurrent rhabdomyolysis. In the next part of the podcast Dr. Matt Barrett interviews Dr. Dan Weintraub about management of neuropsychiatric manifestations of Parkinson disease. The participants had nothing to disclose except Drs. McAllister, Numis and Weintraub. Dr. McAllister receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal; serves on the scientific advisory board of Pfizer Inc, Teva Pharmaceutical Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Eli Lilly and Company, Biogen Idec, Lundbeck Inc., UCB, Bristol-Myers Squibb, CHDI Foundation, Inc, ADCS; receives fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson disease; receives commercial funding for travel from Teva Pharmaceutical Industries Ltd.; gave expert testimony for defense in 2012-2013 in lawsuit related to impulse control disorders in Parkinson disease; receives research support from Novartis, Michael J. Fox Foundation for Parkinson's Research and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 10 2013 Issue

Building foundations for improving health opportunities in sub-Saharan Africa

Published: Monday, 09 Dec 2013 17:00:00 CDT

1) Building foundations for improving health opportunities in sub-Saharan Africa and 2) Topic of the month: Maintenance of Certification. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Wong interviews Dr. Michael Finkel about his paper on building foundations for improving health opportunities in sub-Saharan Africa. Dr. Roy Strowd is reading our e-Pearl of the week about neurapraxia. In the next part of the podcast Dr. Michelle Mauermann interviews Dr. Kerry Levin on part two of the orientation of new processes to the Maintenance of Certification. The participants had nothing to disclose except Drs. Finkel, Strowd and Levin. Dr. Finkel gave expert testimony as a treating physician in 2012. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Levin serves as an editorial board member of Muscle and Nerve; serves on the scientific advisory board of the American Board of Psychiatry and Neurology; received reimbursement for travel to policy meetings and examination writing committees from the American Board of Psychiatry and Neurology; receives royalties from UpToDate.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

December 3 2013 Issue

Practice variability in brain death determination: A call to action

Published: Monday, 02 Dec 2013 17:00:00 CDT

1) Practice variability in brain death determination and 2) Topic of the month: Maintenance of Certification. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Jeff Frank about his paper on practice variability in brain death determination. Dr. Roy Strowd is reading our e-Pearl of the week about prion protein problems. In the next part of the podcast Dr. Elliot Dimberg interviews Dr. Janice Massey on part one of the orientation of new processes to the Maintenance of Certification. The participants had nothing to disclose except Drs. Burns, Strowd and Massey. Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals. Dr. Strowd serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Massey serves on the AAN Board of Directors; the editorial board of Seminars in Neurology; and received unrestricted educational grants from Allergan, Inc. and Merz harmaceuticals, LLC for Annual Duke Advanced EMG and Chemodenervation Workshop.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - December 2013 - Biostatistics II

More topics in biostatistics

Published: Sunday, 01 Dec 2013 03:00:00 CDT

More topics in biostatistics

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 26 2013 Issue

Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior

Published: Monday, 25 Nov 2013 17:00:00 CDT

1) Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Wong interviews Dr. Mary Jo Pugh about her paper on temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior. Dr. Roy Strowd is reading our e-Pearl of the week about Garcin syndrome. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about treatment of functional neurologic symptoms. The participants had nothing to disclose except Drs. Pugh, Strowd and Stone. Dr. Pugh serves as an associate editor of BMC Health Services Research and BMC Geriatrics; serves on the scientific advisory board of the Journal of Managed Care Pharmacy; receives research support from the Veterans Administration health services research and development service. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 19 2013 Issue

Fibroblast growth factor-21 is a sensitive biomarker of mitochondrial disease

Published: Monday, 18 Nov 2013 17:00:00 CDT

1) Fibroblast growth factor-21 being a sensitive biomarker of mitochondrial disease and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. James Addington interviews Dr. Carolyn Sue about her paper on fibroblast growth factor-21 being a sensitive biomarker of mitochondrial disease. Dr. Roy Strowd is reading our e-Pearl of the week about MAD for seizures. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about functional neurologic symptoms and how to discuss this diagnosis with patients. The participants had nothing to disclose except Drs. Sue, Strowd and Stone. Dr. Sue receives research support from the National Health and Medical Research Council of Australia. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 12 2013 Issue

Sensitivity of MRI spine as compared to CT myelography in orthostatic headache with CSF leak

Published: Monday, 11 Nov 2013 17:00:00 CDT

1) Sensitivity of MRI spine compared to CT myelography in orthostatic headache with CSF leak and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Amaal Starling about her paper on sensitivity of MRI spine compared to CT myelography in orthostatic headache with CSF leak. Dr. Roy Strowd is reading our e-Pearl of the week about Rosenthal fibers. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about functional symptoms and conversion disorder within the domain of psychiatry. The participants had nothing to disclose except Drs. Strowd and Stone. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

November 5 2013 Issue

Primary leptomeningeal lymphoma: An International Primary CNS Lymphoma Collaborative Group report

Published: Monday, 04 Nov 2013 17:00:00 CDT

1) Primary leptomeningeal lymphoma and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Schiff about his paper on primary leptomeningeal lymphoma. Dr. Roy Strowd is reading our e-Pearl of the week about anti-NMDA receptor encephalitis. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about definitions and etiology of functional symptoms and conversion disorder. The participants had nothing to disclose except Drs. Burns, Schiff, Strowd and Stone. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals. Dr. Schiff serves as an editorial board member of Neurology® and Neurosurgery; received travel related expenses without personal compensation from Merck Sereno; serves on the scientific advisory board for Genetech, Inc.; is a consultant without personal compensation for Tau Therapeutics; serves on the data and safety monitoring boards for Celldex Therapeutics, Inc. and Vascular Biogenics Ltd. and receives royalties from UptoDate. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - November 2013 - Pediatric Neurology Topics

Autoimmune disorders, stroke, epilepsy, and movement disorders

Published: Friday, 01 Nov 2013 03:00:00 CDT

Autoimmune disorders, stroke, epilepsy, and movement disorders

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 29 2013 Issue

Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy

Published: Monday, 28 Oct 2013 17:00:00 CDT

1) Pretreatment cognitive deficits and treatment effects in childhood epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nick Brenton interviews Dr. Tracy Glauser about his paper on pretreatment cognitive deficits and treatment effects in childhood epilepsy. Lara Marcuse talks about being diagnosed with cancer after listening to Ted Burns discuss his diagnosis in our September 3 podcast. Dr. Adam Numis is reading our e-Pearl of the week about ophthalmologic findings in neurocysticercosis. In the next part of the podcast Dr. Mark Keegan interviews Dr. Douglas Goodin about interferons and copaxone in multiple sclerosis. The participants had nothing to disclose except Drs. Glauser, Numis, Keegan, and Goodin. Dr. Glauser serves on the scientific advisory board for AssureRx Health, Inc.; serves on the speakers' bureau and receives honoraria from Supernus Pharmaceuticals; receives royalties from the publication of the book Pediatric Epilepsy; receives royalty payments for optimization of drug selection software algorithms, AssureRx Health, Inc.; holds stock options in AssureRx Health, Inc.; has patents for optimization of drug selection software algorithms, neurocognitive computing algorithms and suicide prediction algorithms; is a consultant for Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Eisai, Inc., UCB, Lundbeck Inc., Questcor Pharmaceuticals, Inc, Upsher-Smith, AssureRx Health, Inc.; receives license fees from AssureRx Health, Inc. for optimization of drug selection software algorithms and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Goodin receives research support from Novartis; had travel costs reimbursed for occasional community lectures, symposia and/or academic talks sponsored by Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., Merck Serono. Genzyme and Novartis.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 22 2013 Issue

Quality improvement in neurology: Dementia management quality measures

Published: Monday, 21 Oct 2013 17:00:00 CDT

1) Dementia management quality measures and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Amy Sanders about her paper on dementia management quality measures. Dr. Adam Numis is reading our e-Pearl of the week about Leber's hereditary optic neuropathy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Alasdair Coles about alemtuzumab treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Burns, Sanders, Numis, Keegan, and Coles. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Sanders is a member of a federal advisory committee (MEDCAC); received honoraria for serving on peer-review panels from the CMMI and PCORI; and research support from the Einstein CTSA Grant from the National Center for Research Resources, a component of the NIH and NIH roadmap for Medical Research; loan repayment support from LRP/NIA. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Coles is a co-editor of Advances in Clinical Neuroscience and Rehabilitation; serves on the scientific advisory board for the Multiple Sclerosis Society of GB & NI, International Society for Neuroimmunology, Genzyme Corporation steering committee, UK Advisory Board, Merck Serono; is a consultant and receives speakers' honoraria from Nil, Merck Serono, Genzyme Corporation, Bayer Schering Pharma; and has a patent for IL-21 as a marker of autoimmunity after alemtuzumab treatment.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 15 2013 Issue

Evidence-based guideline updated: Vagus nerve stimulation for the treatment of epilepsy

Published: Monday, 14 Oct 2013 17:00:00 CDT

1) Vagus nerve stimulation for the treatment of epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Antel Patel interviews Dr. George Morris about his paper on vagus nerve stimulation for the treatment of epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about vitamin B6 and epilepsy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Robert Fox about dimethylfumarate for multiple sclerosis. The participants had nothing to disclose except Drs. Patel, Morris, Numis, Keegan, and Fox. Dr. Patel serves as Book editor for the Journal of Child Neurology; receives research support from UCB and Eisai Inc. Dr. Morris performs clinical care involving vagus nerve stimulation (5% effort) in his practice; serves on the speakers' bureaus of UCB, Cyberonics, Lundbeck, Inc.; is a consultant for UCB, Cyberonics, Lundbeck, Inc.; receives honoraria from UCB, Cyberonics, Lundbeck. Inc; receives research support from UCB, Cyberonics, Lundbeck. Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Fox serves as an editorial board member of Neurology and Multiple Sclerosis Journal; serves on the scientific advisory board for Biogen Idec, Novartis; is a consultant for Allozyne, Avanir, Biogen Idec, Novartis, Questcor, EMD Serono, and Teva Pharmaceutical Industries Ltd.; receives research support from Novartis, National MS Society and NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 8 2013 Issue

A randomized trial of cognitive speed of processing training in Parkinson disease

Published: Monday, 07 Oct 2013 17:00:00 CDT

1) Cognitive speed of processing training in Parkinson disease and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Jerri Edwards about her paper on cognitive speed of processing training in Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about stiff person syndrome. In the next part of the podcast Dr. Mark Keegan interviews Dr. Jeffrey Cohen about fingolimod therapy for multiple sclerosis. The participants had nothing to disclose except Drs. Edwards, Numis, Keegan, and Cohen. Dr. Edwards receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. Cohen received consulting fees from Novartis and Teva Pharmaceutical Industries Ltd.; receives royalties from the publication of the book Multiple Sclerosis Therapeutics, 4th edition; received research support from the Department of Defense and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - October 2013 - Headaches II

Topics in headache part II

Published: Tuesday, 01 Oct 2013 03:00:00 CDT

Post-traumatic headache, pediatric headache, and pseudotumor cerebri.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

October 1 2013 Issue

Migraine and structural changes in the brain: A systematic review and meta-analysis

Published: Monday, 30 Sep 2013 17:00:00 CDT

1) Migraine and structural changes in the brain and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Messoud Ashina about his paper on migraine and structural changes in the brain. Dr. Adam Numis is reading our e-Pearl of the week about manganese neurotoxicity. In the next part of the podcast Dr. Mark Keegan interviews Dr. Paul O' Connor about teriflunomide for the treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Ashima, Numis, Keegan, and O'Connor. Dr. Ashina serves as an Associate Editor of Cephalalgia; serves on the scientific advisory board for The Journal of Headache and Pain; is a consultant for ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received honoraria for lecturing from Allergan Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT. Dr. O'Connor serves on the scientific advisory boards of Novartis Fingolimod Steering Committee, Sanofi-aventis Teriflunomide Steering Committee, BRAVO (laquinimod) study DMC-chairman, Genetech, Inc. Roche, Acetelion Pharmaceuticals Ltd, Receptos, Inc; received honoraria for attending two Advisory board meetings; served on the editorial advisory board for the MS Journal; serves as a consultant for Biogen Idec, Merck Serono, is currently a consultant for Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Novartis; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec, and from the MS Society of Canada as National Scientific and Clinical Advisor.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 24 2013 Issue

The complexities of acute stroke decision-making

Published: Monday, 23 Sep 2013 17:00:00 CDT

1) The complexities of acute stroke decision-making and 2) Topic of the month: Living Legends Interviews. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Michel Shamy about his paper on the complexities of acute stroke decision-making. Dr. Roy Strowd is reading our e-Pearl of the week about Adie's tonic pupil. In the next part of the podcast Dr. Brett Kissela interviews Dr. Lou Caplan about his medical education and contributions to the field of neurology, interactions with C. Miller Fisher and advice to our younger listeners now beginning their careers. The participants had nothing to disclose except Drs. Kissela, Shamy, Strowd and Caplan. Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring and provides medico-legal reviews. Dr. Shamy serves as an editorial board member of The Neurohospitalist; receives research support from Alberta Innovates Health Solutions Clinical Fellowship, H. Richard Tyler Award for Research in History of Neurology from the American Academy of Neurology. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Caplan serves as an editorial board member of Archives of Neurology; serves as co-editor of Reviews in Neurological Diseases and receive payment for Aruba monitoring.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 17 2013 Issue

Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in just 4 months

Published: Monday, 16 Sep 2013 17:00:00 CDT

1) Helsinki model cutting stroke thrombolysis delays and 2) Topic of the month: Living Legends Interviews. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Atte Meretoja about his paper on Helsinki model cutting stroke thrombolysis delays. Dr. Roy Strowd is reading our e-Pearl of the week about transient global amnesia. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Vanda Lennon about establishing the Neuroimmunology Laboratory at the Mayo Clinic, her contribution to the field of neurology and advice to our younger listeners now beginning their careers. The participants had nothing to disclose except Drs. Southerland, Meretoja, Strowd, Clardy and Lennon. Dr. Southerland serves as Podcast Deputy Editor for Neurology® and serves as Clinical Research Advisor for Totier Technologies, Inc. Dr. Meretoja serves as an editorial board member of the International Journal of Stroke; receives research support from Sigrid Juselius Foundation, Biomedicum Helsinki Foundation and Finnish Medical Foundation. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clardy served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lennon performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation; receives royalties and license fee payments for the intellectual property: Marker for Neuromyelitis Optica; receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 10 2013 Issue

The American Academy of Neurology’s top five choosing wisely recommendations

Published: Monday, 09 Sep 2013 17:00:00 CDT

1) AAN paper on the top five choosing wisely recommendations and 2) Topic of the month: Living Legends Interviews. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Gary Gronseth and Mr. Tom Getchius about the AAN paper on the top five choosing wisely recommendations. Dr. Roy Strowd is reading our e-Pearl of the week about schwannomatosis: more than just NF1 and NF2. In the next part of the podcast Dr. Farrah Mateen interviews Dr. Martin Samuels about his medical education and teaching contributions to the field of neurology and advice to our younger listeners now beginning their careers. The participants had nothing to disclose except Drs. Southerland, Gronseth, Mr. Getchius, Strowd and Mateen. Dr. Southerland serves as Podcast Deputy Editor for Neurology®. Dr. Gronseth serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology. Mr. Getchius is a full time employee of the American Academy of Neurology, spending 100% of his time directing the development and dissemination activities of AAN evidence- based guidelines and receives research support as Project Director of the CDC-RFA-DD10-1012 award. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Mateen has consulted for the World Health Organization, Global Polio Eradication Initiative, and Caritas.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

September 3 2013 Issue

GABAB receptor autoantibody frequency in service serological evaluation

Published: Monday, 02 Sep 2013 17:00:00 CDT

1) GABAB receptor autoantibody frequency in-service serological evaluation and 2) This week's topic: About Ted Burns about being diagnosed with a serious cancer. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Zsofia Hole interviews Dr. Andrew McKeon about his paper on GABAB receptor autoantibody frequency in-service serological evaluation. Dr. Roy Strowd is reading our e-Pearl of the week about Fazio-Londe syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Ted Burns about being diagnosed with a serious cancer and how he has gained insight into what it's like being a patient. The participants had nothing to disclose except Drs. McKeon, Strowd, Espay, and Burns. Dr. McKeon receives research support from the Guthy Jackson Charitable Foundation. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - September 2013 - Headaches I

Topics in headache part I

Published: Sunday, 01 Sep 2013 03:00:00 CDT

Migraine in women and cluster headaches

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 27 2013 Issue

Risk factors for dementia with Lewy bodies: A case-control study

Published: Monday, 26 Aug 2013 17:00:00 CDT

1) Risk factors for dementia with Lewy bodies and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Brendon Boot about his paper on risk factors for dementia with Lewy bodies. Dr. Adam Numis is reading our e-Pearl of the week about reversible cerebral vasoconstriction syndrome. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about therapeutics and future directions in frontotemporal degeneration. The participants had nothing to disclose except Drs. Geldmacher, Numis, Matthews and Seeley. Dr. Geldmacher serves as an editorial board member of Brain Injury; serves on a Data Safety Committee for GlaxoSmithKline; received research support from Baxter International Inc., Elan Corporation, Eisai Inc.; received honoraria for consulting from Abbvie, Janssen Alzheimer Immunotherapy, and Baxter International Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH. Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 20 2013 Issue

Electronic media in neurology education: Progress, promise and pitfalls

Published: Monday, 19 Aug 2013 17:00:00 CDT

1) Electronic media in neurology education and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Shaheen Lakhan about his paper on electronic media in neurology education. Dr. Adam Numis is reading our e-Pearl of the week about hemifacial spasm. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about diagnostic testing and genetics in frontotemporal degeneration. The participants had nothing to disclose except Drs. Lakhan, Numis, Matthews and Seeley. Dr. Lakhan serves on the editorial team for the Neurology® Resident and Fellow Section, serves as Associate Editor for BMC Research Notes and Journal of Medical Case Reports, BioMed Central, serves as an editorial board member of International Archives of Medicine, BioMed Central; serves on the scientific advisory board for OA Pain Medicine, OA Publishing London, Nanotechnology Research Foundation, National Science & Technology Education Partnership, International Physicians Advisory Council, International Cancer Advocacy Network; is a consultant for Global Neuroscience Initiative Foundation and receives research support from Global Neuroscience Initiative Foundation. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH. Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 13 2013 Issue

An index to identify stroke-related versus incidental patent foramen ovale in cryptogenic stroke

Published: Monday, 12 Aug 2013 17:00:00 CDT

1) An index to identify stroke-related versus incidental patent foramen ovale in cryptogenic stroke and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. David Kent about his paper on using an index to identify stroke-related versus incidental patent foramen ovale in cryptogenic stroke. Dr. Adam Numis is reading our e-Pearl of the week about superior quadrantopia. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about clinical presentations and bedside evaluation in frontotemporal degeneration. The participants had nothing to disclose except Drs. Kent, Numis, Matthews and Seeley. Dr. Kent is a consultant for WL Gore Associates and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH. Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

August 6 2013 Issue

The optic nerve head component responses of multifocal electroretinogram in MS

Published: Monday, 05 Aug 2013 17:00:00 CDT

1) Optic nerve head component responses of multifocal electroretinogram in MS and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Beau Bruce interviews Drs. Teresa and Elliot Frohman about their paper on optic nerve head component responses of multifocal electroretinogram in MS. Dr. Adam Numis is reading our e-Pearl of the week about Terson's syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. John Trojanowski about progressive accumulation of tau pathology in patients with Alzheimer disease and how it occurred in a stereotypical manner. The participants had nothing to disclose except Drs. Bruce, Teresa Frohman, Eliot Frohman, Numis, Espay, and Trojanowski. Dr. Bruce is a consultant for Kaiser Permanente of Georgia for the CDC Vaccine Safety Datalink; receives research support from Novartis, Pfizer Inc, TEVA Pharmaceutical Industries, Ltd and the NIH; and was a recipient of the Practice Research Fellowship. Dr. Teresa Frohman serves as an editorial board member of National Multiple Sclerosis Society; is a consultant for Acorda, Novartis; serves on the speakers' bureau of Acorda Therapeutics, Inc., Novartis; receives royalties from the publication of Up-to-Date; received funding for travel from Acorda Therapeutics Inc., Novartis; received research support from the National Multiple Sclerosis Society and the NIH. Dr. Elliot Frohman is a consultant for TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics, Inc., Novartis, Genzyme Corporation, Abbott; serves on the speakers' bureau of TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis; receives royalties from the publication of Up-to-Date; and received funding for travel from TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. Trojanowski serves as an Associate Editor for Alzheimer & Dementia; received research support from The Marian S. Ware Alzheimer Program, Benaroya and the NIH; holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: US Patent 5,580,898, issued 3 Dec 1996; US Patent 5,601,985, issued 11 Feb 1997; US Patent 5,733,734, issued 31 Mar 1998; US Patent 5,792,900, issued 11 Aug 1998; US Patent 5,849,988, issued 15 Dec 1998: US Patent 6,214,334, issued 10 Apr 2001; US Patent 6,358,681, issued 19 Mar 2002; US Patent 6,727,075, issued 27 Mar 2004; US Patent 7,011,827, issued 14 Mar 2006; Penn 0652, K1828, filed 5 Aug 1998; Penn L1986, Filed 13 Nov 1998; Penn R3868 (UPN-4439), filed 28 Feb 2005 and Penn S-4018, DB&R 46406- 217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody and may accrue revenue in the future on patents submitted by the University of Pennsylvania as co-Inventor and received revenue from the sale of Avid to Eli Lilly and Company as co-inventor on imaging related patents submitted by the University of Pennsylvania while receiving research support from the NIH, Bristol-Myers Squibb, AstraZeneca and several non-profits.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

2012-2013 Academic Year In Review - Delayed Recall

2012-2013 Academic Year In Review

Published: Thursday, 01 Aug 2013 03:00:00 CDT

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2012-2013 academic year.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 30 2013 Issue

Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology

Published: Monday, 29 Jul 2013 17:00:00 CDT

1) Evidence-based guideline: Treatment of tardive syndromes and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Roongroj Bhidayasiri and Gary Gronseth about the AAN evidence-based guideline on treatment of tardive syndromes. Dr. Roy Strowd is reading our e-Pearl of the week about CTA spot sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Marsel Mesulam about his H. Houston Merritt Lecture on the selective cognitive impairments and distinct neuropathological entities of the primary progressive aphasias. The participants had nothing to disclose except Drs. Bhidayasiri, Gronseth, Strowd, Espay and Mesulam. Dr. Bhidayasiri served as Editor-in-Chief for The Thai Journal of Neurology; serves on the scientific advisory board for Ministry of Public Heath, Thailand and Excellence Network; serves as Director of Chulalongkorn Center of Excellence on Parkinson's Disease and Related Disorders, Thai Red Cross Society; received funding for trips from BL Hua, GlaxoSmithKline, Medtronic, Inc., Roche; serves on the speakers' bureau of Abbott, BL Hua, Boehringer-Ingelheim, GlaxoSmithKline, Medtronic, Inc., Novartis, Roche; receives royalties from the publication of the books Neurological Differential diagnosis, International Neurology, Movement Disorders: A video atlas; receives research support from Abbott, Immunocal Thailand, Chulalongkorn University, Bangkok, Thailand, Thailand Research Fund and Thai Red Cross Society. Dr. Gronseth serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. Mesulam serves on the scientific advisory board for Cure Alzheimer Fund and Association on Frontotemporal Dementia; serves as an editorial board member of Brain, Annals of Neurology, Human Brain Mapping, Journal of Cognitive Neuroscience; receives royalties from the publication of the book Principles of Behavioral and Cognitive Neurology and receives research support from the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Neurology Resident & Fellow (R&F) Section Podcast

Resident and Fellow Interviews from the 2013 AAN Annual Meeting

Published: Monday, 29 Jul 2013 17:00:00 CDT

In this special Podcast from the Neurology Resident & Fellow (R&F) Section, members of the R&F Editorial team interview some residents who presented posters at the 2013 AAN Annual Meeting in San Diego. Other interesting segments include the Top 10 Ways for Program Directors to the Use the Neurology Resident & Fellow Section and interviews of authors this year's R&F Highlights booklet. The participants had nothing to disclose except Drs. Cahill, Wong, Strowd, Sarkar, Pressman and Clardy. Dr. Cahill serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wong served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Sarkar received honoraria from the Young Researcher Award from CNS. Dr. Pressman serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clardy served on the editorial team for the Neurology® Resident and Fellow Section.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 23 2013 Issue

A case of Rasmussen’s encephalitis treated with natalizumab

Published: Monday, 22 Jul 2013 17:00:00 CDT

1) Rasmussen's encephalitis treated with natalizumab and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Prof. Heinz Wiendl about his paper on Rasmussen's encephalitis treated with natalizumab. Dr. Roy Strowd is reading our e-Pearl of the week about watching for Whipple's: Oculomasticatory myorhythmia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Pooja Khatri on intra-arterial therapy being used as standard treatment for acute stroke. The participants had nothing to disclose except Prof. Wiendl, Drs. Strowd, Espay and Khatri. Prof. Wiendl received honoraria for travel to attend meetings from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi- Aventis, Schering-Plough Corp., Merck Serono, Teva Pharmaceuticals Industries Ltd.; has served as a consultant or is currently a consultant for Merck Serono, Medac, Inc, Sanofi-aventis, Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd., Novo Nordisk; receives research support from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi-aventis, Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, Medac, Inc, Genzyme and Novo Nordisk. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. Khatri received funding for a trip from Genetech, Inc.; provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 16 2013 Issue

Development and validation of a clinical guideline for diagnosing blepharospasm

Published: Monday, 15 Jul 2013 17:00:00 CDT

1) Development and validation of a clinical guideline for diagnosing blepharospasm and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Giovanni Defazio about his paper on development and validation of a clinical guideline for diagnosing blepharospasm. Dr. Roy Strowd is reading our e-Pearl of the week about iatrogenic botulism. In the next part of the podcast Dr. Alberto Espay interviews Dr. Salvatore DiMauro about his Robert Wartenberg Lecture on Mitochondrial encephalomyopathies: 50 years on. The participants had nothing to disclose except Drs. Defazio, Strowd, Espay and DiMauro. Dr. Defazio receives research support from the Italian Ministry of University and Comitato Promotore Telethon. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. DiMauro serves as an editorial board member of Muscle and Nerve, Neuromuscular Disorders, Acta Myologica, MedLink Neurology; serves on the scientific advisory board for Telethon Italia; receives research support from the Muscular Dystrophy Association, Marriott Mitochondrial Disorder Clinical Research Fund and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 9 2013 Issue

Surveillance neuroimaging and neurologic examinations affect care for intracerebral hemorrhage

Published: Monday, 08 Jul 2013 17:00:00 CDT

1) Surveillance neuroimaging and neurologic examinations affecting care for intracerebral hemorrhage and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Matthew Maas about his paper on surveillance neuroimaging and neurologic examinations affecting care for intracerebral hemorrhage. Dr. Roy Strowd is reading our e-Pearl of the week about dopamine dysregulation syndrome in Parkinson disease. In the next part of the podcast Dr. Alberto Espay interviews Drs. Stephen Reich and C. Warren Olanow on levodopa being initiated at time of diagnosis of movement disorders. The participants had nothing to disclose except Drs. Maas, Strowd, Espay, Olanow and Reich. Dr. Maas receives research support from the NIH. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. Olanow serves as Chief Editor for Movement Disorders; serves on the scientific advisory board for Michael J. Fox Foundation, TEVA Pharmaceutical Industries Ltd, Ceregene; is a consultant for TEVA Pharmaceutical Industries Ltd, Lundbeck, Inc., Novartis, Impax Pharmaceuticals, Ceregene, Orion; holds stock options in Ceregene and Clintrex, receives research support from Ceregene and participated in legal proceedings involving welding defense. Dr. Reich receives royalties from the publication of the book Movement Disorders: 100 Instructive Cases; receives research support from Chiltern, Synosia pharmaceuticals, Phytopharm and the NIH.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

July 2 2013 Issue

Depressive symptoms and white matter dysfunction in retired NFL players with concussion history

Published: Monday, 01 Jul 2013 17:00:00 CDT

1) Depressive symptoms and white matter dysfunction in retired NFL players with concussion history and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Christopher Giza interviews Dr. John Hart about his paper on depressive symptoms and white matter dysfunction in retired NFL players. Dr. Adam Numis is reading our e-Pearl of the week about ice-cream headache. In the next part of the podcast Dr. Alberto Espay interviews Drs. Ron Postuma and Brad Boeve about clinicopathologic correlations in 172 cases of REM sleep behavior disorder. The participants had nothing to disclose except Drs. Giza, Hart, Numis, Espay, Postuma and Boeve. Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases. Dr. Hart serves as an editorial board member of Neurocase, Journal of Innovative Optical Health, World Journals of Radiology and Psychiatry, Frontiers in Neuropsychiatric Imaging and Stimulation; receives royalties from the publication of the book Neural Basis of Semantic Memory; receives research support from the Department of Defense, Alzheimer's Association, RGK Foundation and NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press. Dr. Postuma serves on the scientific advisory board for TEVA Pharmaceutical Industries Ltd; serves as an editorial board member of Movement Disorders Journal and Journal of Caffeine Research; receives honoraria from Allergan, Inc., Novartis, TEVA Pharmaceutical Industries Ltd; receives research support from the Canadian Institute of Health Research, Parkinson Society of Canada, Fonds de Recherche de la Sante Quebec, Weston Foundation and Drummond Foundation. Dr. Boeve has served as an investigator for clinical trials sponsored by Cephalon, Inc., Allon Pharmaceuticals and GE Healthcare; receives royalties from the publication of a book Behavioral Neurology of Dementia; received honoraria from the American Academy of Neurology; serves on the scientific advisory board of the Tau Consortium and receives research support from the National Institute on Aging and the Mangurian Foundation.

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

Delayed Recall - July 2013 - Stroke Update 2013

Stroke Update 2013

Published: Monday, 01 Jul 2013 03:00:00 CDT

Stroke Update 2013

CME Opportunity: Listen to this week's Neurology® Podcast and earn 0.5 AMA PRA Category 1 CME Credit(s)™ by answering the multiple-choice questions in the online Podcast quiz (CME quizzes expire three years after podcast publication date or sooner if podcasts are deemed out of date by reviewers). Important Note: Delayed Recall segments and interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program because they include previously aired content.

download this now episode segments

June 11 2013

Summary of evidence-based guideline update: Evaluation and management of concussion in sports

Published: Monday, 10 Jun 2013 17:00:00 CDT

1) Guideline update: Evaluation and management of concussion in sports and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Christopher Giza about this guideline update on evaluation and management of concussion in sports. Dr. Adam Numis is reading our e-Pearl of the week about anti -MuSK antibody myasthenia gravis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Merit Cudkowicz about her plenary session on ALS pathways to treatments. The participants had nothing to disclose except Drs. Goodkin, Giza, Nu